id	sid	tid	token	lemma	pos
aiua-10337	1	1	stesura	stesura	PROPN
aiua-10337	1	2	seveso	seveso	NOUN
aiua-10337	1	3	489archivio	489archivio	PROPN
aiua-10337	1	4	italiano	italiano	ADJ
aiua-10337	1	5	di	di	NOUN
aiua-10337	1	6	urologia	urologia	PROPN
aiua-10337	1	7	e	e	PROPN
aiua-10337	1	8	andrologia	andrologia	NOUN
aiua-10337	1	9	2021	2021	NUM
aiua-10337	1	10	;	;	PUNCT
aiua-10337	1	11	93	93	NUM
aiua-10337	1	12	,	,	PUNCT
aiua-10337	1	13	4	4	NUM
aiua-10337	1	14	original	original	ADJ
aiua-10337	1	15	paper	paper	NOUN
aiua-10337	1	16	no	no	DET
aiua-10337	1	17	conflict	conflict	NOUN
aiua-10337	1	18	of	of	ADP
aiua-10337	1	19	interest	interest	NOUN
aiua-10337	1	20	declared	declare	VERB
aiua-10337	1	21	.	.	PUNCT
aiua-10337	2	1	mammary	mammary	ADJ
aiua-10337	2	2	ducts	duct	NOUN
aiua-10337	2	3	embedded	embed	VERB
aiua-10337	2	4	in	in	ADP
aiua-10337	2	5	a	a	DET
aiua-10337	2	6	fibroconnective	fibroconnective	ADJ
aiua-10337	2	7	tissue	tissue	NOUN
aiua-10337	2	8	stroma	stroma	NOUN
aiua-10337	2	9	.	.	PUNCT
aiua-10337	3	1	gynecomastia	gynecomastia	PROPN
aiua-10337	3	2	is	be	AUX
aiua-10337	3	3	associated	associate	VERB
aiua-10337	3	4	with	with	ADP
aiua-10337	3	5	medical	medical	ADJ
aiua-10337	3	6	conditions	condition	NOUN
aiua-10337	3	7	such	such	ADJ
aiua-10337	3	8	as	as	ADP
aiua-10337	3	9	extreme	extreme	ADJ
aiua-10337	3	10	obesity	obesity	NOUN
aiua-10337	3	11	,	,	PUNCT
aiua-10337	3	12	hypogonadism	hypogonadism	NOUN
aiua-10337	3	13	,	,	PUNCT
aiua-10337	3	14	liver	liver	NOUN
aiua-10337	3	15	,	,	PUNCT
aiua-10337	3	16	and	and	CCONJ
aiua-10337	3	17	kidney	kidney	NOUN
aiua-10337	3	18	failure	failure	NOUN
aiua-10337	3	19	.	.	PUNCT
aiua-10337	4	1	in	in	ADP
aiua-10337	4	2	addition	addition	NOUN
aiua-10337	4	3	,	,	PUNCT
aiua-10337	4	4	the	the	DET
aiua-10337	4	5	administration	administration	NOUN
aiua-10337	4	6	of	of	ADP
aiua-10337	4	7	certain	certain	ADJ
aiua-10337	4	8	drugs	drug	NOUN
aiua-10337	4	9	is	be	AUX
aiua-10337	4	10	a	a	DET
aiua-10337	4	11	known	know	VERB
aiua-10337	4	12	risk	risk	NOUN
aiua-10337	4	13	factor	factor	NOUN
aiua-10337	4	14	for	for	ADP
aiua-10337	4	15	gynecomastia	gynecomastia	NOUN
aiua-10337	4	16	.	.	PUNCT
aiua-10337	5	1	according	accord	VERB
aiua-10337	5	2	to	to	ADP
aiua-10337	5	3	food	food	NOUN
aiua-10337	5	4	and	and	CCONJ
aiua-10337	5	5	drug	drug	PROPN
aiua-10337	5	6	administration	administration	PROPN
aiua-10337	5	7	(	(	PUNCT
aiua-10337	5	8	fda	fda	PROPN
aiua-10337	5	9	)	)	PUNCT
aiua-10337	5	10	adverse	adverse	ADJ
aiua-10337	5	11	event	event	NOUN
aiua-10337	5	12	reporting	reporting	NOUN
aiua-10337	5	13	system	system	NOUN
aiua-10337	5	14	,	,	PUNCT
aiua-10337	5	15	gynecomastia	gynecomastia	NOUN
aiua-10337	5	16	is	be	AUX
aiua-10337	5	17	most	most	ADV
aiua-10337	5	18	frequently	frequently	ADV
aiua-10337	5	19	reported	report	VERB
aiua-10337	5	20	after	after	ADP
aiua-10337	5	21	administration	administration	NOUN
aiua-10337	5	22	of	of	ADP
aiua-10337	5	23	inhibitors	inhibitor	NOUN
aiua-10337	5	24	of	of	ADP
aiua-10337	5	25	5alpha	5alpha	NUM
aiua-10337	5	26	-	-	PUNCT
aiua-10337	5	27	reductase	reductase	NOUN
aiua-10337	5	28	(	(	PUNCT
aiua-10337	5	29	dutasteride	dutasteride	PROPN
aiua-10337	5	30	,	,	PUNCT
aiua-10337	5	31	finasteride	finasteride	ADJ
aiua-10337	5	32	)	)	PUNCT
aiua-10337	5	33	,	,	PUNCT
aiua-10337	5	34	spironolactone	spironolactone	NOUN
aiua-10337	5	35	,	,	PUNCT
aiua-10337	5	36	antipsychotics	antipsychotic	NOUN
aiua-10337	5	37	,	,	PUNCT
aiua-10337	5	38	lipid	lipid	NOUN
aiua-10337	5	39	-	-	PUNCT
aiua-10337	5	40	lowering	lower	VERB
aiua-10337	5	41	agents	agent	NOUN
aiua-10337	5	42	(	(	PUNCT
aiua-10337	5	43	rosuvastatin	rosuvastatin	NOUN
aiua-10337	5	44	,	,	PUNCT
aiua-10337	5	45	atorvastatin	atorvastatin	NOUN
aiua-10337	5	46	,	,	PUNCT
aiua-10337	5	47	and	and	CCONJ
aiua-10337	5	48	simvastatin	simvastatin	NOUN
aiua-10337	5	49	)	)	PUNCT
aiua-10337	5	50	and	and	CCONJ
aiua-10337	5	51	antiandrogens	antiandrogen	NOUN
aiua-10337	5	52	(	(	PUNCT
aiua-10337	5	53	1	1	NUM
aiua-10337	5	54	)	)	PUNCT
aiua-10337	5	55	.	.	PUNCT
aiua-10337	6	1	other	other	ADJ
aiua-10337	6	2	drugs	drug	NOUN
aiua-10337	6	3	causing	cause	VERB
aiua-10337	6	4	gynecomastia	gynecomastia	NOUN
aiua-10337	6	5	include	include	VERB
aiua-10337	6	6	antiretrovirals	antiretroviral	NOUN
aiua-10337	6	7	(	(	PUNCT
aiua-10337	6	8	protease	protease	NOUN
aiua-10337	6	9	inhibitors	inhibitor	NOUN
aiua-10337	6	10	and	and	CCONJ
aiua-10337	6	11	nucleoside	nucleoside	ADV
aiua-10337	6	12	reverse	reverse	VERB
aiua-10337	6	13	transcriptase	transcriptase	NOUN
aiua-10337	6	14	inhibitors	inhibitor	NOUN
aiua-10337	6	15	)	)	PUNCT
aiua-10337	6	16	,	,	PUNCT
aiua-10337	6	17	histamine2	histamine2	NOUN
aiua-10337	6	18	-	-	PUNCT
aiua-10337	6	19	receptor	receptor	NOUN
aiua-10337	6	20	blockers	blocker	NOUN
aiua-10337	6	21	(	(	PUNCT
aiua-10337	6	22	cimetidine	cimetidine	NOUN
aiua-10337	6	23	)	)	PUNCT
aiua-10337	6	24	,	,	PUNCT
aiua-10337	6	25	antimycotics	antimycotic	NOUN
aiua-10337	6	26	(	(	PUNCT
aiua-10337	6	27	long	long	ADJ
aiua-10337	6	28	-	-	PUNCT
aiua-10337	6	29	term	term	NOUN
aiua-10337	6	30	use	use	NOUN
aiua-10337	6	31	of	of	ADP
aiua-10337	6	32	ketoconazole	ketoconazole	NOUN
aiua-10337	6	33	)	)	PUNCT
aiua-10337	6	34	,	,	PUNCT
aiua-10337	6	35	calcium	calcium	NOUN
aiua-10337	6	36	channel	channel	NOUN
aiua-10337	6	37	blockers	blocker	NOUN
aiua-10337	6	38	,	,	PUNCT
aiua-10337	6	39	and	and	CCONJ
aiua-10337	6	40	chemotherapeutic	chemotherapeutic	ADJ
aiua-10337	6	41	agents	agent	NOUN
aiua-10337	6	42	.	.	PUNCT
aiua-10337	7	1	gynecomastia	gynecomastia	PROPN
aiua-10337	7	2	was	be	AUX
aiua-10337	7	3	also	also	ADV
aiua-10337	7	4	reported	report	VERB
aiua-10337	7	5	after	after	ADP
aiua-10337	7	6	intake	intake	NOUN
aiua-10337	7	7	of	of	ADP
aiua-10337	7	8	exogenous	exogenous	ADJ
aiua-10337	7	9	hormones	hormone	NOUN
aiua-10337	7	10	(	(	PUNCT
aiua-10337	7	11	estrogens	estrogen	NOUN
aiua-10337	7	12	)	)	PUNCT
aiua-10337	7	13	or	or	CCONJ
aiua-10337	7	14	steroids	steroid	NOUN
aiua-10337	7	15	(	(	PUNCT
aiua-10337	7	16	in	in	ADP
aiua-10337	7	17	adolescent	adolescent	ADJ
aiua-10337	7	18	boys	boy	NOUN
aiua-10337	7	19	)	)	PUNCT
aiua-10337	7	20	,	,	PUNCT
aiua-10337	7	21	and	and	CCONJ
aiua-10337	7	22	after	after	ADP
aiua-10337	7	23	environmental	environmental	ADJ
aiua-10337	7	24	exposure	exposure	NOUN
aiua-10337	7	25	to	to	ADP
aiua-10337	7	26	phenothrin	phenothrin	NOUN
aiua-10337	7	27	or	or	CCONJ
aiua-10337	7	28	intake	intake	NOUN
aiua-10337	7	29	of	of	ADP
aiua-10337	7	30	phytoestrogens	phytoestrogen	NOUN
aiua-10337	7	31	(	(	PUNCT
aiua-10337	7	32	e.g.	e.g.	ADV
aiua-10337	7	33	,	,	PUNCT
aiua-10337	7	34	large	large	ADJ
aiua-10337	7	35	quantities	quantity	NOUN
aiua-10337	7	36	of	of	ADP
aiua-10337	7	37	phytoestrogencontaining	phytoestrogencontaine	VERB
aiua-10337	7	38	soy	soy	NOUN
aiua-10337	7	39	products	product	NOUN
aiua-10337	7	40	)	)	PUNCT
aiua-10337	7	41	.	.	PUNCT
aiua-10337	8	1	there	there	PRON
aiua-10337	8	2	are	be	VERB
aiua-10337	8	3	numerous	numerous	ADJ
aiua-10337	8	4	reports	report	NOUN
aiua-10337	8	5	on	on	ADP
aiua-10337	8	6	the	the	DET
aiua-10337	8	7	association	association	NOUN
aiua-10337	8	8	between	between	ADP
aiua-10337	8	9	the	the	DET
aiua-10337	8	10	intake	intake	NOUN
aiua-10337	8	11	of	of	ADP
aiua-10337	8	12	certain	certain	ADJ
aiua-10337	8	13	drugs	drug	NOUN
aiua-10337	8	14	and	and	CCONJ
aiua-10337	8	15	gynecomastia	gynecomastia	NOUN
aiua-10337	8	16	,	,	PUNCT
aiua-10337	8	17	but	but	CCONJ
aiua-10337	8	18	no	no	DET
aiua-10337	8	19	meta	meta	ADJ
aiua-10337	8	20	-	-	PUNCT
aiua-10337	8	21	analysis	analysis	NOUN
aiua-10337	8	22	has	have	AUX
aiua-10337	8	23	so	so	ADV
aiua-10337	8	24	far	far	ADV
aiua-10337	8	25	assessed	assess	VERB
aiua-10337	8	26	the	the	DET
aiua-10337	8	27	extent	extent	NOUN
aiua-10337	8	28	of	of	ADP
aiua-10337	8	29	the	the	DET
aiua-10337	8	30	risk	risk	NOUN
aiua-10337	8	31	of	of	ADP
aiua-10337	8	32	gynecomastia	gynecomastia	NOUN
aiua-10337	8	33	linked	link	VERB
aiua-10337	8	34	to	to	ADP
aiua-10337	8	35	specific	specific	ADJ
aiua-10337	8	36	classes	class	NOUN
aiua-10337	8	37	of	of	ADP
aiua-10337	8	38	drugs	drug	NOUN
aiua-10337	8	39	.	.	PUNCT
aiua-10337	9	1	the	the	DET
aiua-10337	9	2	aim	aim	NOUN
aiua-10337	9	3	of	of	ADP
aiua-10337	9	4	this	this	DET
aiua-10337	9	5	work	work	NOUN
aiua-10337	9	6	was	be	AUX
aiua-10337	9	7	to	to	PART
aiua-10337	9	8	review	review	VERB
aiua-10337	9	9	the	the	DET
aiua-10337	9	10	scientific	scientific	ADJ
aiua-10337	9	11	evidence	evidence	NOUN
aiua-10337	9	12	on	on	ADP
aiua-10337	9	13	the	the	DET
aiua-10337	9	14	risk	risk	NOUN
aiua-10337	9	15	of	of	ADP
aiua-10337	9	16	gynecomastia	gynecomastia	NOUN
aiua-10337	9	17	after	after	ADP
aiua-10337	9	18	administration	administration	NOUN
aiua-10337	9	19	of	of	ADP
aiua-10337	9	20	the	the	DET
aiua-10337	9	21	drugs	drug	NOUN
aiua-10337	9	22	that	that	PRON
aiua-10337	9	23	are	be	AUX
aiua-10337	9	24	most	most	ADV
aiua-10337	9	25	frequently	frequently	ADV
aiua-10337	9	26	associated	associate	VERB
aiua-10337	9	27	with	with	ADP
aiua-10337	9	28	the	the	DET
aiua-10337	9	29	occurrence	occurrence	NOUN
aiua-10337	9	30	of	of	ADP
aiua-10337	9	31	this	this	DET
aiua-10337	9	32	side	side	NOUN
aiua-10337	9	33	effect	effect	NOUN
aiua-10337	9	34	.	.	PUNCT
aiua-10337	10	1	materials	material	NOUN
aiua-10337	10	2	and	and	CCONJ
aiua-10337	10	3	methods	method	NOUN
aiua-10337	10	4	electronic	electronic	ADJ
aiua-10337	10	5	databases	database	NOUN
aiua-10337	10	6	(	(	PUNCT
aiua-10337	10	7	e.g.	e.g.	ADV
aiua-10337	10	8	,	,	PUNCT
aiua-10337	10	9	pubmed	pubmed	PROPN
aiua-10337	10	10	and	and	CCONJ
aiua-10337	10	11	embase	embase	NOUN
aiua-10337	10	12	)	)	PUNCT
aiua-10337	10	13	were	be	AUX
aiua-10337	10	14	searched	search	VERB
aiua-10337	10	15	for	for	ADP
aiua-10337	10	16	articles	article	NOUN
aiua-10337	10	17	published	publish	VERB
aiua-10337	10	18	up	up	ADP
aiua-10337	10	19	to	to	PART
aiua-10337	10	20	30	30	NUM
aiua-10337	10	21	june	june	PROPN
aiua-10337	10	22	2021	2021	NUM
aiua-10337	10	23	.	.	PUNCT
aiua-10337	11	1	five	five	NUM
aiua-10337	11	2	separate	separate	ADJ
aiua-10337	11	3	searches	search	NOUN
aiua-10337	11	4	were	be	AUX
aiua-10337	11	5	performed	perform	VERB
aiua-10337	11	6	using	use	VERB
aiua-10337	11	7	the	the	DET
aiua-10337	11	8	following	follow	VERB
aiua-10337	11	9	mesh	mesh	NOUN
aiua-10337	11	10	terms	term	NOUN
aiua-10337	11	11	:	:	PUNCT
aiua-10337	11	12	“	"	PUNCT
aiua-10337	11	13	spironolactone	spironolactone	NOUN
aiua-10337	11	14	and	and	CCONJ
aiua-10337	11	15	gynecomastia	gynecomastia	PROPN
aiua-10337	11	16	”	"	PUNCT
aiua-10337	11	17	,	,	PUNCT
aiua-10337	11	18	“	"	PUNCT
aiua-10337	11	19	antiandrogens	antiandrogen	NOUN
aiua-10337	11	20	and	and	CCONJ
aiua-10337	11	21	gynecomastia	gynecomastia	NOUN
aiua-10337	11	22	”	"	PUNCT
aiua-10337	11	23	,	,	PUNCT
aiua-10337	11	24	“	"	PUNCT
aiua-10337	11	25	(	(	PUNCT
aiua-10337	11	26	finasteride	finasteride	ADJ
aiua-10337	11	27	or	or	CCONJ
aiua-10337	11	28	dutasteride	dutasteride	NOUN
aiua-10337	11	29	)	)	PUNCT
aiua-10337	11	30	and	and	CCONJ
aiua-10337	11	31	gynecomastia	gynecomastia	PROPN
aiua-10337	11	32	”	"	PUNCT
aiua-10337	11	33	,	,	PUNCT
aiua-10337	11	34	“	"	PUNCT
aiua-10337	11	35	psychotropic	psychotropic	ADJ
aiua-10337	11	36	agents	agent	NOUN
aiua-10337	11	37	and	and	CCONJ
aiua-10337	11	38	gynecomastia	gynecomastia	PROPN
aiua-10337	11	39	”	"	PUNCT
aiua-10337	11	40	,	,	PUNCT
aiua-10337	11	41	“	"	PUNCT
aiua-10337	11	42	statins	statin	NOUN
aiua-10337	11	43	and	and	CCONJ
aiua-10337	11	44	gynecomastia	gynecomastia	NOUN
aiua-10337	11	45	”	"	PUNCT
aiua-10337	11	46	.	.	PUNCT
aiua-10337	12	1	title	title	NOUN
aiua-10337	12	2	and	and	CCONJ
aiua-10337	12	3	abstract	abstract	ADJ
aiua-10337	12	4	and	and	CCONJ
aiua-10337	12	5	full	full	ADJ
aiua-10337	12	6	-	-	PUNCT
aiua-10337	12	7	text	text	NOUN
aiua-10337	12	8	screening	screening	NOUN
aiua-10337	12	9	were	be	AUX
aiua-10337	12	10	performed	perform	VERB
aiua-10337	12	11	independently	independently	ADV
aiua-10337	12	12	by	by	ADP
aiua-10337	12	13	two	two	NUM
aiua-10337	12	14	authors	author	NOUN
aiua-10337	12	15	.	.	PUNCT
aiua-10337	13	1	we	we	PRON
aiua-10337	13	2	included	include	VERB
aiua-10337	13	3	randomized	randomize	VERB
aiua-10337	13	4	controlled	control	VERB
aiua-10337	13	5	trials	trial	NOUN
aiua-10337	13	6	(	(	PUNCT
aiua-10337	13	7	rcts	rct	NOUN
aiua-10337	13	8	)	)	PUNCT
aiua-10337	13	9	,	,	PUNCT
aiua-10337	13	10	objective	objective	NOUN
aiua-10337	13	11	:	:	PUNCT
aiua-10337	13	12	to	to	PART
aiua-10337	13	13	review	review	VERB
aiua-10337	13	14	the	the	DET
aiua-10337	13	15	evidence	evidence	NOUN
aiua-10337	13	16	concerning	concern	VERB
aiua-10337	13	17	treatment	treatment	NOUN
aiua-10337	13	18	-	-	PUNCT
aiua-10337	13	19	related	relate	VERB
aiua-10337	13	20	gynecomastia	gynecomastia	NOUN
aiua-10337	13	21	in	in	ADP
aiua-10337	13	22	patients	patient	NOUN
aiua-10337	13	23	taking	take	VERB
aiua-10337	13	24	spironolactone	spironolactone	NOUN
aiua-10337	13	25	,	,	PUNCT
aiua-10337	13	26	antiandrogens	antiandrogen	NOUN
aiua-10337	13	27	,	,	PUNCT
aiua-10337	13	28	5	5	NUM
aiua-10337	13	29	alpha	alpha	NOUN
aiua-10337	13	30	-	-	PUNCT
aiua-10337	13	31	reductase	reductase	NOUN
aiua-10337	13	32	inhibitors	inhibitor	NOUN
aiua-10337	13	33	,	,	PUNCT
aiua-10337	13	34	lipid	lipid	NOUN
aiua-10337	13	35	-	-	PUNCT
aiua-10337	13	36	lowering	lower	VERB
aiua-10337	13	37	and	and	CCONJ
aiua-10337	13	38	psychotropic	psychotropic	ADJ
aiua-10337	13	39	drugs	drug	NOUN
aiua-10337	13	40	.	.	PUNCT
aiua-10337	14	1	material	material	NOUN
aiua-10337	14	2	and	and	CCONJ
aiua-10337	14	3	methods	method	NOUN
aiua-10337	14	4	:	:	PUNCT
aiua-10337	14	5	a	a	DET
aiua-10337	14	6	search	search	NOUN
aiua-10337	14	7	of	of	ADP
aiua-10337	14	8	medline	medline	NOUN
aiua-10337	14	9	and	and	CCONJ
aiua-10337	14	10	embase	embase	NOUN
aiua-10337	14	11	was	be	AUX
aiua-10337	14	12	performed	perform	VERB
aiua-10337	14	13	up	up	ADP
aiua-10337	14	14	to	to	ADP
aiua-10337	14	15	30	30	NUM
aiua-10337	14	16	june	june	PROPN
aiua-10337	14	17	2021	2021	NUM
aiua-10337	14	18	.	.	PUNCT
aiua-10337	15	1	we	we	PRON
aiua-10337	15	2	included	include	VERB
aiua-10337	15	3	randomized	randomize	VERB
aiua-10337	15	4	controlled	control	VERB
aiua-10337	15	5	trials	trial	NOUN
aiua-10337	15	6	comparing	compare	VERB
aiua-10337	15	7	the	the	DET
aiua-10337	15	8	effects	effect	NOUN
aiua-10337	15	9	of	of	ADP
aiua-10337	15	10	a	a	DET
aiua-10337	15	11	drug	drug	NOUN
aiua-10337	15	12	belonging	belong	VERB
aiua-10337	15	13	to	to	ADP
aiua-10337	15	14	these	these	DET
aiua-10337	15	15	classes	class	NOUN
aiua-10337	15	16	versus	versus	ADP
aiua-10337	15	17	placebo	placebo	NOUN
aiua-10337	15	18	or	or	CCONJ
aiua-10337	15	19	versus	versus	ADP
aiua-10337	15	20	a	a	DET
aiua-10337	15	21	drug	drug	NOUN
aiua-10337	15	22	of	of	ADP
aiua-10337	15	23	the	the	DET
aiua-10337	15	24	same	same	ADJ
aiua-10337	15	25	class	class	NOUN
aiua-10337	15	26	.	.	PUNCT
aiua-10337	16	1	results	result	NOUN
aiua-10337	16	2	:	:	PUNCT
aiua-10337	16	3	a	a	DET
aiua-10337	16	4	total	total	NOUN
aiua-10337	16	5	of	of	ADP
aiua-10337	16	6	32	32	NUM
aiua-10337	16	7	randomized	randomized	ADJ
aiua-10337	16	8	controlled	control	VERB
aiua-10337	16	9	trials	trial	NOUN
aiua-10337	16	10	were	be	AUX
aiua-10337	16	11	included	include	VERB
aiua-10337	16	12	in	in	ADP
aiua-10337	16	13	the	the	DET
aiua-10337	16	14	final	final	ADJ
aiua-10337	16	15	review	review	NOUN
aiua-10337	16	16	.	.	PUNCT
aiua-10337	17	1	there	there	PRON
aiua-10337	17	2	was	be	VERB
aiua-10337	17	3	an	an	DET
aiua-10337	17	4	increased	increase	VERB
aiua-10337	17	5	odds	odd	NOUN
aiua-10337	17	6	of	of	ADP
aiua-10337	17	7	gynecomastia	gynecomastia	NOUN
aiua-10337	17	8	in	in	ADP
aiua-10337	17	9	men	man	NOUN
aiua-10337	17	10	receiving	receive	VERB
aiua-10337	17	11	antiandrogens	antiandrogen	NOUN
aiua-10337	17	12	(	(	PUNCT
aiua-10337	17	13	or	or	CCONJ
aiua-10337	17	14	=	=	SYM
aiua-10337	17	15	17.38	17.38	NUM
aiua-10337	17	16	,	,	PUNCT
aiua-10337	17	17	95	95	NUM
aiua-10337	17	18	%	%	NOUN
aiua-10337	17	19	ci	ci	NOUN
aiua-10337	17	20	:	:	PUNCT
aiua-10337	17	21	11.26	11.26	NUM
aiua-10337	17	22	to	to	ADP
aiua-10337	17	23	26.82	26.82	NUM
aiua-10337	17	24	;	;	PUNCT
aiua-10337	17	25	6	6	NUM
aiua-10337	17	26	trials	trial	NOUN
aiua-10337	17	27	,	,	PUNCT
aiua-10337	17	28	9599	9599	NUM
aiua-10337	17	29	participants	participant	NOUN
aiua-10337	17	30	)	)	PUNCT
aiua-10337	17	31	and	and	CCONJ
aiua-10337	17	32	5	5	NUM
aiua-10337	17	33	alpha	alpha	NOUN
aiua-10337	17	34	-	-	PUNCT
aiua-10337	17	35	reductase	reductase	NOUN
aiua-10337	17	36	inhibitors	inhibitor	NOUN
aiua-10337	17	37	compared	compare	VERB
aiua-10337	17	38	to	to	ADP
aiua-10337	17	39	controls	control	NOUN
aiua-10337	17	40	(	(	PUNCT
aiua-10337	17	41	or	or	CCONJ
aiua-10337	17	42	=	=	SYM
aiua-10337	17	43	1.77	1.77	NUM
aiua-10337	17	44	,	,	PUNCT
aiua-10337	17	45	95	95	NUM
aiua-10337	17	46	%	%	NOUN
aiua-10337	17	47	ci	ci	NOUN
aiua-10337	17	48	:	:	PUNCT
aiua-10337	17	49	1.53	1.53	NUM
aiua-10337	17	50	to	to	ADP
aiua-10337	17	51	2.06	2.06	NUM
aiua-10337	17	52	;	;	PUNCT
aiua-10337	17	53	7	7	NUM
aiua-10337	17	54	series	series	NOUN
aiua-10337	17	55	out	out	ADP
aiua-10337	17	56	of	of	ADP
aiua-10337	17	57	6	6	NUM
aiua-10337	17	58	trials	trial	NOUN
aiua-10337	17	59	,	,	PUNCT
aiua-10337	17	60	34860	34860	NUM
aiua-10337	17	61	participants	participant	NOUN
aiua-10337	17	62	)	)	PUNCT
aiua-10337	17	63	.	.	PUNCT
aiua-10337	18	1	the	the	DET
aiua-10337	18	2	use	use	NOUN
aiua-10337	18	3	of	of	ADP
aiua-10337	18	4	spironolactone	spironolactone	NOUN
aiua-10337	18	5	in	in	ADP
aiua-10337	18	6	mixed	mixed	ADJ
aiua-10337	18	7	gender	gender	NOUN
aiua-10337	18	8	populations	population	NOUN
aiua-10337	18	9	was	be	AUX
aiua-10337	18	10	characterized	characterize	VERB
aiua-10337	18	11	by	by	ADP
aiua-10337	18	12	significantly	significantly	ADV
aiua-10337	18	13	higher	high	ADJ
aiua-10337	18	14	odds	odd	NOUN
aiua-10337	18	15	of	of	ADP
aiua-10337	18	16	having	have	VERB
aiua-10337	18	17	gynecomastia	gynecomastia	NOUN
aiua-10337	18	18	compared	compare	VERB
aiua-10337	18	19	to	to	ADP
aiua-10337	18	20	controls	control	NOUN
aiua-10337	18	21	(	(	PUNCT
aiua-10337	18	22	or	or	CCONJ
aiua-10337	18	23	=	=	SYM
aiua-10337	18	24	8.39	8.39	NUM
aiua-10337	18	25	,	,	PUNCT
aiua-10337	18	26	95	95	NUM
aiua-10337	18	27	%	%	NOUN
aiua-10337	18	28	ci	ci	NOUN
aiua-10337	18	29	:	:	PUNCT
aiua-10337	18	30	5.03	5.03	NUM
aiua-10337	18	31	to	to	ADP
aiua-10337	18	32	13.99	13.99	NUM
aiua-10337	18	33	;	;	PUNCT
aiua-10337	18	34	14	14	NUM
aiua-10337	18	35	trials	trial	NOUN
aiua-10337	18	36	,	,	PUNCT
aiua-10337	18	37	3745	3745	NUM
aiua-10337	18	38	participants	participant	NOUN
aiua-10337	18	39	)	)	PUNCT
aiua-10337	18	40	.	.	PUNCT
aiua-10337	19	1	no	no	DET
aiua-10337	19	2	placebo	placebo	NOUN
aiua-10337	19	3	-	-	PUNCT
aiua-10337	19	4	controlled	control	VERB
aiua-10337	19	5	trials	trial	NOUN
aiua-10337	19	6	focusing	focus	VERB
aiua-10337	19	7	on	on	ADP
aiua-10337	19	8	the	the	DET
aiua-10337	19	9	risk	risk	NOUN
aiua-10337	19	10	of	of	ADP
aiua-10337	19	11	gynecomastia	gynecomastia	NOUN
aiua-10337	19	12	in	in	ADP
aiua-10337	19	13	patients	patient	NOUN
aiua-10337	19	14	taking	take	VERB
aiua-10337	19	15	antipsychotic	antipsychotic	ADJ
aiua-10337	19	16	drugs	drug	NOUN
aiua-10337	19	17	was	be	AUX
aiua-10337	19	18	available	available	ADJ
aiua-10337	19	19	,	,	PUNCT
aiua-10337	19	20	although	although	SCONJ
aiua-10337	19	21	there	there	PRON
aiua-10337	19	22	was	be	VERB
aiua-10337	19	23	a	a	DET
aiua-10337	19	24	significant	significant	ADJ
aiua-10337	19	25	difference	difference	NOUN
aiua-10337	19	26	in	in	ADP
aiua-10337	19	27	the	the	DET
aiua-10337	19	28	odds	odd	NOUN
aiua-10337	19	29	of	of	ADP
aiua-10337	19	30	having	have	VERB
aiua-10337	19	31	gynecomastia	gynecomastia	NOUN
aiua-10337	19	32	in	in	ADP
aiua-10337	19	33	a	a	DET
aiua-10337	19	34	comparison	comparison	NOUN
aiua-10337	19	35	between	between	ADP
aiua-10337	19	36	risperidone	risperidone	NOUN
aiua-10337	19	37	and	and	CCONJ
aiua-10337	19	38	quetiapine	quetiapine	NOUN
aiua-10337	19	39	(	(	PUNCT
aiua-10337	19	40	or	or	CCONJ
aiua-10337	19	41	=	=	SYM
aiua-10337	19	42	4.32	4.32	NUM
aiua-10337	19	43	,	,	PUNCT
aiua-10337	19	44	95	95	NUM
aiua-10337	19	45	%	%	NOUN
aiua-10337	19	46	ci	ci	NOUN
aiua-10337	19	47	:	:	PUNCT
aiua-10337	19	48	1.31	1.31	NUM
aiua-10337	19	49	to	to	ADP
aiua-10337	19	50	14.27	14.27	NUM
aiua-10337	19	51	;	;	PUNCT
aiua-10337	19	52	3	3	NUM
aiua-10337	19	53	trials	trial	NOUN
aiua-10337	19	54	,	,	PUNCT
aiua-10337	19	55	343	343	NUM
aiua-10337	19	56	participants	participant	NOUN
aiua-10337	19	57	)	)	PUNCT
aiua-10337	19	58	.	.	PUNCT
aiua-10337	20	1	limited	limited	ADJ
aiua-10337	20	2	evidence	evidence	NOUN
aiua-10337	20	3	about	about	ADP
aiua-10337	20	4	the	the	DET
aiua-10337	20	5	effects	effect	NOUN
aiua-10337	20	6	of	of	ADP
aiua-10337	20	7	statins	statin	NOUN
aiua-10337	20	8	on	on	ADP
aiua-10337	20	9	mammary	mammary	ADJ
aiua-10337	20	10	glands	gland	NOUN
aiua-10337	20	11	was	be	AUX
aiua-10337	20	12	found	find	VERB
aiua-10337	20	13	.	.	PUNCT
aiua-10337	21	1	conclusions	conclusion	NOUN
aiua-10337	21	2	:	:	PUNCT
aiua-10337	21	3	antiandrogens	antiandrogen	NOUN
aiua-10337	21	4	and	and	CCONJ
aiua-10337	21	5	to	to	ADP
aiua-10337	21	6	a	a	DET
aiua-10337	21	7	lesser	less	ADJ
aiua-10337	21	8	extent	extent	NOUN
aiua-10337	21	9	5	5	NUM
aiua-10337	21	10	alphareductase	alphareductase	NOUN
aiua-10337	21	11	inhibitors	inhibitor	NOUN
aiua-10337	21	12	and	and	CCONJ
aiua-10337	21	13	spironolactone	spironolactone	NOUN
aiua-10337	21	14	are	be	AUX
aiua-10337	21	15	associated	associate	VERB
aiua-10337	21	16	with	with	ADP
aiua-10337	21	17	an	an	DET
aiua-10337	21	18	increased	increase	VERB
aiua-10337	21	19	risk	risk	NOUN
aiua-10337	21	20	of	of	ADP
aiua-10337	21	21	developing	develop	VERB
aiua-10337	21	22	gynecomastia	gynecomastia	NOUN
aiua-10337	21	23	.	.	PUNCT
aiua-10337	22	1	such	such	ADJ
aiua-10337	22	2	effect	effect	NOUN
aiua-10337	22	3	can	can	AUX
aiua-10337	22	4	be	be	AUX
aiua-10337	22	5	explained	explain	VERB
aiua-10337	22	6	by	by	ADP
aiua-10337	22	7	a	a	DET
aiua-10337	22	8	modification	modification	NOUN
aiua-10337	22	9	of	of	ADP
aiua-10337	22	10	the	the	DET
aiua-10337	22	11	testosterone	testosterone	NOUN
aiua-10337	22	12	to	to	ADP
aiua-10337	22	13	estradiol	estradiol	PROPN
aiua-10337	22	14	ratio	ratio	PROPN
aiua-10337	22	15	.	.	PUNCT
aiua-10337	23	1	gynecomastia	gynecomastia	PROPN
aiua-10337	23	2	(	(	PUNCT
aiua-10337	23	3	and	and	CCONJ
aiua-10337	23	4	galactorrhea	galactorrhea	PROPN
aiua-10337	23	5	)	)	PUNCT
aiua-10337	23	6	associated	associate	VERB
aiua-10337	23	7	to	to	ADP
aiua-10337	23	8	the	the	DET
aiua-10337	23	9	use	use	NOUN
aiua-10337	23	10	of	of	ADP
aiua-10337	23	11	conventional	conventional	ADJ
aiua-10337	23	12	and	and	CCONJ
aiua-10337	23	13	certain	certain	ADJ
aiua-10337	23	14	atypical	atypical	ADJ
aiua-10337	23	15	antipsychotics	antipsychotic	NOUN
aiua-10337	23	16	can	can	AUX
aiua-10337	23	17	be	be	AUX
aiua-10337	23	18	related	relate	VERB
aiua-10337	23	19	to	to	ADP
aiua-10337	23	20	high	high	ADJ
aiua-10337	23	21	prolactin	prolactin	ADJ
aiua-10337	23	22	levels	level	NOUN
aiua-10337	23	23	.	.	PUNCT
aiua-10337	24	1	key	key	ADJ
aiua-10337	24	2	words	word	NOUN
aiua-10337	24	3	:	:	PUNCT
aiua-10337	24	4	gynecomastia	gynecomastia	NOUN
aiua-10337	24	5	;	;	PUNCT
aiua-10337	24	6	breast	breast	NOUN
aiua-10337	24	7	enlargement	enlargement	NOUN
aiua-10337	24	8	;	;	PUNCT
aiua-10337	24	9	spironolactone	spironolactone	NOUN
aiua-10337	24	10	;	;	PUNCT
aiua-10337	24	11	antiandrogens	antiandrogen	NOUN
aiua-10337	24	12	;	;	PUNCT
aiua-10337	24	13	5	5	NUM
aiua-10337	24	14	alpha	alpha	NOUN
aiua-10337	24	15	-	-	PUNCT
aiua-10337	24	16	reductase	reductase	NOUN
aiua-10337	24	17	inhibitors	inhibitor	NOUN
aiua-10337	24	18	;	;	PUNCT
aiua-10337	24	19	psychotropic	psychotropic	ADJ
aiua-10337	24	20	drugs	drug	NOUN
aiua-10337	24	21	;	;	PUNCT
aiua-10337	24	22	statins	statin	NOUN
aiua-10337	24	23	.	.	PUNCT
aiua-10337	24	24	submitted	submit	VERB
aiua-10337	24	25	20	20	NUM
aiua-10337	24	26	september	september	PROPN
aiua-10337	24	27	2021	2021	NUM
aiua-10337	24	28	;	;	PUNCT
aiua-10337	24	29	accepted	accept	VERB
aiua-10337	24	30	1	1	NUM
aiua-10337	24	31	november	november	PROPN
aiua-10337	24	32	2021	2021	NUM
aiua-10337	24	33	introduction	introduction	NOUN
aiua-10337	24	34	gynecomastia	gynecomastia	NOUN
aiua-10337	24	35	is	be	AUX
aiua-10337	24	36	a	a	DET
aiua-10337	24	37	condition	condition	NOUN
aiua-10337	24	38	in	in	ADP
aiua-10337	24	39	which	which	PRON
aiua-10337	24	40	the	the	DET
aiua-10337	24	41	male	male	ADJ
aiua-10337	24	42	breast	breast	NOUN
aiua-10337	24	43	is	be	AUX
aiua-10337	24	44	enlarged	enlarge	VERB
aiua-10337	24	45	due	due	ADP
aiua-10337	24	46	to	to	ADP
aiua-10337	24	47	an	an	DET
aiua-10337	24	48	increase	increase	NOUN
aiua-10337	24	49	in	in	ADP
aiua-10337	24	50	ductal	ductal	ADJ
aiua-10337	24	51	tissue	tissue	NOUN
aiua-10337	24	52	,	,	PUNCT
aiua-10337	24	53	stroma	stroma	NOUN
aiua-10337	24	54	,	,	PUNCT
aiua-10337	24	55	or	or	CCONJ
aiua-10337	24	56	fat	fat	ADJ
aiua-10337	24	57	.	.	PUNCT
aiua-10337	25	1	histological	histological	ADJ
aiua-10337	25	2	observation	observation	NOUN
aiua-10337	25	3	shows	show	VERB
aiua-10337	25	4	a	a	DET
aiua-10337	25	5	proliferation	proliferation	NOUN
aiua-10337	25	6	of	of	ADP
aiua-10337	25	7	the	the	DET
aiua-10337	25	8	drug	drug	NOUN
aiua-10337	25	9	-	-	PUNCT
aiua-10337	25	10	induced	induce	VERB
aiua-10337	25	11	gynecomastia	gynecomastia	NOUN
aiua-10337	25	12	:	:	PUNCT
aiua-10337	25	13	a	a	DET
aiua-10337	25	14	systematic	systematic	ADJ
aiua-10337	25	15	review	review	NOUN
aiua-10337	25	16	and	and	CCONJ
aiua-10337	25	17	meta	meta	NOUN
aiua-10337	25	18	-	-	PUNCT
aiua-10337	25	19	analysis	analysis	NOUN
aiua-10337	25	20	of	of	ADP
aiua-10337	25	21	randomized	randomized	ADJ
aiua-10337	25	22	clinical	clinical	ADJ
aiua-10337	25	23	trials	trial	NOUN
aiua-10337	25	24	alberto	alberto	ADV
aiua-10337	25	25	trinchieri	trinchieri	PROPN
aiua-10337	25	26	1	1	NUM
aiua-10337	25	27	,	,	PUNCT
aiua-10337	25	28	gianpaolo	gianpaolo	NOUN
aiua-10337	25	29	perletti	perletti	NOUN
aiua-10337	25	30	2	2	NUM
aiua-10337	25	31	,	,	PUNCT
aiua-10337	25	32	3	3	NUM
aiua-10337	25	33	,	,	PUNCT
aiua-10337	25	34	vittorio	vittorio	NOUN
aiua-10337	25	35	magri	magri	VERB
aiua-10337	25	36	4	4	NUM
aiua-10337	25	37	,	,	PUNCT
aiua-10337	25	38	konstantinos	konstantinos	PROPN
aiua-10337	25	39	stamatiou	stamatiou	PROPN
aiua-10337	25	40	5	5	NUM
aiua-10337	25	41	,	,	PUNCT
aiua-10337	25	42	margherita	margherita	PROPN
aiua-10337	25	43	trinchieri	trinchieri	PROPN
aiua-10337	25	44	6	6	NUM
aiua-10337	25	45	,	,	PUNCT
aiua-10337	25	46	emanuele	emanuele	PROPN
aiua-10337	25	47	montanari	montanari	PROPN
aiua-10337	25	48	7	7	NUM
aiua-10337	25	49	1	1	NUM
aiua-10337	25	50	school	school	NOUN
aiua-10337	25	51	of	of	ADP
aiua-10337	25	52	urology	urology	NOUN
aiua-10337	25	53	,	,	PUNCT
aiua-10337	25	54	university	university	PROPN
aiua-10337	25	55	of	of	ADP
aiua-10337	25	56	milan	milan	PROPN
aiua-10337	25	57	,	,	PUNCT
aiua-10337	25	58	milan	milan	PROPN
aiua-10337	25	59	,	,	PUNCT
aiua-10337	25	60	italy	italy	PROPN
aiua-10337	25	61	;	;	PUNCT
aiua-10337	25	62	2	2	NUM
aiua-10337	25	63	department	department	NOUN
aiua-10337	25	64	of	of	ADP
aiua-10337	25	65	biotechnology	biotechnology	NOUN
aiua-10337	25	66	and	and	CCONJ
aiua-10337	25	67	life	life	NOUN
aiua-10337	25	68	sciences	science	NOUN
aiua-10337	25	69	,	,	PUNCT
aiua-10337	25	70	section	section	NOUN
aiua-10337	25	71	of	of	ADP
aiua-10337	25	72	medical	medical	ADJ
aiua-10337	25	73	and	and	CCONJ
aiua-10337	25	74	surgical	surgical	ADJ
aiua-10337	25	75	sciences	science	NOUN
aiua-10337	25	76	,	,	PUNCT
aiua-10337	25	77	university	university	NOUN
aiua-10337	25	78	of	of	ADP
aiua-10337	25	79	insubria	insubria	PROPN
aiua-10337	25	80	,	,	PUNCT
aiua-10337	25	81	varese	varese	PROPN
aiua-10337	25	82	,	,	PUNCT
aiua-10337	25	83	italy	italy	PROPN
aiua-10337	25	84	;	;	PUNCT
aiua-10337	25	85	3	3	NUM
aiua-10337	25	86	faculty	faculty	NOUN
aiua-10337	25	87	of	of	ADP
aiua-10337	25	88	medicine	medicine	NOUN
aiua-10337	25	89	and	and	CCONJ
aiua-10337	25	90	medical	medical	ADJ
aiua-10337	25	91	sciences	sciences	PROPN
aiua-10337	25	92	,	,	PUNCT
aiua-10337	25	93	ghent	ghent	PROPN
aiua-10337	25	94	university	university	PROPN
aiua-10337	25	95	,	,	PUNCT
aiua-10337	25	96	belgium	belgium	NOUN
aiua-10337	25	97	;	;	PUNCT
aiua-10337	25	98	4	4	NUM
aiua-10337	25	99	urology	urology	NOUN
aiua-10337	25	100	secondary	secondary	ADJ
aiua-10337	25	101	care	care	NOUN
aiua-10337	25	102	clinic	clinic	NOUN
aiua-10337	25	103	,	,	PUNCT
aiua-10337	25	104	asst	asst	NOUN
aiua-10337	25	105	-	-	PUNCT
aiua-10337	25	106	nord	nord	PROPN
aiua-10337	25	107	,	,	PUNCT
aiua-10337	25	108	milan	milan	PROPN
aiua-10337	25	109	,	,	PUNCT
aiua-10337	25	110	italy	italy	PROPN
aiua-10337	25	111	;	;	PUNCT
aiua-10337	25	112	5	5	NUM
aiua-10337	25	113	department	department	NOUN
aiua-10337	25	114	of	of	ADP
aiua-10337	25	115	urology	urology	NOUN
aiua-10337	25	116	,	,	PUNCT
aiua-10337	25	117	tzaneio	tzaneio	ADJ
aiua-10337	25	118	hospital	hospital	PROPN
aiua-10337	25	119	,	,	PUNCT
aiua-10337	25	120	pireus	pireus	PROPN
aiua-10337	25	121	,	,	PUNCT
aiua-10337	25	122	greece	greece	PROPN
aiua-10337	25	123	;	;	PUNCT
aiua-10337	25	124	6	6	NUM
aiua-10337	25	125	department	department	NOUN
aiua-10337	25	126	of	of	ADP
aiua-10337	25	127	neuroscience	neuroscience	NOUN
aiua-10337	25	128	,	,	PUNCT
aiua-10337	25	129	psychiatric	psychiatric	ADJ
aiua-10337	25	130	unit	unit	NOUN
aiua-10337	25	131	,	,	PUNCT
aiua-10337	25	132	university	university	NOUN
aiua-10337	25	133	of	of	ADP
aiua-10337	25	134	parma	parma	PROPN
aiua-10337	25	135	,	,	PUNCT
aiua-10337	25	136	parma	parma	PROPN
aiua-10337	25	137	,	,	PUNCT
aiua-10337	25	138	italy	italy	PROPN
aiua-10337	25	139	;	;	PUNCT
aiua-10337	25	140	7	7	NUM
aiua-10337	25	141	department	department	NOUN
aiua-10337	25	142	of	of	ADP
aiua-10337	25	143	urology	urology	NOUN
aiua-10337	25	144	,	,	PUNCT
aiua-10337	25	145	irccs	irccs	NOUN
aiua-10337	25	146	ca	ca	NOUN
aiua-10337	25	147	’	'	PUNCT
aiua-10337	25	148	granda	granda	PROPN
aiua-10337	25	149	ospedale	ospedale	PROPN
aiua-10337	25	150	maggiore	maggiore	PROPN
aiua-10337	25	151	policlinico	policlinico	PROPN
aiua-10337	25	152	university	university	PROPN
aiua-10337	25	153	of	of	ADP
aiua-10337	25	154	milan	milan	PROPN
aiua-10337	25	155	,	,	PUNCT
aiua-10337	25	156	milan	milan	PROPN
aiua-10337	25	157	,	,	PUNCT
aiua-10337	25	158	italy	italy	PROPN
aiua-10337	25	159	.	.	PUNCT
aiua-10337	26	1	doi	doi	PROPN
aiua-10337	26	2	:	:	PUNCT
aiua-10337	26	3	10.4081	10.4081	NUM
aiua-10337	26	4	/	/	SYM
aiua-10337	26	5	aiua.2021.4.489	aiua.2021.4.489	NOUN
aiua-10337	26	6	summary	summary	NOUN
aiua-10337	26	7	archivio	archivio	NOUN
aiua-10337	26	8	italiano	italiano	X
aiua-10337	26	9	di	di	X
aiua-10337	26	10	urologia	urologia	PROPN
aiua-10337	26	11	e	e	PROPN
aiua-10337	26	12	andrologia	andrologia	NOUN
aiua-10337	26	13	2021	2021	NUM
aiua-10337	26	14	;	;	PUNCT
aiua-10337	26	15	93	93	NUM
aiua-10337	26	16	,	,	PUNCT
aiua-10337	26	17	4	4	NUM
aiua-10337	26	18	a.	a.	NOUN
aiua-10337	26	19	trinchieri	trinchieri	PROPN
aiua-10337	26	20	,	,	PUNCT
aiua-10337	26	21	g.	g.	PROPN
aiua-10337	26	22	perletti	perletti	PROPN
aiua-10337	26	23	,	,	PUNCT
aiua-10337	26	24	v.	v.	ADP
aiua-10337	26	25	magri	magri	NOUN
aiua-10337	26	26	,	,	PUNCT
aiua-10337	26	27	k.	k.	PROPN
aiua-10337	26	28	stamatiou	stamatiou	PROPN
aiua-10337	26	29	,	,	PUNCT
aiua-10337	26	30	m.	m.	NOUN
aiua-10337	26	31	trinchieri	trinchieri	PROPN
aiua-10337	26	32	,	,	PUNCT
aiua-10337	26	33	e.	e.	PROPN
aiua-10337	26	34	montanari	montanari	PROPN
aiua-10337	26	35	490	490	NUM
aiua-10337	26	36	with	with	ADP
aiua-10337	26	37	an	an	DET
aiua-10337	26	38	open	open	ADJ
aiua-10337	26	39	-	-	PUNCT
aiua-10337	26	40	label	label	NOUN
aiua-10337	26	41	or	or	CCONJ
aiua-10337	26	42	single	single	ADJ
aiua-10337	26	43	/	/	SYM
aiua-10337	26	44	double	double	ADJ
aiua-10337	26	45	blinded	blind	VERB
aiua-10337	26	46	design	design	NOUN
aiua-10337	26	47	,	,	PUNCT
aiua-10337	26	48	which	which	PRON
aiua-10337	26	49	enrolled	enrol	VERB
aiua-10337	26	50	patients	patient	NOUN
aiua-10337	26	51	treated	treat	VERB
aiua-10337	26	52	for	for	ADP
aiua-10337	26	53	at	at	ADV
aiua-10337	26	54	least	least	ADV
aiua-10337	26	55	6	6	NUM
aiua-10337	26	56	weeks	week	NOUN
aiua-10337	26	57	with	with	ADP
aiua-10337	26	58	antiandrogens	antiandrogen	NOUN
aiua-10337	26	59	,	,	PUNCT
aiua-10337	26	60	5	5	NUM
aiua-10337	26	61	alpha	alpha	NOUN
aiua-10337	26	62	-	-	PUNCT
aiua-10337	26	63	reductase	reductase	NOUN
aiua-10337	26	64	inhibitors	inhibitor	NOUN
aiua-10337	26	65	,	,	PUNCT
aiua-10337	26	66	spironolactone	spironolactone	NOUN
aiua-10337	26	67	,	,	PUNCT
aiua-10337	26	68	psychotropic	psychotropic	ADJ
aiua-10337	26	69	drugs	drug	NOUN
aiua-10337	26	70	,	,	PUNCT
aiua-10337	26	71	and	and	CCONJ
aiua-10337	26	72	statins	statin	NOUN
aiua-10337	26	73	.	.	PROPN
aiua-10337	27	1	included	include	VERB
aiua-10337	27	2	studies	study	NOUN
aiua-10337	27	3	should	should	AUX
aiua-10337	27	4	include	include	VERB
aiua-10337	27	5	a	a	DET
aiua-10337	27	6	primary	primary	ADJ
aiua-10337	27	7	or	or	CCONJ
aiua-10337	27	8	secondary	secondary	ADJ
aiua-10337	27	9	safety	safety	NOUN
aiua-10337	27	10	endpoint	endpoint	NOUN
aiua-10337	27	11	focusing	focus	VERB
aiua-10337	27	12	on	on	ADP
aiua-10337	27	13	the	the	DET
aiua-10337	27	14	side	side	NOUN
aiua-10337	27	15	effects	effect	NOUN
aiua-10337	27	16	of	of	ADP
aiua-10337	27	17	treatment	treatment	NOUN
aiua-10337	27	18	.	.	PUNCT
aiua-10337	28	1	the	the	DET
aiua-10337	28	2	following	follow	VERB
aiua-10337	28	3	information	information	NOUN
aiua-10337	28	4	was	be	AUX
aiua-10337	28	5	extracted	extract	VERB
aiua-10337	28	6	from	from	ADP
aiua-10337	28	7	each	each	DET
aiua-10337	28	8	study	study	NOUN
aiua-10337	28	9	:	:	PUNCT
aiua-10337	28	10	author(s	author(s	NOUN
aiua-10337	28	11	)	)	PUNCT
aiua-10337	28	12	,	,	PUNCT
aiua-10337	28	13	publication	publication	NOUN
aiua-10337	28	14	year	year	NOUN
aiua-10337	28	15	;	;	PUNCT
aiua-10337	28	16	study	study	NOUN
aiua-10337	28	17	design	design	NOUN
aiua-10337	28	18	;	;	PUNCT
aiua-10337	28	19	population	population	NOUN
aiua-10337	28	20	;	;	PUNCT
aiua-10337	28	21	intervention	intervention	NOUN
aiua-10337	28	22	;	;	PUNCT
aiua-10337	28	23	rate	rate	NOUN
aiua-10337	28	24	of	of	ADP
aiua-10337	28	25	gynecomastia	gynecomastia	NOUN
aiua-10337	28	26	(	(	PUNCT
aiua-10337	28	27	or	or	CCONJ
aiua-10337	28	28	breast	breast	NOUN
aiua-10337	28	29	enlargement	enlargement	NOUN
aiua-10337	28	30	or	or	CCONJ
aiua-10337	28	31	breast	breast	NOUN
aiua-10337	28	32	tenderness	tenderness	NOUN
aiua-10337	28	33	or	or	CCONJ
aiua-10337	28	34	pain	pain	NOUN
aiua-10337	28	35	or	or	CCONJ
aiua-10337	28	36	galacthorrea	galacthorrea	NOUN
aiua-10337	28	37	)	)	PUNCT
aiua-10337	28	38	.	.	PUNCT
aiua-10337	29	1	two	two	NUM
aiua-10337	29	2	authors	author	NOUN
aiua-10337	29	3	independently	independently	ADV
aiua-10337	29	4	performed	perform	VERB
aiua-10337	29	5	the	the	DET
aiua-10337	29	6	quality	quality	NOUN
aiua-10337	29	7	assessment	assessment	NOUN
aiua-10337	29	8	by	by	ADP
aiua-10337	29	9	identifying	identify	VERB
aiua-10337	29	10	potential	potential	ADJ
aiua-10337	29	11	biases	bias	NOUN
aiua-10337	29	12	using	use	VERB
aiua-10337	29	13	the	the	DET
aiua-10337	29	14	cochrane	cochrane	NOUN
aiua-10337	29	15	risk	risk	NOUN
aiua-10337	29	16	of	of	ADP
aiua-10337	29	17	bias	bias	NOUN
aiua-10337	29	18	tool	tool	NOUN
aiua-10337	29	19	(	(	PUNCT
aiua-10337	29	20	2	2	NUM
aiua-10337	29	21	)	)	PUNCT
aiua-10337	29	22	,	,	PUNCT
aiua-10337	29	23	focusing	focus	VERB
aiua-10337	29	24	on	on	ADP
aiua-10337	29	25	the	the	DET
aiua-10337	29	26	following	follow	VERB
aiua-10337	29	27	items	item	NOUN
aiua-10337	29	28	:	:	PUNCT
aiua-10337	29	29	random	random	ADJ
aiua-10337	29	30	sequence	sequence	NOUN
aiua-10337	29	31	generation	generation	NOUN
aiua-10337	29	32	,	,	PUNCT
aiua-10337	29	33	allocation	allocation	NOUN
aiua-10337	29	34	concealment	concealment	NOUN
aiua-10337	29	35	,	,	PUNCT
aiua-10337	29	36	blinding	blind	VERB
aiua-10337	29	37	of	of	ADP
aiua-10337	29	38	participants	participant	NOUN
aiua-10337	29	39	and	and	CCONJ
aiua-10337	29	40	personnel	personnel	NOUN
aiua-10337	29	41	,	,	PUNCT
aiua-10337	29	42	blinding	blind	VERB
aiua-10337	29	43	of	of	ADP
aiua-10337	29	44	outcome	outcome	NOUN
aiua-10337	29	45	assessors	assessor	NOUN
aiua-10337	29	46	,	,	PUNCT
aiua-10337	29	47	incomplete	incomplete	ADJ
aiua-10337	29	48	outcomes	outcome	NOUN
aiua-10337	29	49	,	,	PUNCT
aiua-10337	29	50	selective	selective	ADJ
aiua-10337	29	51	reporting	reporting	NOUN
aiua-10337	29	52	and	and	CCONJ
aiua-10337	29	53	other	other	ADJ
aiua-10337	29	54	biases	bias	NOUN
aiua-10337	29	55	.	.	PUNCT
aiua-10337	30	1	the	the	DET
aiua-10337	30	2	risk	risk	NOUN
aiua-10337	30	3	of	of	ADP
aiua-10337	30	4	bias	bias	NOUN
aiua-10337	30	5	(	(	PUNCT
aiua-10337	30	6	rob	rob	PROPN
aiua-10337	30	7	)	)	PUNCT
aiua-10337	30	8	was	be	AUX
aiua-10337	30	9	graded	grade	VERB
aiua-10337	30	10	as	as	ADP
aiua-10337	30	11	high	high	ADJ
aiua-10337	30	12	,	,	PUNCT
aiua-10337	30	13	low	low	ADJ
aiua-10337	30	14	or	or	CCONJ
aiua-10337	30	15	unclear	unclear	ADJ
aiua-10337	30	16	.	.	PUNCT
aiua-10337	31	1	publication	publication	NOUN
aiua-10337	31	2	bias	bias	NOUN
aiua-10337	31	3	was	be	AUX
aiua-10337	31	4	assessed	assess	VERB
aiua-10337	31	5	by	by	ADP
aiua-10337	31	6	visual	visual	ADJ
aiua-10337	31	7	inspection	inspection	NOUN
aiua-10337	31	8	of	of	ADP
aiua-10337	31	9	funnel	funnel	NOUN
aiua-10337	31	10	plots	plot	NOUN
aiua-10337	31	11	and	and	CCONJ
aiua-10337	31	12	by	by	ADP
aiua-10337	31	13	the	the	DET
aiua-10337	31	14	egger	egger	NOUN
aiua-10337	31	15	's	's	PART
aiua-10337	31	16	regression	regression	NOUN
aiua-10337	31	17	test	test	NOUN
aiua-10337	31	18	.	.	PUNCT
aiua-10337	32	1	dichotomous	dichotomous	ADJ
aiua-10337	32	2	data	datum	NOUN
aiua-10337	32	3	(	(	PUNCT
aiua-10337	32	4	presence	presence	NOUN
aiua-10337	32	5	/	/	SYM
aiua-10337	32	6	absence	absence	NOUN
aiua-10337	32	7	of	of	ADP
aiua-10337	32	8	gynecomastia	gynecomastia	NOUN
aiua-10337	32	9	)	)	PUNCT
aiua-10337	32	10	and	and	CCONJ
aiua-10337	32	11	number	number	NOUN
aiua-10337	32	12	of	of	ADP
aiua-10337	32	13	per	per	ADP
aiua-10337	32	14	-	-	PUNCT
aiua-10337	32	15	protocol	protocol	NOUN
aiua-10337	32	16	or	or	CCONJ
aiua-10337	32	17	intent	intent	NOUN
aiua-10337	32	18	-	-	PUNCT
aiua-10337	32	19	to	to	ADP
aiua-10337	32	20	-	-	PUNCT
aiua-10337	32	21	treat	treat	NOUN
aiua-10337	32	22	patients	patient	NOUN
aiua-10337	32	23	were	be	AUX
aiua-10337	32	24	extracted	extract	VERB
aiua-10337	32	25	to	to	PART
aiua-10337	32	26	calculate	calculate	VERB
aiua-10337	32	27	odds	odd	NOUN
aiua-10337	32	28	ratios	ratio	NOUN
aiua-10337	32	29	(	(	PUNCT
aiua-10337	32	30	or	or	CCONJ
aiua-10337	32	31	)	)	PUNCT
aiua-10337	32	32	,	,	PUNCT
aiua-10337	32	33	confidence	confidence	NOUN
aiua-10337	32	34	intervals	interval	NOUN
aiua-10337	32	35	(	(	PUNCT
aiua-10337	32	36	ci	ci	NOUN
aiua-10337	32	37	)	)	PUNCT
aiua-10337	32	38	to	to	ADP
aiua-10337	32	39	odds	odd	NOUN
aiua-10337	32	40	-	-	PUNCT
aiua-10337	32	41	ratios	ratio	NOUN
aiua-10337	32	42	,	,	PUNCT
aiua-10337	32	43	and	and	CCONJ
aiua-10337	32	44	z	z	NOUN
aiua-10337	32	45	statistics	statistic	NOUN
aiua-10337	32	46	according	accord	VERB
aiua-10337	32	47	to	to	ADP
aiua-10337	32	48	the	the	DET
aiua-10337	32	49	mantel	mantel	NOUN
aiua-10337	32	50	-	-	PUNCT
aiua-10337	32	51	haenszel	haenszel	NOUN
aiua-10337	32	52	method	method	NOUN
aiua-10337	32	53	.	.	PUNCT
aiua-10337	33	1	meta	meta	ADJ
aiua-10337	33	2	-	-	PUNCT
aiua-10337	33	3	analysis	analysis	NOUN
aiua-10337	33	4	was	be	AUX
aiua-10337	33	5	performed	perform	VERB
aiua-10337	33	6	using	use	VERB
aiua-10337	33	7	a	a	DET
aiua-10337	33	8	random	random	ADJ
aiua-10337	33	9	-	-	PUNCT
aiua-10337	33	10	effects	effect	NOUN
aiua-10337	33	11	model	model	NOUN
aiua-10337	33	12	.	.	PUNCT
aiua-10337	34	1	heterogeneity	heterogeneity	PROPN
aiua-10337	34	2	was	be	AUX
aiua-10337	34	3	assessed	assess	VERB
aiua-10337	34	4	by	by	ADP
aiua-10337	34	5	i2	i2	PROPN
aiua-10337	34	6	statistics	statistic	NOUN
aiua-10337	34	7	,	,	PUNCT
aiua-10337	34	8	reported	report	VERB
aiua-10337	34	9	with	with	ADP
aiua-10337	34	10	95	95	NUM
aiua-10337	34	11	%	%	NOUN
aiua-10337	34	12	cis	cis	NOUN
aiua-10337	34	13	,	,	PUNCT
aiua-10337	34	14	and	and	CCONJ
aiua-10337	34	15	interpreted	interpret	VERB
aiua-10337	34	16	as	as	ADP
aiua-10337	34	17	of	of	ADP
aiua-10337	34	18	lesser	less	ADJ
aiua-10337	34	19	importance	importance	NOUN
aiua-10337	34	20	(	(	PUNCT
aiua-10337	34	21	≤	≤	NUM
aiua-10337	34	22	40	40	NUM
aiua-10337	34	23	%	%	NOUN
aiua-10337	34	24	)	)	PUNCT
aiua-10337	34	25	,	,	PUNCT
aiua-10337	34	26	moderate	moderate	ADJ
aiua-10337	34	27	(	(	PUNCT
aiua-10337	34	28	30%-60	30%-60	NUM
aiua-10337	34	29	%	%	NOUN
aiua-10337	34	30	)	)	PUNCT
aiua-10337	34	31	,	,	PUNCT
aiua-10337	34	32	substantial	substantial	ADJ
aiua-10337	34	33	(	(	PUNCT
aiua-10337	34	34	50%-90	50%-90	NUM
aiua-10337	34	35	%	%	NOUN
aiua-10337	34	36	)	)	PUNCT
aiua-10337	34	37	or	or	CCONJ
aiua-10337	34	38	considerable	considerable	ADJ
aiua-10337	34	39	(	(	PUNCT
aiua-10337	34	40	≥	≥	NUM
aiua-10337	34	41	75	75	NUM
aiua-10337	34	42	%	%	NOUN
aiua-10337	34	43	)	)	PUNCT
aiua-10337	34	44	,	,	PUNCT
aiua-10337	34	45	according	accord	VERB
aiua-10337	34	46	to	to	ADP
aiua-10337	34	47	cochrane	cochrane	NOUN
aiua-10337	34	48	criteria	criterion	NOUN
aiua-10337	34	49	.	.	PUNCT
aiua-10337	35	1	the	the	DET
aiua-10337	35	2	review	review	NOUN
aiua-10337	35	3	(	(	PUNCT
aiua-10337	35	4	prospero	prospero	NOUN
aiua-10337	35	5	registration	registration	NOUN
aiua-10337	35	6	number	number	NOUN
aiua-10337	35	7	:	:	PUNCT
aiua-10337	35	8	crd42021276781	crd42021276781	ADJ
aiua-10337	35	9	)	)	PUNCT
aiua-10337	35	10	was	be	AUX
aiua-10337	35	11	conducted	conduct	VERB
aiua-10337	35	12	in	in	ADP
aiua-10337	35	13	accordance	accordance	NOUN
aiua-10337	35	14	with	with	ADP
aiua-10337	35	15	prisma	prisma	NOUN
aiua-10337	35	16	(	(	PUNCT
aiua-10337	35	17	preferred	prefer	VERB
aiua-10337	35	18	reporting	reporting	NOUN
aiua-10337	35	19	items	item	NOUN
aiua-10337	35	20	for	for	ADP
aiua-10337	35	21	systematic	systematic	ADJ
aiua-10337	35	22	reviews	review	NOUN
aiua-10337	35	23	and	and	CCONJ
aiua-10337	35	24	meta	meta	NOUN
aiua-10337	35	25	-	-	PUNCT
aiua-10337	35	26	analyses	analysis	NOUN
aiua-10337	35	27	)	)	PUNCT
aiua-10337	35	28	guidelines	guideline	NOUN
aiua-10337	35	29	(	(	PUNCT
aiua-10337	35	30	3	3	NUM
aiua-10337	35	31	)	)	PUNCT
aiua-10337	35	32	.	.	PUNCT
aiua-10337	36	1	statistical	statistical	ADJ
aiua-10337	36	2	analysis	analysis	NOUN
aiua-10337	36	3	was	be	AUX
aiua-10337	36	4	performed	perform	VERB
aiua-10337	36	5	using	use	VERB
aiua-10337	36	6	the	the	DET
aiua-10337	36	7	revman5	revman5	PROPN
aiua-10337	36	8	software	software	NOUN
aiua-10337	36	9	.	.	PUNCT
aiua-10337	37	1	the	the	DET
aiua-10337	37	2	egger	egger	NOUN
aiua-10337	37	3	’s	’s	PART
aiua-10337	37	4	test	test	NOUN
aiua-10337	37	5	was	be	AUX
aiua-10337	37	6	performed	perform	VERB
aiua-10337	37	7	using	use	VERB
aiua-10337	37	8	the	the	DET
aiua-10337	37	9	metaessentials	metaessential	NOUN
aiua-10337	37	10	software	software	NOUN
aiua-10337	37	11	(	(	PUNCT
aiua-10337	37	12	rotterdam	rotterdam	PROPN
aiua-10337	37	13	school	school	NOUN
aiua-10337	37	14	of	of	ADP
aiua-10337	37	15	management	management	NOUN
aiua-10337	37	16	,	,	PUNCT
aiua-10337	37	17	erasmus	erasmus	PROPN
aiua-10337	37	18	university	university	PROPN
aiua-10337	37	19	,	,	PUNCT
aiua-10337	37	20	the	the	DET
aiua-10337	37	21	netherlands	netherlands	PROPN
aiua-10337	37	22	)	)	PUNCT
aiua-10337	37	23	.	.	PUNCT
aiua-10337	38	1	results	result	VERB
aiua-10337	38	2	database	database	NOUN
aiua-10337	38	3	search	search	NOUN
aiua-10337	38	4	for	for	ADP
aiua-10337	38	5	the	the	DET
aiua-10337	38	6	association	association	NOUN
aiua-10337	38	7	between	between	ADP
aiua-10337	38	8	gynecomastia	gynecomastia	NOUN
aiua-10337	38	9	and	and	CCONJ
aiua-10337	38	10	treatment	treatment	NOUN
aiua-10337	38	11	with	with	ADP
aiua-10337	38	12	spironolactone	spironolactone	NOUN
aiua-10337	38	13	,	,	PUNCT
aiua-10337	38	14	antiandrogens	antiandrogen	NOUN
aiua-10337	38	15	,	,	PUNCT
aiua-10337	38	16	alphareductase	alphareductase	NOUN
aiua-10337	38	17	inhibitors	inhibitor	NOUN
aiua-10337	38	18	,	,	PUNCT
aiua-10337	38	19	and	and	CCONJ
aiua-10337	38	20	antipsychotics	antipsychotic	NOUN
aiua-10337	38	21	retrieved	retrieve	VERB
aiua-10337	38	22	74	74	NUM
aiua-10337	38	23	,	,	PUNCT
aiua-10337	38	24	215	215	NUM
aiua-10337	38	25	,	,	PUNCT
aiua-10337	38	26	42	42	NUM
aiua-10337	38	27	and	and	CCONJ
aiua-10337	38	28	74	74	NUM
aiua-10337	38	29	papers	paper	NOUN
aiua-10337	38	30	respectively	respectively	ADV
aiua-10337	38	31	.	.	PUNCT
aiua-10337	39	1	a	a	DET
aiua-10337	39	2	total	total	NOUN
aiua-10337	39	3	of	of	ADP
aiua-10337	39	4	68	68	NUM
aiua-10337	39	5	papers	paper	NOUN
aiua-10337	39	6	was	be	AUX
aiua-10337	39	7	screened	screen	VERB
aiua-10337	39	8	by	by	ADP
aiua-10337	39	9	title	title	NOUN
aiua-10337	39	10	/	/	SYM
aiua-10337	39	11	abstract	abstract	ADJ
aiua-10337	39	12	.	.	PUNCT
aiua-10337	40	1	after	after	ADP
aiua-10337	40	2	full	full	ADJ
aiua-10337	40	3	-	-	PUNCT
aiua-10337	40	4	text	text	NOUN
aiua-10337	40	5	screening	screening	NOUN
aiua-10337	40	6	with	with	ADP
aiua-10337	40	7	removal	removal	NOUN
aiua-10337	40	8	of	of	ADP
aiua-10337	40	9	duplicates	duplicate	NOUN
aiua-10337	40	10	or	or	CCONJ
aiua-10337	40	11	of	of	ADP
aiua-10337	40	12	articles	article	NOUN
aiua-10337	40	13	describing	describe	VERB
aiua-10337	40	14	series	series	NOUN
aiua-10337	40	15	reported	report	VERB
aiua-10337	40	16	in	in	ADP
aiua-10337	40	17	other	other	ADJ
aiua-10337	40	18	reports	report	NOUN
aiua-10337	40	19	we	we	PRON
aiua-10337	40	20	included	include	VERB
aiua-10337	40	21	32	32	NUM
aiua-10337	40	22	papers	paper	NOUN
aiua-10337	40	23	in	in	ADP
aiua-10337	40	24	this	this	DET
aiua-10337	40	25	systematic	systematic	ADJ
aiua-10337	40	26	review	review	NOUN
aiua-10337	40	27	(	(	PUNCT
aiua-10337	40	28	4	4	NUM
aiua-10337	40	29	-	-	NUM
aiua-10337	40	30	35	35	NUM
aiua-10337	40	31	)	)	PUNCT
aiua-10337	40	32	.	.	PUNCT
aiua-10337	41	1	out	out	ADP
aiua-10337	41	2	of	of	ADP
aiua-10337	41	3	them	they	PRON
aiua-10337	41	4	30	30	NUM
aiua-10337	41	5	reports	report	NOUN
aiua-10337	41	6	were	be	AUX
aiua-10337	41	7	included	include	VERB
aiua-10337	41	8	in	in	ADP
aiua-10337	41	9	the	the	DET
aiua-10337	41	10	quantitative	quantitative	ADJ
aiua-10337	41	11	analysis	analysis	NOUN
aiua-10337	41	12	(	(	PUNCT
aiua-10337	41	13	4	4	NUM
aiua-10337	41	14	-	-	SYM
aiua-10337	41	15	33	33	NUM
aiua-10337	41	16	)	)	PUNCT
aiua-10337	41	17	.	.	PUNCT
aiua-10337	42	1	a	a	DET
aiua-10337	42	2	prisma	prisma	NOUN
aiua-10337	42	3	flow	flow	NOUN
aiua-10337	42	4	-	-	PUNCT
aiua-10337	42	5	chart	chart	NOUN
aiua-10337	42	6	of	of	ADP
aiua-10337	42	7	the	the	DET
aiua-10337	42	8	study	study	NOUN
aiua-10337	42	9	selection	selection	NOUN
aiua-10337	42	10	process	process	NOUN
aiua-10337	42	11	is	be	AUX
aiua-10337	42	12	shown	show	VERB
aiua-10337	42	13	in	in	ADP
aiua-10337	42	14	figure	figure	NOUN
aiua-10337	42	15	1	1	NUM
aiua-10337	42	16	.	.	PUNCT
aiua-10337	43	1	the	the	DET
aiua-10337	43	2	supplementary	supplementary	ADJ
aiua-10337	43	3	appendix	appendix	NOUN
aiua-10337	43	4	provides	provide	VERB
aiua-10337	43	5	figure	figure	NOUN
aiua-10337	43	6	1	1	NUM
aiua-10337	43	7	.	.	PUNCT
aiua-10337	44	1	prisma	prisma	PROPN
aiua-10337	44	2	flow	flow	PROPN
aiua-10337	44	3	chart	chart	PROPN
aiua-10337	44	4	summary	summary	NOUN
aiua-10337	44	5	of	of	ADP
aiua-10337	44	6	the	the	DET
aiua-10337	44	7	study	study	NOUN
aiua-10337	44	8	selection	selection	NOUN
aiua-10337	44	9	procedure	procedure	NOUN
aiua-10337	44	10	.	.	PUNCT
aiua-10337	45	1	491archivio	491archivio	NOUN
aiua-10337	45	2	italiano	italiano	NOUN
aiua-10337	45	3	di	di	X
aiua-10337	45	4	urologia	urologia	PROPN
aiua-10337	45	5	e	e	PROPN
aiua-10337	45	6	andrologia	andrologia	NOUN
aiua-10337	45	7	2021	2021	NUM
aiua-10337	45	8	;	;	PUNCT
aiua-10337	45	9	93	93	NUM
aiua-10337	45	10	,	,	PUNCT
aiua-10337	45	11	4	4	NUM
aiua-10337	45	12	drug	drug	NOUN
aiua-10337	45	13	-	-	PUNCT
aiua-10337	45	14	induced	induce	VERB
aiua-10337	45	15	gynecomastia	gynecomastia	NOUN
aiua-10337	45	16	a	a	DET
aiua-10337	45	17	list	list	NOUN
aiua-10337	45	18	of	of	ADP
aiua-10337	45	19	included	include	VERB
aiua-10337	45	20	studies	study	NOUN
aiua-10337	45	21	(	(	PUNCT
aiua-10337	45	22	supplementary	supplementary	ADJ
aiua-10337	45	23	materials	material	NOUN
aiua-10337	45	24	)	)	PUNCT
aiua-10337	45	25	,	,	PUNCT
aiua-10337	45	26	characteristics	characteristic	NOUN
aiua-10337	45	27	of	of	ADP
aiua-10337	45	28	the	the	DET
aiua-10337	45	29	included	include	VERB
aiua-10337	45	30	trials	trial	NOUN
aiua-10337	45	31	and	and	CCONJ
aiua-10337	45	32	the	the	DET
aiua-10337	45	33	risk	risk	NOUN
aiua-10337	45	34	-	-	PUNCT
aiua-10337	45	35	of	of	ADP
aiua-10337	45	36	-	-	PUNCT
aiua-10337	45	37	bias	bias	NOUN
aiua-10337	45	38	assessment	assessment	NOUN
aiua-10337	45	39	.	.	PUNCT
aiua-10337	46	1	we	we	PRON
aiua-10337	46	2	included	include	VERB
aiua-10337	46	3	the	the	DET
aiua-10337	46	4	most	most	ADV
aiua-10337	46	5	recent	recent	ADJ
aiua-10337	46	6	paper	paper	NOUN
aiua-10337	46	7	reporting	report	VERB
aiua-10337	46	8	the	the	DET
aiua-10337	46	9	cumulative	cumulative	ADJ
aiua-10337	46	10	results	result	NOUN
aiua-10337	46	11	at	at	ADP
aiua-10337	46	12	10	10	NUM
aiua-10337	46	13	-	-	PUNCT
aiua-10337	46	14	year	year	NOUN
aiua-10337	46	15	follow	follow	NOUN
aiua-10337	46	16	-	-	PUNCT
aiua-10337	46	17	up	up	NOUN
aiua-10337	46	18	of	of	ADP
aiua-10337	46	19	three	three	NUM
aiua-10337	46	20	studies	study	NOUN
aiua-10337	46	21	of	of	ADP
aiua-10337	46	22	the	the	DET
aiua-10337	46	23	administration	administration	NOUN
aiua-10337	46	24	of	of	ADP
aiua-10337	46	25	bicalutamide	bicalutamide	NOUN
aiua-10337	46	26	in	in	ADP
aiua-10337	46	27	the	the	DET
aiua-10337	46	28	frame	frame	NOUN
aiua-10337	46	29	of	of	ADP
aiua-10337	46	30	the	the	DET
aiua-10337	46	31	early	early	ADJ
aiua-10337	46	32	prostate	prostate	NOUN
aiua-10337	46	33	cancer	cancer	NOUN
aiua-10337	46	34	(	(	PUNCT
aiua-10337	46	35	epc	epc	PROPN
aiua-10337	46	36	)	)	PUNCT
aiua-10337	46	37	program	program	NOUN
aiua-10337	46	38	which	which	PRON
aiua-10337	46	39	includes	include	VERB
aiua-10337	46	40	three	three	NUM
aiua-10337	46	41	large	large	ADJ
aiua-10337	46	42	,	,	PUNCT
aiua-10337	46	43	randomized	randomize	VERB
aiua-10337	46	44	trials	trial	NOUN
aiua-10337	46	45	conducted	conduct	VERB
aiua-10337	46	46	in	in	ADP
aiua-10337	46	47	the	the	DET
aiua-10337	46	48	united	united	PROPN
aiua-10337	46	49	states	states	PROPN
aiua-10337	46	50	,	,	PUNCT
aiua-10337	46	51	europe	europe	PROPN
aiua-10337	46	52	,	,	PUNCT
aiua-10337	46	53	mexico	mexico	PROPN
aiua-10337	46	54	and	and	CCONJ
aiua-10337	46	55	australia	australia	PROPN
aiua-10337	46	56	(	(	PUNCT
aiua-10337	46	57	4	4	NUM
aiua-10337	46	58	)	)	PUNCT
aiua-10337	46	59	.	.	PUNCT
aiua-10337	47	1	random	random	ADJ
aiua-10337	47	2	-	-	PUNCT
aiua-10337	47	3	effects	effect	NOUN
aiua-10337	47	4	meta	meta	ADJ
aiua-10337	47	5	-	-	PUNCT
aiua-10337	47	6	analysis	analysis	NOUN
aiua-10337	47	7	revealed	reveal	VERB
aiua-10337	47	8	that	that	SCONJ
aiua-10337	47	9	antiandrogen	antiandrogen	NOUN
aiua-10337	47	10	therapy	therapy	NOUN
aiua-10337	47	11	is	be	AUX
aiua-10337	47	12	associated	associate	VERB
aiua-10337	47	13	with	with	ADP
aiua-10337	47	14	significantly	significantly	ADV
aiua-10337	47	15	higher	high	ADJ
aiua-10337	47	16	odds	odd	NOUN
aiua-10337	47	17	of	of	ADP
aiua-10337	47	18	gynecomastia	gynecomastia	NOUN
aiua-10337	47	19	(	(	PUNCT
aiua-10337	47	20	odds	odd	NOUN
aiua-10337	47	21	ratio	ratio	NOUN
aiua-10337	47	22	,	,	PUNCT
aiua-10337	47	23	or	or	CCONJ
aiua-10337	47	24	=	=	NOUN
aiua-10337	47	25	17.38	17.38	NUM
aiua-10337	47	26	,	,	PUNCT
aiua-10337	47	27	95	95	NUM
aiua-10337	47	28	%	%	NOUN
aiua-10337	47	29	ci	ci	NOUN
aiua-10337	47	30	:	:	PUNCT
aiua-10337	47	31	11.26	11.26	NUM
aiua-10337	47	32	to	to	ADP
aiua-10337	47	33	26.82	26.82	NUM
aiua-10337	47	34	;	;	PUNCT
aiua-10337	47	35	6	6	NUM
aiua-10337	47	36	trials	trial	NOUN
aiua-10337	47	37	,	,	PUNCT
aiua-10337	47	38	9599	9599	NUM
aiua-10337	47	39	participants	participant	NOUN
aiua-10337	47	40	)	)	PUNCT
aiua-10337	47	41	compared	compare	VERB
aiua-10337	47	42	with	with	ADP
aiua-10337	47	43	placebo	placebo	NOUN
aiua-10337	47	44	(	(	PUNCT
aiua-10337	47	45	4	4	NUM
aiua-10337	47	46	,	,	PUNCT
aiua-10337	47	47	5	5	NUM
aiua-10337	47	48	,	,	PUNCT
aiua-10337	47	49	7	7	NUM
aiua-10337	47	50	-	-	SYM
aiua-10337	47	51	9	9	NUM
aiua-10337	47	52	)	)	PUNCT
aiua-10337	47	53	or	or	CCONJ
aiua-10337	47	54	no	no	DET
aiua-10337	47	55	treatment	treatment	NOUN
aiua-10337	47	56	(	(	PUNCT
aiua-10337	47	57	6	6	NUM
aiua-10337	47	58	)	)	PUNCT
aiua-10337	47	59	(	(	PUNCT
aiua-10337	47	60	figure	figure	NOUN
aiua-10337	47	61	2a	2a	NUM
aiua-10337	47	62	)	)	PUNCT
aiua-10337	47	63	.	.	PUNCT
aiua-10337	48	1	similarly	similarly	ADV
aiua-10337	48	2	,	,	PUNCT
aiua-10337	48	3	alpha-5	alpha-5	PROPN
aiua-10337	48	4	-	-	PUNCT
aiua-10337	48	5	reductase	reductase	NOUN
aiua-10337	48	6	inhibitors	inhibitor	NOUN
aiua-10337	48	7	(	(	PUNCT
aiua-10337	48	8	or	or	CCONJ
aiua-10337	48	9	=	=	SYM
aiua-10337	48	10	1.77	1.77	NUM
aiua-10337	48	11	,	,	PUNCT
aiua-10337	48	12	95	95	NUM
aiua-10337	48	13	%	%	NOUN
aiua-10337	48	14	ci	ci	NOUN
aiua-10337	48	15	:	:	PUNCT
aiua-10337	48	16	1.53	1.53	NUM
aiua-10337	48	17	to	to	ADP
aiua-10337	48	18	2.06	2.06	NUM
aiua-10337	48	19	;	;	PUNCT
aiua-10337	48	20	6	6	NUM
aiua-10337	48	21	trials	trial	NOUN
aiua-10337	48	22	,	,	PUNCT
aiua-10337	48	23	34860	34860	NUM
aiua-10337	48	24	participants	participant	NOUN
aiua-10337	48	25	)	)	PUNCT
aiua-10337	48	26	and	and	CCONJ
aiua-10337	48	27	spironolactone	spironolactone	NOUN
aiua-10337	48	28	(	(	PUNCT
aiua-10337	48	29	or	or	CCONJ
aiua-10337	48	30	=	=	SYM
aiua-10337	48	31	8.39	8.39	NUM
aiua-10337	48	32	,	,	PUNCT
aiua-10337	48	33	95	95	NUM
aiua-10337	48	34	%	%	NOUN
aiua-10337	48	35	ci	ci	NOUN
aiua-10337	48	36	:	:	PUNCT
aiua-10337	48	37	5.03	5.03	NUM
aiua-10337	48	38	to	to	ADP
aiua-10337	48	39	13.99	13.99	NUM
aiua-10337	48	40	;	;	PUNCT
aiua-10337	48	41	14	14	NUM
aiua-10337	48	42	trials	trial	NOUN
aiua-10337	48	43	,	,	PUNCT
aiua-10337	48	44	3745	3745	NUM
aiua-10337	48	45	participants	participant	NOUN
aiua-10337	48	46	)	)	PUNCT
aiua-10337	48	47	were	be	AUX
aiua-10337	48	48	significantly	significantly	ADV
aiua-10337	48	49	associated	associate	VERB
aiua-10337	48	50	with	with	ADP
aiua-10337	48	51	gynecomastia	gynecomastia	NOUN
aiua-10337	48	52	(	(	PUNCT
aiua-10337	48	53	10	10	NUM
aiua-10337	48	54	-	-	SYM
aiua-10337	48	55	16	16	NUM
aiua-10337	48	56	)	)	PUNCT
aiua-10337	48	57	(	(	PUNCT
aiua-10337	48	58	figures	figure	NOUN
aiua-10337	48	59	2b-2c	2b-2c	NUM
aiua-10337	48	60	)	)	PUNCT
aiua-10337	48	61	.	.	PUNCT
aiua-10337	49	1	it	it	PRON
aiua-10337	49	2	is	be	AUX
aiua-10337	49	3	known	know	VERB
aiua-10337	49	4	that	that	SCONJ
aiua-10337	49	5	dutasteride	dutasteride	NOUN
aiua-10337	49	6	can	can	AUX
aiua-10337	49	7	inhibit	inhibit	VERB
aiua-10337	49	8	the	the	DET
aiua-10337	49	9	activity	activity	NOUN
aiua-10337	49	10	of	of	ADP
aiua-10337	49	11	both	both	DET
aiua-10337	49	12	type	type	NOUN
aiua-10337	49	13	i	i	PRON
aiua-10337	49	14	and	and	CCONJ
aiua-10337	49	15	ii	ii	PROPN
aiua-10337	49	16	reductases	reductase	NOUN
aiua-10337	49	17	,	,	PUNCT
aiua-10337	49	18	whereas	whereas	SCONJ
aiua-10337	49	19	finasteride	finasteride	ADJ
aiua-10337	49	20	is	be	AUX
aiua-10337	49	21	not	not	PART
aiua-10337	49	22	active	active	ADJ
aiua-10337	49	23	on	on	ADP
aiua-10337	49	24	isoform	isoform	PROPN
aiua-10337	49	25	ii	ii	PROPN
aiua-10337	49	26	.	.	PUNCT
aiua-10337	50	1	this	this	PRON
aiua-10337	50	2	might	might	AUX
aiua-10337	50	3	suggest	suggest	VERB
aiua-10337	50	4	an	an	DET
aiua-10337	50	5	increased	increase	VERB
aiua-10337	50	6	risk	risk	NOUN
aiua-10337	50	7	of	of	ADP
aiua-10337	50	8	gynecomastia	gynecomastia	NOUN
aiua-10337	50	9	in	in	ADP
aiua-10337	50	10	patients	patient	NOUN
aiua-10337	50	11	taking	take	VERB
aiua-10337	50	12	dutasteride	dutasteride	ADV
aiua-10337	50	13	.	.	PUNCT
aiua-10337	51	1	however	however	ADV
aiua-10337	51	2	,	,	PUNCT
aiua-10337	51	3	the	the	DET
aiua-10337	51	4	comparison	comparison	NOUN
aiua-10337	51	5	between	between	ADP
aiua-10337	51	6	dutasteride	dutasteride	NOUN
aiua-10337	51	7	and	and	CCONJ
aiua-10337	51	8	finasteride	finasteride	ADV
aiua-10337	51	9	resulted	result	VERB
aiua-10337	51	10	in	in	ADP
aiua-10337	51	11	non	non	ADJ
aiua-10337	51	12	-	-	ADJ
aiua-10337	51	13	significantly	significantly	ADV
aiua-10337	51	14	different	different	ADJ
aiua-10337	51	15	(	(	PUNCT
aiua-10337	51	16	p	p	X
aiua-10337	51	17	=	=	NOUN
aiua-10337	51	18	0.31	0.31	NUM
aiua-10337	51	19	)	)	PUNCT
aiua-10337	51	20	odds	odd	NOUN
aiua-10337	51	21	of	of	ADP
aiua-10337	51	22	gynecomastia	gynecomastia	NOUN
aiua-10337	51	23	(	(	PUNCT
aiua-10337	51	24	or	or	CCONJ
aiua-10337	51	25	=	=	SYM
aiua-10337	51	26	0.66	0.66	NUM
aiua-10337	51	27	,	,	PUNCT
aiua-10337	51	28	95	95	NUM
aiua-10337	51	29	%	%	NOUN
aiua-10337	51	30	ci	ci	NOUN
aiua-10337	51	31	0.30	0.30	NUM
aiua-10337	51	32	-	-	SYM
aiua-10337	51	33	1.48	1.48	NUM
aiua-10337	51	34	;	;	PUNCT
aiua-10337	51	35	2	2	NUM
aiua-10337	51	36	trials	trial	NOUN
aiua-10337	51	37	;	;	PUNCT
aiua-10337	51	38	1697	1697	NUM
aiua-10337	51	39	participants	participant	NOUN
aiua-10337	51	40	)	)	PUNCT
aiua-10337	51	41	(	(	PUNCT
aiua-10337	51	42	forest	forest	NOUN
aiua-10337	51	43	plot	plot	NOUN
aiua-10337	51	44	not	not	PART
aiua-10337	51	45	shown	show	VERB
aiua-10337	51	46	)	)	PUNCT
aiua-10337	51	47	.	.	PUNCT
aiua-10337	52	1	risperidone	risperidone	NOUN
aiua-10337	52	2	was	be	AUX
aiua-10337	52	3	significantly	significantly	ADV
aiua-10337	52	4	(	(	PUNCT
aiua-10337	52	5	p	p	X
aiua-10337	52	6	=	=	NOUN
aiua-10337	52	7	0.02	0.02	NUM
aiua-10337	52	8	)	)	PUNCT
aiua-10337	52	9	associated	associate	VERB
aiua-10337	52	10	with	with	ADP
aiua-10337	52	11	higher	high	ADJ
aiua-10337	52	12	odds	odd	NOUN
aiua-10337	52	13	of	of	ADP
aiua-10337	52	14	gynecomastia	gynecomastia	NOUN
aiua-10337	52	15	compared	compare	VERB
aiua-10337	52	16	to	to	ADP
aiua-10337	52	17	quetiapine	quetiapine	NOUN
aiua-10337	52	18	(	(	PUNCT
aiua-10337	52	19	or	or	CCONJ
aiua-10337	52	20	=	=	SYM
aiua-10337	52	21	4.32	4.32	NUM
aiua-10337	52	22	,	,	PUNCT
aiua-10337	52	23	95	95	NUM
aiua-10337	52	24	%	%	NOUN
aiua-10337	52	25	ci	ci	NOUN
aiua-10337	52	26	:	:	PUNCT
aiua-10337	52	27	1.31	1.31	NUM
aiua-10337	52	28	to	to	ADP
aiua-10337	52	29	14.27	14.27	NUM
aiua-10337	52	30	;	;	PUNCT
aiua-10337	52	31	3	3	NUM
aiua-10337	52	32	trials	trial	NOUN
aiua-10337	52	33	,	,	PUNCT
aiua-10337	52	34	343	343	NUM
aiua-10337	52	35	participants	participant	NOUN
aiua-10337	52	36	)	)	PUNCT
aiua-10337	52	37	(	(	PUNCT
aiua-10337	52	38	figure	figure	NOUN
aiua-10337	52	39	2d	2d	NOUN
aiua-10337	52	40	)	)	PUNCT
aiua-10337	52	41	,	,	PUNCT
aiua-10337	52	42	but	but	CCONJ
aiua-10337	52	43	not	not	PART
aiua-10337	52	44	olanzapine	olanzapine	NOUN
aiua-10337	52	45	(	(	PUNCT
aiua-10337	52	46	forest	forest	NOUN
aiua-10337	52	47	plot	plot	NOUN
aiua-10337	52	48	not	not	PART
aiua-10337	52	49	shown	show	VERB
aiua-10337	52	50	)	)	PUNCT
aiua-10337	52	51	.	.	PUNCT
aiua-10337	53	1	figure	figure	NOUN
aiua-10337	53	2	3	3	NUM
aiua-10337	53	3	shows	show	VERB
aiua-10337	53	4	the	the	DET
aiua-10337	53	5	funnel	funnel	NOUN
aiua-10337	53	6	plots	plot	NOUN
aiua-10337	53	7	for	for	ADP
aiua-10337	53	8	publication	publication	NOUN
aiua-10337	53	9	bias	bias	NOUN
aiua-10337	53	10	.	.	PUNCT
aiua-10337	54	1	no	no	DET
aiua-10337	54	2	significant	significant	ADJ
aiua-10337	54	3	bias	bias	NOUN
aiua-10337	54	4	was	be	AUX
aiua-10337	54	5	identified	identify	VERB
aiua-10337	54	6	by	by	ADP
aiua-10337	54	7	visual	visual	ADJ
aiua-10337	54	8	inspection	inspection	NOUN
aiua-10337	54	9	and	and	CCONJ
aiua-10337	54	10	statistical	statistical	ADJ
aiua-10337	54	11	analysis	analysis	NOUN
aiua-10337	54	12	of	of	ADP
aiua-10337	54	13	funnel	funnel	NOUN
aiua-10337	54	14	plots	plot	NOUN
aiua-10337	54	15	.	.	PUNCT
aiua-10337	55	1	accordingly	accordingly	ADV
aiua-10337	55	2	,	,	PUNCT
aiua-10337	55	3	the	the	DET
aiua-10337	55	4	egger	egger	NOUN
aiua-10337	55	5	’s	’s	PART
aiua-10337	55	6	test	test	NOUN
aiua-10337	55	7	(	(	PUNCT
aiua-10337	55	8	antiandrogens	antiandrogen	NOUN
aiua-10337	55	9	/	/	SYM
aiua-10337	55	10	placebo	placebo	NOUN
aiua-10337	55	11	,	,	PUNCT
aiua-10337	55	12	p	p	NOUN
aiua-10337	55	13	=	=	NOUN
aiua-10337	55	14	0.43	0.43	NUM
aiua-10337	55	15	;	;	PUNCT
aiua-10337	55	16	5	5	NUM
aiua-10337	55	17	-	-	PUNCT
aiua-10337	55	18	alpha	alpha	ADJ
aiua-10337	55	19	reductase	reductase	NOUN
aiua-10337	55	20	inhibitors	inhibitor	NOUN
aiua-10337	55	21	/	/	SYM
aiua-10337	55	22	placebo	placebo	NOUN
aiua-10337	55	23	,	,	PUNCT
aiua-10337	55	24	p	p	NOUN
aiua-10337	55	25	=	=	NOUN
aiua-10337	55	26	0.37	0.37	NUM
aiua-10337	55	27	;	;	PUNCT
aiua-10337	55	28	spironolattone	spironolattone	NOUN
aiua-10337	55	29	/	/	SYM
aiua-10337	55	30	placebo	placebo	NOUN
aiua-10337	55	31	,	,	PUNCT
aiua-10337	55	32	p	p	NOUN
aiua-10337	55	33	=	=	NOUN
aiua-10337	55	34	0.53	0.53	NUM
aiua-10337	55	35	;	;	PUNCT
aiua-10337	55	36	risperidone	risperidone	NOUN
aiua-10337	55	37	/	/	SYM
aiua-10337	55	38	quetiapine	quetiapine	NOUN
aiua-10337	55	39	,	,	PUNCT
aiua-10337	55	40	p	p	X
aiua-10337	55	41	=	=	NOUN
aiua-10337	55	42	0.17	0.17	NUM
aiua-10337	55	43	)	)	PUNCT
aiua-10337	55	44	.	.	PUNCT
aiua-10337	56	1	between	between	ADP
aiua-10337	56	2	-	-	PUNCT
aiua-10337	56	3	study	study	NOUN
aiua-10337	56	4	heterogeneity	heterogeneity	NOUN
aiua-10337	56	5	was	be	AUX
aiua-10337	56	6	moderate	moderate	ADJ
aiua-10337	56	7	for	for	ADP
aiua-10337	56	8	the	the	DET
aiua-10337	56	9	antiandrogens	antiandrogen	NOUN
aiua-10337	56	10	vs.	vs.	ADP
aiua-10337	56	11	controls	control	NOUN
aiua-10337	56	12	comparison	comparison	NOUN
aiua-10337	56	13	(	(	PUNCT
aiua-10337	56	14	i2	i2	NOUN
aiua-10337	56	15	=	=	PUNCT
aiua-10337	56	16	49	49	NUM
aiua-10337	56	17	%	%	NOUN
aiua-10337	56	18	)	)	PUNCT
aiua-10337	56	19	,	,	PUNCT
aiua-10337	56	20	and	and	CCONJ
aiua-10337	56	21	of	of	ADP
aiua-10337	56	22	lesser	less	ADJ
aiua-10337	56	23	importance	importance	NOUN
aiua-10337	56	24	for	for	ADP
aiua-10337	56	25	all	all	DET
aiua-10337	56	26	other	other	ADJ
aiua-10337	56	27	analyses	analysis	NOUN
aiua-10337	56	28	.	.	PUNCT
aiua-10337	57	1	table	table	NOUN
aiua-10337	57	2	1	1	NUM
aiua-10337	57	3	presents	present	VERB
aiua-10337	57	4	the	the	DET
aiua-10337	57	5	summary	summary	NOUN
aiua-10337	57	6	of	of	ADP
aiua-10337	57	7	the	the	DET
aiua-10337	57	8	findings	finding	NOUN
aiua-10337	57	9	of	of	ADP
aiua-10337	57	10	our	our	PRON
aiua-10337	57	11	pooled	pool	VERB
aiua-10337	57	12	analyses	analysis	NOUN
aiua-10337	57	13	,	,	PUNCT
aiua-10337	57	14	also	also	ADV
aiua-10337	57	15	including	include	VERB
aiua-10337	57	16	an	an	DET
aiua-10337	57	17	evaluation	evaluation	NOUN
aiua-10337	57	18	of	of	ADP
aiua-10337	57	19	the	the	DET
aiua-10337	57	20	quality	quality	NOUN
aiua-10337	57	21	of	of	ADP
aiua-10337	57	22	the	the	DET
aiua-10337	57	23	evidence	evidence	NOUN
aiua-10337	57	24	,	,	PUNCT
aiua-10337	57	25	performed	perform	VERB
aiua-10337	57	26	according	accord	VERB
aiua-10337	57	27	to	to	ADP
aiua-10337	57	28	grade	grade	NOUN
aiua-10337	57	29	criteria	criterion	NOUN
aiua-10337	57	30	.	.	PUNCT
aiua-10337	58	1	discussion	discussion	NOUN
aiua-10337	58	2	mechanisms	mechanism	NOUN
aiua-10337	58	3	regulating	regulate	VERB
aiua-10337	58	4	the	the	DET
aiua-10337	58	5	growth	growth	NOUN
aiua-10337	58	6	of	of	ADP
aiua-10337	58	7	the	the	DET
aiua-10337	58	8	breast	breast	NOUN
aiua-10337	58	9	tissue	tissue	NOUN
aiua-10337	58	10	are	be	AUX
aiua-10337	58	11	complex	complex	ADJ
aiua-10337	58	12	and	and	CCONJ
aiua-10337	58	13	not	not	PART
aiua-10337	58	14	fully	fully	ADV
aiua-10337	58	15	elucidated	elucidated	ADJ
aiua-10337	58	16	(	(	PUNCT
aiua-10337	58	17	36	36	NUM
aiua-10337	58	18	,	,	PUNCT
aiua-10337	58	19	37	37	NUM
aiua-10337	58	20	)	)	PUNCT
aiua-10337	58	21	.	.	PUNCT
aiua-10337	59	1	the	the	DET
aiua-10337	59	2	breast	breast	NOUN
aiua-10337	59	3	tissue	tissue	NOUN
aiua-10337	59	4	expresses	express	VERB
aiua-10337	59	5	receptors	receptor	NOUN
aiua-10337	59	6	for	for	ADP
aiua-10337	59	7	both	both	DET
aiua-10337	59	8	estrogens	estrogen	NOUN
aiua-10337	59	9	and	and	CCONJ
aiua-10337	59	10	androgens	androgen	NOUN
aiua-10337	59	11	,	,	PUNCT
aiua-10337	59	12	which	which	PRON
aiua-10337	59	13	can	can	AUX
aiua-10337	59	14	induce	induce	VERB
aiua-10337	59	15	the	the	DET
aiua-10337	59	16	proliferation	proliferation	NOUN
aiua-10337	59	17	or	or	CCONJ
aiua-10337	59	18	inhibition	inhibition	NOUN
aiua-10337	59	19	of	of	ADP
aiua-10337	59	20	the	the	DET
aiua-10337	59	21	growth	growth	NOUN
aiua-10337	59	22	and	and	CCONJ
aiua-10337	59	23	differentiation	differentiation	NOUN
aiua-10337	59	24	of	of	ADP
aiua-10337	59	25	the	the	DET
aiua-10337	59	26	mammary	mammary	ADJ
aiua-10337	59	27	gland	gland	NOUN
aiua-10337	59	28	,	,	PUNCT
aiua-10337	59	29	respectively	respectively	ADV
aiua-10337	59	30	.	.	PUNCT
aiua-10337	60	1	gynecomastia	gynecomastia	PROPN
aiua-10337	60	2	can	can	AUX
aiua-10337	60	3	be	be	AUX
aiua-10337	60	4	caused	cause	VERB
aiua-10337	60	5	either	either	CCONJ
aiua-10337	60	6	by	by	ADP
aiua-10337	60	7	overt	overt	ADJ
aiua-10337	60	8	reduction	reduction	NOUN
aiua-10337	60	9	of	of	ADP
aiua-10337	60	10	circulating	circulate	VERB
aiua-10337	60	11	estrogen	estrogen	NOUN
aiua-10337	60	12	levels	level	NOUN
aiua-10337	60	13	or	or	CCONJ
aiua-10337	60	14	table	table	NOUN
aiua-10337	60	15	1	1	NUM
aiua-10337	60	16	.	.	PUNCT
aiua-10337	61	1	drugs	drug	NOUN
aiua-10337	61	2	compared	compare	VERB
aiua-10337	61	3	with	with	ADP
aiua-10337	61	4	placebo	placebo	NOUN
aiua-10337	61	5	or	or	CCONJ
aiua-10337	61	6	active	active	ADJ
aiua-10337	61	7	comparators	comparator	NOUN
aiua-10337	61	8	endpoint	endpoint	VERB
aiua-10337	61	9	:	:	PUNCT
aiua-10337	61	10	gynecomastia	gynecomastia	NOUN
aiua-10337	61	11	.	.	PUNCT
aiua-10337	62	1	patient	patient	NOUN
aiua-10337	62	2	or	or	CCONJ
aiua-10337	62	3	population	population	NOUN
aiua-10337	62	4	:	:	PUNCT
aiua-10337	63	1	various	various	ADJ
aiua-10337	63	2	.	.	PUNCT
aiua-10337	64	1	settings	setting	NOUN
aiua-10337	64	2	:	:	PUNCT
aiua-10337	64	3	outpatient	outpatient	NOUN
aiua-10337	64	4	.	.	PUNCT
aiua-10337	65	1	intervention	intervention	NOUN
aiua-10337	65	2	:	:	PUNCT
aiua-10337	65	3	antiandrogens	antiandrogen	NOUN
aiua-10337	65	4	,	,	PUNCT
aiua-10337	65	5	5	5	NUM
aiua-10337	65	6	-	-	PUNCT
aiua-10337	65	7	alpha	alpha	ADJ
aiua-10337	65	8	reductase	reductase	NOUN
aiua-10337	65	9	inhibitors	inhibitor	NOUN
aiua-10337	65	10	,	,	PUNCT
aiua-10337	65	11	spironolactone	spironolactone	NOUN
aiua-10337	65	12	,	,	PUNCT
aiua-10337	65	13	risperidone	risperidone	NOUN
aiua-10337	65	14	,	,	PUNCT
aiua-10337	65	15	quetiapine	quetiapine	NOUN
aiua-10337	65	16	.	.	PUNCT
aiua-10337	66	1	comparison	comparison	NOUN
aiua-10337	66	2	:	:	PUNCT
aiua-10337	66	3	placebo	placebo	NOUN
aiua-10337	66	4	or	or	CCONJ
aiua-10337	66	5	active	active	ADJ
aiua-10337	66	6	comparator	comparator	NOUN
aiua-10337	66	7	.	.	PUNCT
aiua-10337	67	1	comparisons	comparison	NOUN
aiua-10337	67	2	illustrative	illustrative	ADJ
aiua-10337	67	3	comparative	comparative	ADJ
aiua-10337	67	4	risks	risk	NOUN
aiua-10337	67	5	(	(	PUNCT
aiua-10337	67	6	95	95	NUM
aiua-10337	67	7	%	%	NOUN
aiua-10337	67	8	ci	ci	NOUN
aiua-10337	67	9	)	)	PUNCT
aiua-10337	67	10	relative	relative	ADJ
aiua-10337	67	11	effect	effect	NOUN
aiua-10337	67	12	no	no	PRON
aiua-10337	67	13	of	of	ADP
aiua-10337	67	14	participants	participant	NOUN
aiua-10337	67	15	quality	quality	NOUN
aiua-10337	67	16	of	of	ADP
aiua-10337	67	17	the	the	DET
aiua-10337	67	18	evidence	evidence	NOUN
aiua-10337	67	19	comments	comment	NOUN
aiua-10337	67	20	assumed	assume	VERB
aiua-10337	67	21	corresponding	correspond	VERB
aiua-10337	67	22	(	(	PUNCT
aiua-10337	67	23	95	95	NUM
aiua-10337	67	24	%	%	NOUN
aiua-10337	67	25	ci	ci	NOUN
aiua-10337	67	26	)	)	PUNCT
aiua-10337	67	27	(	(	PUNCT
aiua-10337	67	28	studies	study	NOUN
aiua-10337	67	29	or	or	CCONJ
aiua-10337	67	30	comparisons	comparison	NOUN
aiua-10337	67	31	)	)	PUNCT
aiua-10337	67	32	(	(	PUNCT
aiua-10337	67	33	grade	grade	NOUN
aiua-10337	67	34	)	)	PUNCT
aiua-10337	67	35	control	control	NOUN
aiua-10337	67	36	risk	risk	NOUN
aiua-10337	67	37	intervention	intervention	NOUN
aiua-10337	67	38	risk	risk	NOUN
aiua-10337	67	39	placebo	placebo	NOUN
aiua-10337	67	40	/	/	SYM
aiua-10337	67	41	active	active	ADJ
aiua-10337	67	42	drug	drug	NOUN
aiua-10337	67	43	intervention	intervention	NOUN
aiua-10337	67	44	antiandrogens	antiandrogen	NOUN
aiua-10337	67	45	vs.	vs.	ADP
aiua-10337	67	46	placebo	placebo	NOUN
aiua-10337	67	47	81.24	81.24	NUM
aiua-10337	67	48	per	per	ADP
aiua-10337	67	49	1000	1000	NUM
aiua-10337	67	50	605.8	605.8	NUM
aiua-10337	67	51	per	per	ADP
aiua-10337	67	52	1000	1000	NUM
aiua-10337	67	53	or	or	CCONJ
aiua-10337	68	1	17.38	17.38	NUM
aiua-10337	68	2	9599	9599	NUM
aiua-10337	68	3	⊕⊕⊕⊝	⊕⊕⊕⊝	NOUN
aiua-10337	68	4	reasons	reason	NOUN
aiua-10337	68	5	for	for	ADP
aiua-10337	68	6	upgrading	upgrade	VERB
aiua-10337	68	7	:	:	PUNCT
aiua-10337	68	8	(	(	PUNCT
aiua-10337	68	9	498.91	498.91	NUM
aiua-10337	68	10	to	to	ADP
aiua-10337	68	11	703.40	703.40	NUM
aiua-10337	68	12	)	)	PUNCT
aiua-10337	68	13	(	(	PUNCT
aiua-10337	68	14	11.26	11.26	NUM
aiua-10337	68	15	to	to	ADP
aiua-10337	68	16	26.82	26.82	NUM
aiua-10337	68	17	)	)	PUNCT
aiua-10337	68	18	(	(	PUNCT
aiua-10337	68	19	6	6	NUM
aiua-10337	68	20	)	)	PUNCT
aiua-10337	68	21	moderate	moderate	ADJ
aiua-10337	68	22	large	large	ADJ
aiua-10337	68	23	magnitude	magnitude	NOUN
aiua-10337	68	24	of	of	ADP
aiua-10337	68	25	effect	effect	NOUN
aiua-10337	68	26	reasons	reason	NOUN
aiua-10337	68	27	for	for	ADP
aiua-10337	68	28	downgrading	downgrading	NOUN
aiua-10337	68	29	:	:	PUNCT
aiua-10337	68	30	indirectness	indirectness	NOUN
aiua-10337	68	31	of	of	ADP
aiua-10337	68	32	evidence	evidence	NOUN
aiua-10337	68	33	risk	risk	NOUN
aiua-10337	68	34	of	of	ADP
aiua-10337	68	35	bias	bias	NOUN
aiua-10337	68	36	5	5	NUM
aiua-10337	68	37	-	-	PUNCT
aiua-10337	68	38	alpha	alpha	NOUN
aiua-10337	68	39	reductase	reductase	NOUN
aiua-10337	68	40	inhibitors	inhibitor	NOUN
aiua-10337	68	41	19.54	19.54	NUM
aiua-10337	68	42	per	per	ADP
aiua-10337	68	43	1000	1000	NUM
aiua-10337	68	44	34.07	34.07	NUM
aiua-10337	68	45	per	per	ADP
aiua-10337	68	46	1000	1000	NUM
aiua-10337	68	47	or	or	CCONJ
aiua-10337	68	48	1.77	1.77	NUM
aiua-10337	68	49	34860	34860	NUM
aiua-10337	68	50	⊕⊕⊝⊝	⊕⊕⊝⊝	NOUN
aiua-10337	68	51	reasons	reason	NOUN
aiua-10337	68	52	for	for	ADP
aiua-10337	68	53	upgrading	upgrade	VERB
aiua-10337	68	54	:	:	PUNCT
aiua-10337	68	55	vs.	vs.	X
aiua-10337	68	56	placebo	placebo	NOUN
aiua-10337	68	57	(	(	PUNCT
aiua-10337	68	58	29.59	29.59	NUM
aiua-10337	68	59	to	to	ADP
aiua-10337	68	60	39.44	39.44	NUM
aiua-10337	68	61	)	)	PUNCT
aiua-10337	68	62	(	(	PUNCT
aiua-10337	68	63	1.53	1.53	NUM
aiua-10337	68	64	to	to	ADP
aiua-10337	68	65	2.06	2.06	NUM
aiua-10337	68	66	)	)	PUNCT
aiua-10337	68	67	(	(	PUNCT
aiua-10337	68	68	7	7	X
aiua-10337	68	69	)	)	PUNCT
aiua-10337	68	70	low	low	ADJ
aiua-10337	68	71	none	none	NOUN
aiua-10337	68	72	reasons	reason	NOUN
aiua-10337	68	73	for	for	ADP
aiua-10337	68	74	downgrading	downgrading	NOUN
aiua-10337	68	75	:	:	PUNCT
aiua-10337	68	76	risk	risk	NOUN
aiua-10337	68	77	of	of	ADP
aiua-10337	68	78	bias	bias	NOUN
aiua-10337	68	79	indirectness	indirectness	ADJ
aiua-10337	68	80	of	of	ADP
aiua-10337	68	81	evidence	evidence	NOUN
aiua-10337	68	82	spironolactone	spironolactone	NOUN
aiua-10337	68	83	vs.	vs.	ADP
aiua-10337	68	84	placebo	placebo	NOUN
aiua-10337	68	85	6.5	6.5	NUM
aiua-10337	68	86	per	per	ADP
aiua-10337	68	87	1000	1000	NUM
aiua-10337	68	88	52.09	52.09	NUM
aiua-10337	68	89	per	per	ADP
aiua-10337	68	90	1000	1000	NUM
aiua-10337	68	91	or	or	CCONJ
aiua-10337	68	92	8.39	8.39	NUM
aiua-10337	68	93	3745	3745	NUM
aiua-10337	68	94	⊕⊕⊕⊝	⊕⊕⊕⊝	PROPN
aiua-10337	68	95	reasons	reason	NOUN
aiua-10337	68	96	for	for	ADP
aiua-10337	68	97	upgrading	upgrade	VERB
aiua-10337	68	98	:	:	PUNCT
aiua-10337	68	99	(	(	PUNCT
aiua-10337	68	100	31.89	31.89	NUM
aiua-10337	68	101	to	to	ADP
aiua-10337	68	102	83.94	83.94	NUM
aiua-10337	68	103	)	)	PUNCT
aiua-10337	68	104	(	(	PUNCT
aiua-10337	68	105	5.03	5.03	NUM
aiua-10337	68	106	to	to	ADP
aiua-10337	68	107	13.99	13.99	NUM
aiua-10337	68	108	)	)	PUNCT
aiua-10337	68	109	(	(	PUNCT
aiua-10337	68	110	14	14	NUM
aiua-10337	68	111	)	)	PUNCT
aiua-10337	68	112	moderate	moderate	ADJ
aiua-10337	68	113	large	large	ADJ
aiua-10337	68	114	magnitude	magnitude	NOUN
aiua-10337	68	115	of	of	ADP
aiua-10337	68	116	effect	effect	NOUN
aiua-10337	68	117	reasons	reason	NOUN
aiua-10337	68	118	for	for	ADP
aiua-10337	68	119	downgrading	downgrading	NOUN
aiua-10337	68	120	:	:	PUNCT
aiua-10337	68	121	risk	risk	NOUN
aiua-10337	68	122	of	of	ADP
aiua-10337	68	123	bias	bias	NOUN
aiua-10337	68	124	indirectness	indirectness	ADJ
aiua-10337	68	125	of	of	ADP
aiua-10337	68	126	evidence	evidence	NOUN
aiua-10337	68	127	risperidone	risperidone	NOUN
aiua-10337	68	128	vs.	vs.	ADP
aiua-10337	68	129	quetiapine	quetiapine	NOUN
aiua-10337	68	130	19.35	19.35	NUM
aiua-10337	68	131	per	per	ADP
aiua-10337	68	132	1000	1000	NUM
aiua-10337	68	133	78.56	78.56	NUM
aiua-10337	68	134	per	per	ADP
aiua-10337	68	135	1000	1000	NUM
aiua-10337	68	136	or	or	CCONJ
aiua-10337	68	137	4.32	4.32	NUM
aiua-10337	68	138	343	343	NUM
aiua-10337	68	139	⊕⊕⊕⊝	⊕⊕⊕⊝	PROPN
aiua-10337	68	140	reasons	reason	NOUN
aiua-10337	68	141	for	for	ADP
aiua-10337	68	142	upgrading	upgrade	VERB
aiua-10337	68	143	:	:	PUNCT
aiua-10337	68	144	(	(	PUNCT
aiua-10337	68	145	25.20	25.20	NUM
aiua-10337	68	146	to	to	ADP
aiua-10337	68	147	219.75	219.75	NUM
aiua-10337	68	148	)	)	PUNCT
aiua-10337	68	149	(	(	PUNCT
aiua-10337	68	150	1.31	1.31	NUM
aiua-10337	68	151	to	to	ADP
aiua-10337	68	152	14.27	14.27	NUM
aiua-10337	68	153	)	)	PUNCT
aiua-10337	68	154	(	(	PUNCT
aiua-10337	68	155	3	3	X
aiua-10337	68	156	)	)	PUNCT
aiua-10337	68	157	moderate	moderate	ADJ
aiua-10337	68	158	large	large	ADJ
aiua-10337	68	159	magnitude	magnitude	NOUN
aiua-10337	68	160	of	of	ADP
aiua-10337	68	161	effect	effect	NOUN
aiua-10337	68	162	reasons	reason	NOUN
aiua-10337	68	163	for	for	ADP
aiua-10337	68	164	downgrading	downgrading	NOUN
aiua-10337	68	165	:	:	PUNCT
aiua-10337	68	166	imprecision	imprecision	NOUN
aiua-10337	68	167	(	(	PUNCT
aiua-10337	68	168	small	small	ADJ
aiua-10337	68	169	sample	sample	NOUN
aiua-10337	68	170	size	size	NOUN
aiua-10337	68	171	,	,	PUNCT
aiua-10337	68	172	wide	wide	ADJ
aiua-10337	68	173	95%ci	95%ci	NUM
aiua-10337	68	174	)	)	PUNCT
aiua-10337	68	175	risk	risk	NOUN
aiua-10337	68	176	of	of	ADP
aiua-10337	68	177	bias	bias	NOUN
aiua-10337	68	178	indirectness	indirectness	ADJ
aiua-10337	68	179	of	of	ADP
aiua-10337	68	180	evidence	evidence	NOUN
aiua-10337	68	181	the	the	DET
aiua-10337	68	182	corresponding	corresponding	ADJ
aiua-10337	68	183	intervention	intervention	NOUN
aiua-10337	68	184	risk	risk	NOUN
aiua-10337	68	185	(	(	PUNCT
aiua-10337	68	186	and	and	CCONJ
aiua-10337	68	187	its	its	PRON
aiua-10337	68	188	95	95	NUM
aiua-10337	68	189	%	%	NOUN
aiua-10337	68	190	confidence	confidence	NOUN
aiua-10337	68	191	interval	interval	NOUN
aiua-10337	68	192	)	)	PUNCT
aiua-10337	68	193	is	be	AUX
aiua-10337	68	194	based	base	VERB
aiua-10337	68	195	on	on	ADP
aiua-10337	68	196	the	the	DET
aiua-10337	68	197	assumed	assume	VERB
aiua-10337	68	198	control	control	NOUN
aiua-10337	68	199	risk	risk	NOUN
aiua-10337	68	200	in	in	ADP
aiua-10337	68	201	the	the	DET
aiua-10337	68	202	comparison	comparison	NOUN
aiua-10337	68	203	group	group	NOUN
aiua-10337	68	204	and	and	CCONJ
aiua-10337	68	205	the	the	DET
aiua-10337	68	206	relative	relative	ADJ
aiua-10337	68	207	effect	effect	NOUN
aiua-10337	68	208	of	of	ADP
aiua-10337	68	209	the	the	DET
aiua-10337	68	210	intervention	intervention	NOUN
aiua-10337	68	211	(	(	PUNCT
aiua-10337	68	212	and	and	CCONJ
aiua-10337	68	213	its	its	PRON
aiua-10337	68	214	95	95	NUM
aiua-10337	68	215	%	%	NOUN
aiua-10337	68	216	ci	ci	NOUN
aiua-10337	68	217	)	)	PUNCT
aiua-10337	68	218	.	.	PUNCT
aiua-10337	69	1	it	it	PRON
aiua-10337	69	2	is	be	AUX
aiua-10337	69	3	calculated	calculate	VERB
aiua-10337	69	4	from	from	ADP
aiua-10337	69	5	the	the	DET
aiua-10337	69	6	odds	odd	NOUN
aiua-10337	69	7	ratio	ratio	NOUN
aiua-10337	69	8	using	use	VERB
aiua-10337	69	9	the	the	DET
aiua-10337	69	10	formula	formula	NOUN
aiua-10337	69	11	:	:	PUNCT
aiua-10337	69	12	or/[1	or/[1	NUM
aiua-10337	69	13	-	-	NOUN
aiua-10337	69	14	acr	acr	NOUN
aiua-10337	69	15	x	x	SYM
aiua-10337	69	16	(	(	PUNCT
aiua-10337	69	17	1	1	NUM
aiua-10337	69	18	-	-	NUM
aiua-10337	69	19	or	or	CCONJ
aiua-10337	69	20	)	)	PUNCT
aiua-10337	69	21	]	]	PUNCT
aiua-10337	69	22	.	.	PUNCT
aiua-10337	70	1	ci	ci	NOUN
aiua-10337	70	2	:	:	PUNCT
aiua-10337	70	3	confidence	confidence	NOUN
aiua-10337	70	4	interval	interval	NOUN
aiua-10337	70	5	.	.	PUNCT
aiua-10337	71	1	or	or	CCONJ
aiua-10337	71	2	:	:	PUNCT
aiua-10337	71	3	odds	odd	NOUN
aiua-10337	71	4	ratio	ratio	NOUN
aiua-10337	71	5	.	.	PUNCT
aiua-10337	72	1	acr	acr	PROPN
aiua-10337	72	2	:	:	PUNCT
aiua-10337	72	3	assumed	assume	VERB
aiua-10337	72	4	control	control	NOUN
aiua-10337	72	5	risk	risk	NOUN
aiua-10337	72	6	.	.	PUNCT
aiua-10337	73	1	grade	grade	NOUN
aiua-10337	73	2	working	working	NOUN
aiua-10337	73	3	group	group	NOUN
aiua-10337	73	4	grades	grade	NOUN
aiua-10337	73	5	of	of	ADP
aiua-10337	73	6	evidence	evidence	NOUN
aiua-10337	73	7	.	.	PUNCT
aiua-10337	74	1	high	high	ADJ
aiua-10337	74	2	quality	quality	NOUN
aiua-10337	74	3	:	:	PUNCT
aiua-10337	74	4	further	further	ADJ
aiua-10337	74	5	research	research	NOUN
aiua-10337	74	6	is	be	AUX
aiua-10337	74	7	very	very	ADV
aiua-10337	74	8	unlikely	unlikely	ADJ
aiua-10337	74	9	to	to	PART
aiua-10337	74	10	change	change	VERB
aiua-10337	74	11	our	our	PRON
aiua-10337	74	12	confidence	confidence	NOUN
aiua-10337	74	13	in	in	ADP
aiua-10337	74	14	the	the	DET
aiua-10337	74	15	estimate	estimate	NOUN
aiua-10337	74	16	of	of	ADP
aiua-10337	74	17	effect	effect	NOUN
aiua-10337	74	18	.	.	PUNCT
aiua-10337	75	1	moderate	moderate	ADJ
aiua-10337	75	2	quality	quality	NOUN
aiua-10337	75	3	:	:	PUNCT
aiua-10337	75	4	further	further	ADJ
aiua-10337	75	5	research	research	NOUN
aiua-10337	75	6	is	be	AUX
aiua-10337	75	7	likely	likely	ADJ
aiua-10337	75	8	to	to	PART
aiua-10337	75	9	have	have	VERB
aiua-10337	75	10	an	an	DET
aiua-10337	75	11	important	important	ADJ
aiua-10337	75	12	impact	impact	NOUN
aiua-10337	75	13	on	on	ADP
aiua-10337	75	14	our	our	PRON
aiua-10337	75	15	confidence	confidence	NOUN
aiua-10337	75	16	in	in	ADP
aiua-10337	75	17	the	the	DET
aiua-10337	75	18	estimate	estimate	NOUN
aiua-10337	75	19	of	of	ADP
aiua-10337	75	20	effect	effect	NOUN
aiua-10337	75	21	and	and	CCONJ
aiua-10337	75	22	may	may	AUX
aiua-10337	75	23	change	change	VERB
aiua-10337	75	24	the	the	DET
aiua-10337	75	25	estimate	estimate	NOUN
aiua-10337	75	26	.	.	PUNCT
aiua-10337	76	1	low	low	ADJ
aiua-10337	76	2	quality	quality	NOUN
aiua-10337	76	3	:	:	PUNCT
aiua-10337	76	4	further	further	ADJ
aiua-10337	76	5	research	research	NOUN
aiua-10337	76	6	is	be	AUX
aiua-10337	76	7	very	very	ADV
aiua-10337	76	8	likely	likely	ADJ
aiua-10337	76	9	to	to	PART
aiua-10337	76	10	have	have	VERB
aiua-10337	76	11	an	an	DET
aiua-10337	76	12	important	important	ADJ
aiua-10337	76	13	impact	impact	NOUN
aiua-10337	76	14	on	on	ADP
aiua-10337	76	15	our	our	PRON
aiua-10337	76	16	confidence	confidence	NOUN
aiua-10337	76	17	in	in	ADP
aiua-10337	76	18	the	the	DET
aiua-10337	76	19	estimate	estimate	NOUN
aiua-10337	76	20	of	of	ADP
aiua-10337	76	21	effect	effect	NOUN
aiua-10337	76	22	and	and	CCONJ
aiua-10337	76	23	is	be	AUX
aiua-10337	76	24	likely	likely	ADJ
aiua-10337	76	25	to	to	PART
aiua-10337	76	26	change	change	VERB
aiua-10337	76	27	the	the	DET
aiua-10337	76	28	estimate	estimate	NOUN
aiua-10337	76	29	.	.	PUNCT
aiua-10337	77	1	very	very	ADV
aiua-10337	77	2	low	low	ADJ
aiua-10337	77	3	quality	quality	NOUN
aiua-10337	77	4	:	:	PUNCT
aiua-10337	77	5	we	we	PRON
aiua-10337	77	6	are	be	AUX
aiua-10337	77	7	very	very	ADV
aiua-10337	77	8	uncertain	uncertain	ADJ
aiua-10337	77	9	about	about	ADP
aiua-10337	77	10	the	the	DET
aiua-10337	77	11	estimate	estimate	NOUN
aiua-10337	77	12	.	.	PUNCT
aiua-10337	78	1	archivio	archivio	NOUN
aiua-10337	78	2	italiano	italiano	PROPN
aiua-10337	78	3	di	di	X
aiua-10337	78	4	urologia	urologia	PROPN
aiua-10337	78	5	e	e	PROPN
aiua-10337	78	6	andrologia	andrologia	NOUN
aiua-10337	78	7	2021	2021	NUM
aiua-10337	78	8	;	;	PUNCT
aiua-10337	78	9	93	93	NUM
aiua-10337	78	10	,	,	PUNCT
aiua-10337	78	11	4	4	NUM
aiua-10337	78	12	a.	a.	NOUN
aiua-10337	78	13	trinchieri	trinchieri	PROPN
aiua-10337	78	14	,	,	PUNCT
aiua-10337	78	15	g.	g.	PROPN
aiua-10337	78	16	perletti	perletti	PROPN
aiua-10337	78	17	,	,	PUNCT
aiua-10337	78	18	v.	v.	ADP
aiua-10337	78	19	magri	magri	NOUN
aiua-10337	78	20	,	,	PUNCT
aiua-10337	78	21	k.	k.	PROPN
aiua-10337	78	22	stamatiou	stamatiou	PROPN
aiua-10337	78	23	,	,	PUNCT
aiua-10337	78	24	m.	m.	NOUN
aiua-10337	78	25	trinchieri	trinchieri	PROPN
aiua-10337	78	26	,	,	PUNCT
aiua-10337	78	27	e.	e.	PROPN
aiua-10337	78	28	montanari	montanari	PROPN
aiua-10337	78	29	492	492	NUM
aiua-10337	78	30	figure	figure	NOUN
aiua-10337	78	31	2	2	NUM
aiua-10337	78	32	.	.	PUNCT
aiua-10337	78	33	pooled	pool	VERB
aiua-10337	78	34	analysis	analysis	NOUN
aiua-10337	78	35	of	of	ADP
aiua-10337	78	36	the	the	DET
aiua-10337	78	37	comparisons	comparison	NOUN
aiua-10337	78	38	between	between	ADP
aiua-10337	78	39	antiandrogens	antiandrogen	NOUN
aiua-10337	78	40	and	and	CCONJ
aiua-10337	78	41	placebo	placebo	NOUN
aiua-10337	78	42	(	(	PUNCT
aiua-10337	78	43	panel	panel	NOUN
aiua-10337	78	44	a	a	X
aiua-10337	78	45	)	)	PUNCT
aiua-10337	78	46	,	,	PUNCT
aiua-10337	78	47	5	5	NUM
aiua-10337	78	48	-	-	PUNCT
aiua-10337	78	49	alpha	alpha	NOUN
aiua-10337	78	50	-	-	PUNCT
aiua-10337	78	51	reductase	reductase	NOUN
aiua-10337	78	52	inhibitors	inhibitor	NOUN
aiua-10337	78	53	and	and	CCONJ
aiua-10337	78	54	placebo	placebo	NOUN
aiua-10337	78	55	(	(	PUNCT
aiua-10337	78	56	panel	panel	NOUN
aiua-10337	78	57	b	b	NOUN
aiua-10337	78	58	)	)	PUNCT
aiua-10337	78	59	,	,	PUNCT
aiua-10337	78	60	spironolactone	spironolactone	NOUN
aiua-10337	78	61	and	and	CCONJ
aiua-10337	78	62	placebo	placebo	NOUN
aiua-10337	78	63	(	(	PUNCT
aiua-10337	78	64	panel	panel	NOUN
aiua-10337	78	65	c	c	NOUN
aiua-10337	78	66	)	)	PUNCT
aiua-10337	78	67	and	and	CCONJ
aiua-10337	78	68	risperidone	risperidone	NOUN
aiua-10337	78	69	and	and	CCONJ
aiua-10337	78	70	quetiapine	quetiapine	NOUN
aiua-10337	78	71	(	(	PUNCT
aiua-10337	78	72	panel	panel	NOUN
aiua-10337	78	73	d	d	NOUN
aiua-10337	78	74	)	)	PUNCT
aiua-10337	78	75	.	.	PUNCT
aiua-10337	79	1	the	the	DET
aiua-10337	79	2	diamonds	diamond	NOUN
aiua-10337	79	3	show	show	VERB
aiua-10337	79	4	the	the	DET
aiua-10337	79	5	position	position	NOUN
aiua-10337	79	6	of	of	ADP
aiua-10337	79	7	the	the	DET
aiua-10337	79	8	pooled	pool	VERB
aiua-10337	79	9	odds	odd	NOUN
aiua-10337	79	10	-	-	PUNCT
aiua-10337	79	11	ratios	ratio	NOUN
aiua-10337	79	12	,	,	PUNCT
aiua-10337	79	13	extending	extend	VERB
aiua-10337	79	14	to	to	ADP
aiua-10337	79	15	the	the	DET
aiua-10337	79	16	95	95	NUM
aiua-10337	79	17	%	%	NOUN
aiua-10337	79	18	confidence	confidence	NOUN
aiua-10337	79	19	interval	interval	NOUN
aiua-10337	79	20	limits	limit	NOUN
aiua-10337	79	21	.	.	PUNCT
aiua-10337	80	1	values	value	NOUN
aiua-10337	80	2	to	to	ADP
aiua-10337	80	3	the	the	DET
aiua-10337	80	4	right	right	NOUN
aiua-10337	80	5	of	of	ADP
aiua-10337	80	6	the	the	DET
aiua-10337	80	7	no	no	DET
aiua-10337	80	8	-	-	PUNCT
aiua-10337	80	9	effect	effect	NOUN
aiua-10337	80	10	vertical	vertical	ADJ
aiua-10337	80	11	axis	axis	NOUN
aiua-10337	80	12	show	show	NOUN
aiua-10337	80	13	increased	increase	VERB
aiua-10337	80	14	odds	odd	NOUN
aiua-10337	80	15	for	for	ADP
aiua-10337	80	16	gynecomastia	gynecomastia	NOUN
aiua-10337	80	17	.	.	PUNCT
aiua-10337	81	1	493archivio	493archivio	PROPN
aiua-10337	81	2	italiano	italiano	NOUN
aiua-10337	81	3	di	di	X
aiua-10337	81	4	urologia	urologia	PROPN
aiua-10337	81	5	e	e	PROPN
aiua-10337	81	6	andrologia	andrologia	NOUN
aiua-10337	81	7	2021	2021	NUM
aiua-10337	81	8	;	;	PUNCT
aiua-10337	81	9	93	93	NUM
aiua-10337	81	10	,	,	PUNCT
aiua-10337	81	11	4	4	NUM
aiua-10337	81	12	drug	drug	NOUN
aiua-10337	81	13	-	-	PUNCT
aiua-10337	81	14	induced	induce	VERB
aiua-10337	81	15	gynecomastia	gynecomastia	NOUN
aiua-10337	81	16	by	by	ADP
aiua-10337	81	17	an	an	DET
aiua-10337	81	18	increase	increase	NOUN
aiua-10337	81	19	of	of	ADP
aiua-10337	81	20	androgen	androgen	NOUN
aiua-10337	81	21	serum	serum	NOUN
aiua-10337	81	22	levels	level	NOUN
aiua-10337	81	23	.	.	PUNCT
aiua-10337	82	1	in	in	ADP
aiua-10337	82	2	addition	addition	NOUN
aiua-10337	82	3	,	,	PUNCT
aiua-10337	82	4	imbalances	imbalance	NOUN
aiua-10337	82	5	between	between	ADP
aiua-10337	82	6	estrogen	estrogen	NOUN
aiua-10337	82	7	and	and	CCONJ
aiua-10337	82	8	androgen	androgen	NOUN
aiua-10337	82	9	levels	level	NOUN
aiua-10337	82	10	,	,	PUNCT
aiua-10337	82	11	which	which	PRON
aiua-10337	82	12	may	may	AUX
aiua-10337	82	13	retain	retain	VERB
aiua-10337	82	14	serum	serum	NOUN
aiua-10337	82	15	concentrations	concentration	NOUN
aiua-10337	82	16	within	within	ADP
aiua-10337	82	17	the	the	DET
aiua-10337	82	18	normal	normal	ADJ
aiua-10337	82	19	ranges	range	NOUN
aiua-10337	82	20	,	,	PUNCT
aiua-10337	82	21	may	may	AUX
aiua-10337	82	22	cause	cause	VERB
aiua-10337	82	23	such	such	ADJ
aiua-10337	82	24	effects	effect	NOUN
aiua-10337	82	25	.	.	PUNCT
aiua-10337	83	1	furthermore	furthermore	ADV
aiua-10337	83	2	,	,	PUNCT
aiua-10337	83	3	activity	activity	NOUN
aiua-10337	83	4	of	of	ADP
aiua-10337	83	5	estrogens	estrogen	NOUN
aiua-10337	83	6	and	and	CCONJ
aiua-10337	83	7	androgens	androgen	NOUN
aiua-10337	83	8	can	can	AUX
aiua-10337	83	9	be	be	AUX
aiua-10337	83	10	locally	locally	ADV
aiua-10337	83	11	modulated	modulate	VERB
aiua-10337	83	12	in	in	ADP
aiua-10337	83	13	the	the	DET
aiua-10337	83	14	breast	breast	NOUN
aiua-10337	83	15	tissue	tissue	NOUN
aiua-10337	83	16	(	(	PUNCT
aiua-10337	83	17	i	i	NOUN
aiua-10337	83	18	)	)	PUNCT
aiua-10337	83	19	by	by	ADP
aiua-10337	83	20	increased	increase	VERB
aiua-10337	83	21	local	local	ADJ
aiua-10337	83	22	production	production	NOUN
aiua-10337	83	23	of	of	ADP
aiua-10337	83	24	estrogens	estrogen	NOUN
aiua-10337	83	25	or	or	CCONJ
aiua-10337	83	26	decreased	decrease	VERB
aiua-10337	83	27	inactivation	inactivation	NOUN
aiua-10337	83	28	of	of	ADP
aiua-10337	83	29	estrogens	estrogen	NOUN
aiua-10337	83	30	,	,	PUNCT
aiua-10337	83	31	(	(	PUNCT
aiua-10337	83	32	ii	ii	NOUN
aiua-10337	83	33	)	)	PUNCT
aiua-10337	83	34	by	by	ADP
aiua-10337	83	35	decreased	decrease	VERB
aiua-10337	83	36	local	local	ADJ
aiua-10337	83	37	production	production	NOUN
aiua-10337	83	38	of	of	ADP
aiua-10337	83	39	androgens	androgen	NOUN
aiua-10337	83	40	,	,	PUNCT
aiua-10337	83	41	or	or	CCONJ
aiua-10337	83	42	(	(	PUNCT
aiua-10337	83	43	iii	iii	NOUN
aiua-10337	83	44	)	)	PUNCT
aiua-10337	83	45	by	by	ADP
aiua-10337	83	46	changes	change	NOUN
aiua-10337	83	47	in	in	ADP
aiua-10337	83	48	the	the	DET
aiua-10337	83	49	number	number	NOUN
aiua-10337	83	50	and/or	and/or	CCONJ
aiua-10337	83	51	activity	activity	NOUN
aiua-10337	83	52	of	of	ADP
aiua-10337	83	53	androgen	androgen	NOUN
aiua-10337	83	54	or	or	CCONJ
aiua-10337	83	55	estrogen	estrogen	NOUN
aiua-10337	83	56	receptors	receptor	NOUN
aiua-10337	83	57	.	.	PUNCT
aiua-10337	84	1	besides	besides	SCONJ
aiua-10337	84	2	androgens	androgen	NOUN
aiua-10337	84	3	and	and	CCONJ
aiua-10337	84	4	estrogens	estrogen	NOUN
aiua-10337	84	5	,	,	PUNCT
aiua-10337	84	6	other	other	ADJ
aiua-10337	84	7	hormones	hormone	NOUN
aiua-10337	84	8	can	can	AUX
aiua-10337	84	9	interfere	interfere	VERB
aiua-10337	84	10	with	with	ADP
aiua-10337	84	11	the	the	DET
aiua-10337	84	12	growth	growth	NOUN
aiua-10337	84	13	of	of	ADP
aiua-10337	84	14	men	man	NOUN
aiua-10337	84	15	’s	’s	PART
aiua-10337	84	16	breast	breast	NOUN
aiua-10337	84	17	tissue	tissue	NOUN
aiua-10337	84	18	,	,	PUNCT
aiua-10337	84	19	which	which	PRON
aiua-10337	84	20	presents	present	VERB
aiua-10337	84	21	receptors	receptor	NOUN
aiua-10337	84	22	for	for	ADP
aiua-10337	84	23	prolactin	prolactin	NOUN
aiua-10337	84	24	,	,	PUNCT
aiua-10337	84	25	progesterone	progesterone	NOUN
aiua-10337	84	26	,	,	PUNCT
aiua-10337	84	27	insulin	insulin	NOUN
aiua-10337	84	28	-	-	PUNCT
aiua-10337	84	29	like	like	ADJ
aiua-10337	84	30	growth	growth	NOUN
aiua-10337	84	31	factor	factor	NOUN
aiua-10337	84	32	(	(	PUNCT
aiua-10337	84	33	igf)-1	igf)-1	ADJ
aiua-10337	84	34	,	,	PUNCT
aiua-10337	84	35	igf-2	igf-2	NOUN
aiua-10337	84	36	,	,	PUNCT
aiua-10337	84	37	luteinizing	luteinize	VERB
aiua-10337	84	38	hormone	hormone	NOUN
aiua-10337	84	39	(	(	PUNCT
aiua-10337	84	40	lh	lh	PROPN
aiua-10337	84	41	)	)	PUNCT
aiua-10337	84	42	and/or	and/or	CCONJ
aiua-10337	84	43	human	human	ADJ
aiua-10337	84	44	chorionic	chorionic	ADJ
aiua-10337	84	45	gonadotropin	gonadotropin	NOUN
aiua-10337	84	46	(	(	PUNCT
aiua-10337	84	47	hcg	hcg	PROPN
aiua-10337	84	48	)	)	PUNCT
aiua-10337	84	49	.	.	PUNCT
aiua-10337	85	1	our	our	PRON
aiua-10337	85	2	metaanalysis	metaanalysis	NOUN
aiua-10337	85	3	confirmed	confirm	VERB
aiua-10337	85	4	that	that	SCONJ
aiua-10337	85	5	antiandrogens	antiandrogen	NOUN
aiua-10337	85	6	are	be	AUX
aiua-10337	85	7	associated	associate	VERB
aiua-10337	85	8	with	with	ADP
aiua-10337	85	9	the	the	DET
aiua-10337	85	10	highest	high	ADJ
aiua-10337	85	11	risk	risk	NOUN
aiua-10337	85	12	of	of	ADP
aiua-10337	85	13	gynecomastia	gynecomastia	NOUN
aiua-10337	85	14	.	.	PUNCT
aiua-10337	86	1	antiandrogens	antiandrogen	NOUN
aiua-10337	86	2	are	be	AUX
aiua-10337	86	3	used	use	VERB
aiua-10337	86	4	for	for	ADP
aiua-10337	86	5	the	the	DET
aiua-10337	86	6	treatment	treatment	NOUN
aiua-10337	86	7	of	of	ADP
aiua-10337	86	8	prostate	prostate	NOUN
aiua-10337	86	9	cancer	cancer	NOUN
aiua-10337	86	10	as	as	ADP
aiua-10337	86	11	monotherapy	monotherapy	NOUN
aiua-10337	86	12	or	or	CCONJ
aiua-10337	86	13	in	in	ADP
aiua-10337	86	14	combination	combination	NOUN
aiua-10337	86	15	with	with	ADP
aiua-10337	86	16	lhrh	lhrh	NOUN
aiua-10337	86	17	inhibitors	inhibitor	NOUN
aiua-10337	86	18	.	.	PUNCT
aiua-10337	87	1	bicalutamide	bicalutamide	VERB
aiua-10337	87	2	is	be	AUX
aiua-10337	87	3	the	the	DET
aiua-10337	87	4	most	most	ADV
aiua-10337	87	5	used	used	ADJ
aiua-10337	87	6	antiandrogen	antiandrogen	NOUN
aiua-10337	87	7	,	,	PUNCT
aiua-10337	87	8	though	though	SCONJ
aiua-10337	87	9	other	other	ADJ
aiua-10337	87	10	agents	agent	NOUN
aiua-10337	87	11	,	,	PUNCT
aiua-10337	87	12	either	either	CCONJ
aiua-10337	87	13	steroidal	steroidal	NOUN
aiua-10337	87	14	like	like	ADP
aiua-10337	87	15	cyproterone	cyproterone	NOUN
aiua-10337	87	16	acetate	acetate	NOUN
aiua-10337	87	17	or	or	CCONJ
aiua-10337	87	18	non	non	ADJ
aiua-10337	87	19	-	-	ADJ
aiua-10337	87	20	steroidal	steroidal	ADJ
aiua-10337	87	21	like	like	ADP
aiua-10337	87	22	flutamide	flutamide	NOUN
aiua-10337	87	23	,	,	PUNCT
aiua-10337	87	24	have	have	AUX
aiua-10337	87	25	also	also	ADV
aiua-10337	87	26	been	be	AUX
aiua-10337	87	27	used	use	VERB
aiua-10337	87	28	for	for	ADP
aiua-10337	87	29	the	the	DET
aiua-10337	87	30	treatment	treatment	NOUN
aiua-10337	87	31	of	of	ADP
aiua-10337	87	32	prostate	prostate	NOUN
aiua-10337	87	33	cancer	cancer	NOUN
aiua-10337	87	34	.	.	PUNCT
aiua-10337	88	1	these	these	DET
aiua-10337	88	2	agents	agent	NOUN
aiua-10337	88	3	bind	bind	VERB
aiua-10337	88	4	to	to	ADP
aiua-10337	88	5	androgen	androgen	NOUN
aiua-10337	88	6	receptors	receptor	NOUN
aiua-10337	88	7	competitively	competitively	ADV
aiua-10337	88	8	,	,	PUNCT
aiua-10337	88	9	thus	thus	ADV
aiua-10337	88	10	inhibiting	inhibit	VERB
aiua-10337	88	11	testosterone	testosterone	NOUN
aiua-10337	88	12	or	or	CCONJ
aiua-10337	88	13	dihydrotestosterone	dihydrotestosterone	NOUN
aiua-10337	88	14	receptor	receptor	NOUN
aiua-10337	88	15	binding	bind	VERB
aiua-10337	88	16	and	and	CCONJ
aiua-10337	88	17	activity	activity	NOUN
aiua-10337	88	18	.	.	PUNCT
aiua-10337	89	1	the	the	DET
aiua-10337	89	2	administration	administration	NOUN
aiua-10337	89	3	of	of	ADP
aiua-10337	89	4	non	non	ADJ
aiua-10337	89	5	-	-	ADJ
aiua-10337	89	6	steroidal	steroidal	ADJ
aiua-10337	89	7	antiandrogens	antiandrogen	NOUN
aiua-10337	89	8	,	,	PUNCT
aiua-10337	89	9	as	as	ADP
aiua-10337	89	10	bicalutamide	bicalutamide	NOUN
aiua-10337	89	11	,	,	PUNCT
aiua-10337	89	12	causes	cause	VERB
aiua-10337	89	13	an	an	DET
aiua-10337	89	14	increase	increase	NOUN
aiua-10337	89	15	in	in	ADP
aiua-10337	89	16	the	the	DET
aiua-10337	89	17	synthesis	synthesis	NOUN
aiua-10337	89	18	of	of	ADP
aiua-10337	89	19	testosterone	testosterone	NOUN
aiua-10337	89	20	due	due	ADP
aiua-10337	89	21	to	to	ADP
aiua-10337	89	22	the	the	DET
aiua-10337	89	23	inhibition	inhibition	NOUN
aiua-10337	89	24	of	of	ADP
aiua-10337	89	25	the	the	DET
aiua-10337	89	26	negative	negative	ADJ
aiua-10337	89	27	feedback	feedback	NOUN
aiua-10337	89	28	of	of	ADP
aiua-10337	89	29	the	the	DET
aiua-10337	89	30	hypothalamic	hypothalamic	ADJ
aiua-10337	89	31	-	-	PUNCT
aiua-10337	89	32	pituitary	pituitary	ADJ
aiua-10337	89	33	-	-	PUNCT
aiua-10337	89	34	gonadal	gonadal	NOUN
aiua-10337	89	35	axis	axis	NOUN
aiua-10337	89	36	.	.	PUNCT
aiua-10337	90	1	increased	increase	VERB
aiua-10337	90	2	availability	availability	NOUN
aiua-10337	90	3	of	of	ADP
aiua-10337	90	4	testosterone	testosterone	NOUN
aiua-10337	90	5	causes	cause	VERB
aiua-10337	90	6	an	an	DET
aiua-10337	90	7	increase	increase	NOUN
aiua-10337	90	8	in	in	ADP
aiua-10337	90	9	estradiol	estradiol	PROPN
aiua-10337	90	10	levels	level	NOUN
aiua-10337	90	11	due	due	ADP
aiua-10337	90	12	to	to	ADP
aiua-10337	90	13	aromatization	aromatization	NOUN
aiua-10337	90	14	of	of	ADP
aiua-10337	90	15	testosterone	testosterone	NOUN
aiua-10337	90	16	.	.	PUNCT
aiua-10337	91	1	these	these	DET
aiua-10337	91	2	hormonal	hormonal	ADJ
aiua-10337	91	3	changes	change	NOUN
aiua-10337	91	4	explain	explain	VERB
aiua-10337	91	5	the	the	DET
aiua-10337	91	6	high	high	ADJ
aiua-10337	91	7	risk	risk	NOUN
aiua-10337	91	8	of	of	ADP
aiua-10337	91	9	gynecomastia	gynecomastia	NOUN
aiua-10337	91	10	,	,	PUNCT
aiua-10337	91	11	which	which	PRON
aiua-10337	91	12	tends	tend	VERB
aiua-10337	91	13	to	to	PART
aiua-10337	91	14	occur	occur	VERB
aiua-10337	91	15	in	in	ADP
aiua-10337	91	16	the	the	DET
aiua-10337	91	17	first	first	ADJ
aiua-10337	91	18	year	year	NOUN
aiua-10337	91	19	of	of	ADP
aiua-10337	91	20	administration	administration	NOUN
aiua-10337	91	21	.	.	PUNCT
aiua-10337	92	1	the	the	DET
aiua-10337	92	2	evaluation	evaluation	NOUN
aiua-10337	92	3	at	at	ADP
aiua-10337	92	4	different	different	ADJ
aiua-10337	92	5	time	time	NOUN
aiua-10337	92	6	intervals	interval	NOUN
aiua-10337	92	7	of	of	ADP
aiua-10337	92	8	the	the	DET
aiua-10337	92	9	rates	rate	NOUN
aiua-10337	92	10	of	of	ADP
aiua-10337	92	11	gynecomastia	gynecomastia	NOUN
aiua-10337	92	12	in	in	ADP
aiua-10337	92	13	patients	patient	NOUN
aiua-10337	92	14	taking	take	VERB
aiua-10337	92	15	bicalutamide	bicalutamide	NOUN
aiua-10337	92	16	included	include	VERB
aiua-10337	92	17	in	in	ADP
aiua-10337	92	18	the	the	DET
aiua-10337	92	19	same	same	ADJ
aiua-10337	92	20	series	series	NOUN
aiua-10337	92	21	of	of	ADP
aiua-10337	92	22	early	early	ADJ
aiua-10337	92	23	prostate	prostate	NOUN
aiua-10337	92	24	cancer	cancer	NOUN
aiua-10337	92	25	program	program	NOUN
aiua-10337	92	26	showed	show	VERB
aiua-10337	92	27	rates	rate	NOUN
aiua-10337	92	28	of	of	ADP
aiua-10337	92	29	gynecomastia	gynecomastia	NOUN
aiua-10337	92	30	and	and	CCONJ
aiua-10337	92	31	breast	breast	NOUN
aiua-10337	92	32	pain	pain	NOUN
aiua-10337	92	33	of	of	ADP
aiua-10337	92	34	64.9	64.9	NUM
aiua-10337	92	35	%	%	NOUN
aiua-10337	92	36	and	and	CCONJ
aiua-10337	92	37	65.1	65.1	NUM
aiua-10337	92	38	%	%	NOUN
aiua-10337	92	39	after	after	ADP
aiua-10337	92	40	a	a	DET
aiua-10337	92	41	median	median	NOUN
aiua-10337	92	42	follow	follow	VERB
aiua-10337	92	43	up	up	ADP
aiua-10337	92	44	of	of	ADP
aiua-10337	92	45	2.6	2.6	NUM
aiua-10337	92	46	years	year	NOUN
aiua-10337	92	47	(	(	PUNCT
aiua-10337	92	48	38	38	NUM
aiua-10337	92	49	)	)	PUNCT
aiua-10337	92	50	,	,	PUNCT
aiua-10337	92	51	66.3	66.3	NUM
aiua-10337	92	52	%	%	NOUN
aiua-10337	92	53	and	and	CCONJ
aiua-10337	92	54	67.9	67.9	NUM
aiua-10337	92	55	%	%	NOUN
aiua-10337	92	56	at	at	ADP
aiua-10337	92	57	5.1	5.1	NUM
aiua-10337	92	58	years	year	NOUN
aiua-10337	92	59	(	(	PUNCT
aiua-10337	92	60	39	39	NUM
aiua-10337	92	61	)	)	PUNCT
aiua-10337	92	62	and	and	CCONJ
aiua-10337	92	63	66.8	66.8	NUM
aiua-10337	92	64	and	and	CCONJ
aiua-10337	92	65	73.7	73.7	NUM
aiua-10337	92	66	%	%	NOUN
aiua-10337	92	67	at	at	ADP
aiua-10337	92	68	9.7	9.7	NUM
aiua-10337	92	69	years	year	NOUN
aiua-10337	92	70	(	(	PUNCT
aiua-10337	92	71	40	40	NUM
aiua-10337	92	72	)	)	PUNCT
aiua-10337	92	73	.	.	PUNCT
aiua-10337	93	1	cyproterone	cyproterone	NOUN
aiua-10337	93	2	acetate	acetate	NOUN
aiua-10337	93	3	is	be	AUX
aiua-10337	93	4	expected	expect	VERB
aiua-10337	93	5	to	to	PART
aiua-10337	93	6	involve	involve	VERB
aiua-10337	93	7	a	a	DET
aiua-10337	93	8	lower	low	ADJ
aiua-10337	93	9	risk	risk	NOUN
aiua-10337	93	10	of	of	ADP
aiua-10337	93	11	gynecomastia	gynecomastia	NOUN
aiua-10337	93	12	because	because	SCONJ
aiua-10337	93	13	,	,	PUNCT
aiua-10337	93	14	in	in	ADP
aiua-10337	93	15	contrast	contrast	NOUN
aiua-10337	93	16	to	to	ADP
aiua-10337	93	17	nonsteroidal	nonsteroidal	NOUN
aiua-10337	93	18	antiandrogens	antiandrogen	NOUN
aiua-10337	93	19	,	,	PUNCT
aiua-10337	93	20	it	it	PRON
aiua-10337	93	21	can	can	AUX
aiua-10337	93	22	decrease	decrease	VERB
aiua-10337	93	23	estrogen	estrogen	NOUN
aiua-10337	93	24	levels	level	NOUN
aiua-10337	93	25	via	via	ADP
aiua-10337	93	26	inhibition	inhibition	NOUN
aiua-10337	93	27	of	of	ADP
aiua-10337	93	28	the	the	DET
aiua-10337	93	29	secretion	secretion	NOUN
aiua-10337	93	30	of	of	ADP
aiua-10337	93	31	gonadotropins	gonadotropin	NOUN
aiua-10337	93	32	.	.	PUNCT
aiua-10337	94	1	however	however	ADV
aiua-10337	94	2	,	,	PUNCT
aiua-10337	94	3	a	a	DET
aiua-10337	94	4	comparative	comparative	ADJ
aiua-10337	94	5	study	study	NOUN
aiua-10337	94	6	by	by	ADP
aiua-10337	94	7	eortc	eortc	ADJ
aiua-10337	94	8	described	describe	VERB
aiua-10337	94	9	similar	similar	ADJ
aiua-10337	94	10	gynecomastia	gynecomastia	NOUN
aiua-10337	94	11	rates	rate	NOUN
aiua-10337	94	12	in	in	ADP
aiua-10337	94	13	patients	patient	NOUN
aiua-10337	94	14	treated	treat	VERB
aiua-10337	94	15	with	with	ADP
aiua-10337	94	16	cyproterone	cyproterone	NOUN
aiua-10337	94	17	or	or	CCONJ
aiua-10337	94	18	flutamide	flutamide	NOUN
aiua-10337	94	19	,	,	PUNCT
aiua-10337	94	20	though	though	SCONJ
aiua-10337	94	21	the	the	DET
aiua-10337	94	22	latter	latter	ADJ
aiua-10337	94	23	was	be	AUX
aiua-10337	94	24	more	more	ADV
aiua-10337	94	25	frequently	frequently	ADV
aiua-10337	94	26	associated	associate	VERB
aiua-10337	94	27	with	with	ADP
aiua-10337	94	28	painful	painful	ADJ
aiua-10337	94	29	gynecomastia	gynecomastia	NOUN
aiua-10337	94	30	(	(	PUNCT
aiua-10337	94	31	35	35	NUM
aiua-10337	94	32	)	)	PUNCT
aiua-10337	94	33	.	.	PUNCT
aiua-10337	95	1	inhibitors	inhibitor	NOUN
aiua-10337	95	2	of	of	ADP
aiua-10337	95	3	5	5	NUM
aiua-10337	95	4	-	-	PUNCT
aiua-10337	95	5	alpha	alpha	NOUN
aiua-10337	95	6	-	-	PUNCT
aiua-10337	95	7	reductase	reductase	NOUN
aiua-10337	95	8	are	be	AUX
aiua-10337	95	9	widely	widely	ADV
aiua-10337	95	10	used	use	VERB
aiua-10337	95	11	for	for	ADP
aiua-10337	95	12	the	the	DET
aiua-10337	95	13	treatment	treatment	NOUN
aiua-10337	95	14	of	of	ADP
aiua-10337	95	15	benign	benign	ADJ
aiua-10337	95	16	prostatic	prostatic	ADJ
aiua-10337	95	17	hyperplasia	hyperplasia	NOUN
aiua-10337	95	18	.	.	PUNCT
aiua-10337	96	1	these	these	DET
aiua-10337	96	2	agents	agent	NOUN
aiua-10337	96	3	inhibit	inhibit	VERB
aiua-10337	96	4	the	the	DET
aiua-10337	96	5	conversion	conversion	NOUN
aiua-10337	96	6	of	of	ADP
aiua-10337	96	7	testosterone	testosterone	NOUN
aiua-10337	96	8	to	to	ADP
aiua-10337	96	9	dihydrotestosterone	dihydrotestosterone	NOUN
aiua-10337	96	10	through	through	ADP
aiua-10337	96	11	inhibition	inhibition	NOUN
aiua-10337	96	12	of	of	ADP
aiua-10337	96	13	the	the	DET
aiua-10337	96	14	5	5	NUM
aiua-10337	96	15	-	-	PUNCT
aiua-10337	96	16	alpha	alpha	NOUN
aiua-10337	96	17	-	-	PUNCT
aiua-10337	96	18	reductase	reductase	NOUN
aiua-10337	96	19	enzyme	enzyme	NOUN
aiua-10337	96	20	,	,	PUNCT
aiua-10337	96	21	thus	thus	ADV
aiua-10337	96	22	reducing	reduce	VERB
aiua-10337	96	23	prostate	prostate	NOUN
aiua-10337	96	24	cell	cell	NOUN
aiua-10337	96	25	proliferation	proliferation	NOUN
aiua-10337	96	26	.	.	PUNCT
aiua-10337	97	1	they	they	PRON
aiua-10337	97	2	also	also	ADV
aiua-10337	97	3	cause	cause	VERB
aiua-10337	97	4	an	an	DET
aiua-10337	97	5	increase	increase	NOUN
aiua-10337	97	6	in	in	ADP
aiua-10337	97	7	the	the	DET
aiua-10337	97	8	synthesis	synthesis	NOUN
aiua-10337	97	9	of	of	ADP
aiua-10337	97	10	testosterone	testosterone	NOUN
aiua-10337	97	11	and	and	CCONJ
aiua-10337	97	12	,	,	PUNCT
aiua-10337	97	13	consequently	consequently	ADV
aiua-10337	97	14	,	,	PUNCT
aiua-10337	97	15	of	of	ADP
aiua-10337	97	16	estrogen	estrogen	NOUN
aiua-10337	97	17	through	through	ADP
aiua-10337	97	18	aromatization	aromatization	NOUN
aiua-10337	97	19	of	of	ADP
aiua-10337	97	20	figure	figure	NOUN
aiua-10337	97	21	3	3	NUM
aiua-10337	97	22	.	.	PUNCT
aiua-10337	97	23	funnel	funnel	NOUN
aiua-10337	97	24	plots	plot	NOUN
aiua-10337	97	25	for	for	ADP
aiua-10337	97	26	publication	publication	NOUN
aiua-10337	97	27	bias	bias	NOUN
aiua-10337	97	28	analysis	analysis	NOUN
aiua-10337	97	29	.	.	PUNCT
aiua-10337	98	1	top	top	ADJ
aiua-10337	98	2	-	-	PUNCT
aiua-10337	98	3	left	left	ADJ
aiua-10337	98	4	,	,	PUNCT
aiua-10337	98	5	antiandrogens	antiandrogen	NOUN
aiua-10337	98	6	vs.	vs.	ADP
aiua-10337	98	7	placebo	placebo	NOUN
aiua-10337	98	8	;	;	PUNCT
aiua-10337	98	9	top	top	ADJ
aiua-10337	98	10	-	-	PUNCT
aiua-10337	98	11	right	right	ADJ
aiua-10337	98	12	,	,	PUNCT
aiua-10337	98	13	5	5	NUM
aiua-10337	98	14	-	-	PUNCT
aiua-10337	98	15	alpha	alpha	NOUN
aiua-10337	98	16	-	-	PUNCT
aiua-10337	98	17	reductase	reductase	NOUN
aiua-10337	98	18	inhibitors	inhibitor	NOUN
aiua-10337	98	19	vs.	vs.	ADP
aiua-10337	98	20	placebo	placebo	NOUN
aiua-10337	98	21	;	;	PUNCT
aiua-10337	98	22	bottom	bottom	ADV
aiua-10337	98	23	-	-	PUNCT
aiua-10337	98	24	left	left	ADJ
aiua-10337	98	25	,	,	PUNCT
aiua-10337	98	26	spironolactone	spironolactone	NOUN
aiua-10337	98	27	vs.	vs.	ADP
aiua-10337	98	28	placebo	placebo	NOUN
aiua-10337	98	29	;	;	PUNCT
aiua-10337	98	30	bottom	bottom	ADJ
aiua-10337	98	31	-	-	PUNCT
aiua-10337	98	32	right	right	NOUN
aiua-10337	98	33	,	,	PUNCT
aiua-10337	98	34	risperidone	risperidone	NOUN
aiua-10337	98	35	vs.	vs.	X
aiua-10337	98	36	quetiapine	quetiapine	NOUN
aiua-10337	98	37	.	.	PUNCT
aiua-10337	99	1	archivio	archivio	NOUN
aiua-10337	99	2	italiano	italiano	PROPN
aiua-10337	99	3	di	di	X
aiua-10337	99	4	urologia	urologia	PROPN
aiua-10337	99	5	e	e	PROPN
aiua-10337	99	6	andrologia	andrologia	NOUN
aiua-10337	99	7	2021	2021	NUM
aiua-10337	99	8	;	;	PUNCT
aiua-10337	99	9	93	93	NUM
aiua-10337	99	10	,	,	PUNCT
aiua-10337	99	11	4	4	NUM
aiua-10337	99	12	a.	a.	NOUN
aiua-10337	99	13	trinchieri	trinchieri	PROPN
aiua-10337	99	14	,	,	PUNCT
aiua-10337	99	15	g.	g.	PROPN
aiua-10337	99	16	perletti	perletti	PROPN
aiua-10337	99	17	,	,	PUNCT
aiua-10337	99	18	v.	v.	ADP
aiua-10337	99	19	magri	magri	NOUN
aiua-10337	99	20	,	,	PUNCT
aiua-10337	99	21	k.	k.	PROPN
aiua-10337	99	22	stamatiou	stamatiou	PROPN
aiua-10337	99	23	,	,	PUNCT
aiua-10337	99	24	m.	m.	NOUN
aiua-10337	99	25	trinchieri	trinchieri	PROPN
aiua-10337	99	26	,	,	PUNCT
aiua-10337	99	27	e.	e.	PROPN
aiua-10337	99	28	montanari	montanari	PROPN
aiua-10337	99	29	494	494	NUM
aiua-10337	99	30	testosterone	testosterone	NOUN
aiua-10337	99	31	.	.	PUNCT
aiua-10337	100	1	spironolactone	spironolactone	NOUN
aiua-10337	100	2	may	may	AUX
aiua-10337	100	3	induce	induce	VERB
aiua-10337	100	4	gynecomastia	gynecomastia	NOUN
aiua-10337	100	5	by	by	ADP
aiua-10337	100	6	several	several	ADJ
aiua-10337	100	7	mechanisms	mechanism	NOUN
aiua-10337	100	8	:	:	PUNCT
aiua-10337	100	9	(	(	PUNCT
aiua-10337	100	10	i	i	NOUN
aiua-10337	100	11	)	)	PUNCT
aiua-10337	100	12	increased	increase	VERB
aiua-10337	100	13	peripheral	peripheral	ADJ
aiua-10337	100	14	conversion	conversion	NOUN
aiua-10337	100	15	of	of	ADP
aiua-10337	100	16	testosterone	testosterone	NOUN
aiua-10337	100	17	to	to	ADP
aiua-10337	100	18	estradiol	estradiol	PROPN
aiua-10337	100	19	,	,	PUNCT
aiua-10337	100	20	(	(	PUNCT
aiua-10337	100	21	ii	ii	NOUN
aiua-10337	100	22	)	)	PUNCT
aiua-10337	100	23	displacement	displacement	NOUN
aiua-10337	100	24	of	of	ADP
aiua-10337	100	25	testosterone	testosterone	NOUN
aiua-10337	100	26	from	from	ADP
aiua-10337	100	27	shbg	shbg	NOUN
aiua-10337	100	28	,	,	PUNCT
aiua-10337	100	29	or	or	CCONJ
aiua-10337	100	30	(	(	PUNCT
aiua-10337	100	31	iii	iii	NOUN
aiua-10337	100	32	)	)	PUNCT
aiua-10337	100	33	binding	bind	VERB
aiua-10337	100	34	to	to	ADP
aiua-10337	100	35	peripheral	peripheral	ADJ
aiua-10337	100	36	androgen	androgen	NOUN
aiua-10337	100	37	receptors	receptor	NOUN
aiua-10337	100	38	to	to	PART
aiua-10337	100	39	competitively	competitively	ADV
aiua-10337	100	40	inhibit	inhibit	VERB
aiua-10337	100	41	testosterone	testosterone	NOUN
aiua-10337	100	42	and	and	CCONJ
aiua-10337	100	43	dihydrotestosterone	dihydrotestosterone	NOUN
aiua-10337	100	44	.	.	PUNCT
aiua-10337	101	1	our	our	PRON
aiua-10337	101	2	meta	meta	ADJ
aiua-10337	101	3	-	-	PUNCT
aiua-10337	101	4	analysis	analysis	NOUN
aiua-10337	101	5	confirms	confirm	VERB
aiua-10337	101	6	that	that	SCONJ
aiua-10337	101	7	spironolactone	spironolactone	NOUN
aiua-10337	101	8	and	and	CCONJ
aiua-10337	101	9	5	5	NUM
aiua-10337	101	10	-	-	PUNCT
aiua-10337	101	11	alpha	alpha	NOUN
aiua-10337	101	12	-	-	PUNCT
aiua-10337	101	13	reductase	reductase	NOUN
aiua-10337	101	14	inhibitors	inhibitor	NOUN
aiua-10337	101	15	are	be	AUX
aiua-10337	101	16	associated	associate	VERB
aiua-10337	101	17	with	with	ADP
aiua-10337	101	18	an	an	DET
aiua-10337	101	19	increased	increase	VERB
aiua-10337	101	20	risk	risk	NOUN
aiua-10337	101	21	of	of	ADP
aiua-10337	101	22	gynecomastia	gynecomastia	NOUN
aiua-10337	101	23	,	,	PUNCT
aiua-10337	101	24	although	although	SCONJ
aiua-10337	101	25	to	to	ADP
aiua-10337	101	26	a	a	DET
aiua-10337	101	27	lesser	less	ADJ
aiua-10337	101	28	extent	extent	NOUN
aiua-10337	101	29	than	than	ADP
aiua-10337	101	30	antiandrogens	antiandrogen	NOUN
aiua-10337	101	31	.	.	PUNCT
aiua-10337	102	1	although	although	SCONJ
aiua-10337	102	2	an	an	DET
aiua-10337	102	3	increased	increase	VERB
aiua-10337	102	4	risk	risk	NOUN
aiua-10337	102	5	of	of	ADP
aiua-10337	102	6	gynecomastia	gynecomastia	NOUN
aiua-10337	102	7	could	could	AUX
aiua-10337	102	8	be	be	AUX
aiua-10337	102	9	expected	expect	VERB
aiua-10337	102	10	in	in	ADP
aiua-10337	102	11	patients	patient	NOUN
aiua-10337	102	12	taking	take	VERB
aiua-10337	102	13	dutasteride	dutasteride	PROPN
aiua-10337	102	14	,	,	PUNCT
aiua-10337	102	15	which	which	PRON
aiua-10337	102	16	inhibits	inhibit	VERB
aiua-10337	102	17	the	the	DET
aiua-10337	102	18	activity	activity	NOUN
aiua-10337	102	19	of	of	ADP
aiua-10337	102	20	both	both	DET
aiua-10337	102	21	type	type	NOUN
aiua-10337	102	22	1	1	NUM
aiua-10337	102	23	and	and	CCONJ
aiua-10337	102	24	2	2	NUM
aiua-10337	102	25	reductases	reductase	NOUN
aiua-10337	102	26	,	,	PUNCT
aiua-10337	102	27	our	our	PRON
aiua-10337	102	28	metaanalysis	metaanalysis	NOUN
aiua-10337	102	29	could	could	AUX
aiua-10337	102	30	not	not	PART
aiua-10337	102	31	demonstrate	demonstrate	VERB
aiua-10337	102	32	a	a	DET
aiua-10337	102	33	different	different	ADJ
aiua-10337	102	34	risk	risk	NOUN
aiua-10337	102	35	of	of	ADP
aiua-10337	102	36	gynecomastia	gynecomastia	NOUN
aiua-10337	102	37	between	between	ADP
aiua-10337	102	38	finasteride	finasteride	NOUN
aiua-10337	102	39	and	and	CCONJ
aiua-10337	102	40	dutasteride	dutasteride	PROPN
aiua-10337	102	41	(	(	PUNCT
aiua-10337	102	42	16	16	NUM
aiua-10337	102	43	)	)	PUNCT
aiua-10337	102	44	.	.	PUNCT
aiua-10337	103	1	statins	statin	NOUN
aiua-10337	103	2	are	be	AUX
aiua-10337	103	3	inhibitors	inhibitor	NOUN
aiua-10337	103	4	of	of	ADP
aiua-10337	103	5	the	the	DET
aiua-10337	103	6	3	3	NUM
aiua-10337	103	7	-	-	PUNCT
aiua-10337	103	8	hydroxy-3	hydroxy-3	NUM
aiua-10337	103	9	-	-	PUNCT
aiua-10337	103	10	methylglutaryl	methylglutaryl	NOUN
aiua-10337	103	11	coenzyme	coenzyme	PROPN
aiua-10337	103	12	a	a	PRON
aiua-10337	103	13	(	(	PUNCT
aiua-10337	103	14	hmg	hmg	NOUN
aiua-10337	103	15	-	-	PUNCT
aiua-10337	103	16	coa	coa	NOUN
aiua-10337	103	17	)	)	PUNCT
aiua-10337	103	18	reductase	reductase	NOUN
aiua-10337	103	19	,	,	PUNCT
aiua-10337	103	20	an	an	DET
aiua-10337	103	21	enzyme	enzyme	NOUN
aiua-10337	103	22	that	that	PRON
aiua-10337	103	23	lowers	lower	VERB
aiua-10337	103	24	the	the	DET
aiua-10337	103	25	serum	serum	NOUN
aiua-10337	103	26	levels	level	NOUN
aiua-10337	103	27	of	of	ADP
aiua-10337	103	28	lipids	lipid	NOUN
aiua-10337	103	29	by	by	ADP
aiua-10337	103	30	blocking	block	VERB
aiua-10337	103	31	the	the	DET
aiua-10337	103	32	pathways	pathway	NOUN
aiua-10337	103	33	of	of	ADP
aiua-10337	103	34	cholesterol	cholesterol	NOUN
aiua-10337	103	35	synthesis	synthesis	NOUN
aiua-10337	103	36	.	.	PUNCT
aiua-10337	104	1	inhibition	inhibition	NOUN
aiua-10337	104	2	of	of	ADP
aiua-10337	104	3	adrenal	adrenal	ADJ
aiua-10337	104	4	and	and	CCONJ
aiua-10337	104	5	gonadal	gonadal	ADJ
aiua-10337	104	6	steroid	steroid	NOUN
aiua-10337	104	7	synthesis	synthesis	NOUN
aiua-10337	104	8	may	may	AUX
aiua-10337	104	9	entail	entail	VERB
aiua-10337	104	10	to	to	ADP
aiua-10337	104	11	an	an	DET
aiua-10337	104	12	increased	increased	ADJ
aiua-10337	104	13	estradiol	estradiol	NOUN
aiua-10337	104	14	:	:	PUNCT
aiua-10337	104	15	testosterone	testosterone	NOUN
aiua-10337	104	16	ratio	ratio	NOUN
aiua-10337	104	17	.	.	PUNCT
aiua-10337	105	1	a	a	DET
aiua-10337	105	2	meta	meta	ADJ
aiua-10337	105	3	-	-	PUNCT
aiua-10337	105	4	analysis	analysis	NOUN
aiua-10337	105	5	showed	show	VERB
aiua-10337	105	6	that	that	SCONJ
aiua-10337	105	7	a	a	DET
aiua-10337	105	8	reduction	reduction	NOUN
aiua-10337	105	9	in	in	ADP
aiua-10337	105	10	circulating	circulate	VERB
aiua-10337	105	11	testosterone	testosterone	NOUN
aiua-10337	105	12	levels	level	NOUN
aiua-10337	105	13	in	in	ADP
aiua-10337	105	14	patients	patient	NOUN
aiua-10337	105	15	receiving	receive	VERB
aiua-10337	105	16	statin	statin	NOUN
aiua-10337	105	17	(	(	PUNCT
aiua-10337	105	18	41	41	NUM
aiua-10337	105	19	)	)	PUNCT
aiua-10337	105	20	.	.	PUNCT
aiua-10337	106	1	our	our	PRON
aiua-10337	106	2	search	search	NOUN
aiua-10337	106	3	did	do	AUX
aiua-10337	106	4	not	not	PART
aiua-10337	106	5	retrieve	retrieve	VERB
aiua-10337	106	6	randomized	randomize	VERB
aiua-10337	106	7	controlled	control	VERB
aiua-10337	106	8	studies	study	NOUN
aiua-10337	106	9	that	that	PRON
aiua-10337	106	10	evaluated	evaluate	VERB
aiua-10337	106	11	the	the	DET
aiua-10337	106	12	possible	possible	ADJ
aiua-10337	106	13	occurrence	occurrence	NOUN
aiua-10337	106	14	of	of	ADP
aiua-10337	106	15	gynecomastia	gynecomastia	NOUN
aiua-10337	106	16	after	after	ADP
aiua-10337	106	17	treatment	treatment	NOUN
aiua-10337	106	18	with	with	ADP
aiua-10337	106	19	statins	statin	NOUN
aiua-10337	106	20	.	.	PUNCT
aiua-10337	107	1	it	it	PRON
aiua-10337	107	2	was	be	AUX
aiua-10337	107	3	therefore	therefore	ADV
aiua-10337	107	4	not	not	PART
aiua-10337	107	5	possible	possible	ADJ
aiua-10337	107	6	to	to	PART
aiua-10337	107	7	investigate	investigate	VERB
aiua-10337	107	8	the	the	DET
aiua-10337	107	9	potential	potential	ADJ
aiua-10337	107	10	risk	risk	NOUN
aiua-10337	107	11	of	of	ADP
aiua-10337	107	12	gynecomastia	gynecomastia	NOUN
aiua-10337	107	13	associated	associate	VERB
aiua-10337	107	14	with	with	ADP
aiua-10337	107	15	the	the	DET
aiua-10337	107	16	use	use	NOUN
aiua-10337	107	17	of	of	ADP
aiua-10337	107	18	these	these	DET
aiua-10337	107	19	drugs	drug	NOUN
aiua-10337	107	20	,	,	PUNCT
aiua-10337	107	21	which	which	PRON
aiua-10337	107	22	was	be	AUX
aiua-10337	107	23	observed	observe	VERB
aiua-10337	107	24	following	follow	VERB
aiua-10337	107	25	treatment	treatment	NOUN
aiua-10337	107	26	with	with	ADP
aiua-10337	107	27	statins	statin	NOUN
aiua-10337	107	28	in	in	ADP
aiua-10337	107	29	a	a	DET
aiua-10337	107	30	case	case	NOUN
aiua-10337	107	31	-	-	PUNCT
aiua-10337	107	32	control	control	NOUN
aiua-10337	107	33	cohort	cohort	NOUN
aiua-10337	107	34	study	study	NOUN
aiua-10337	107	35	(	(	PUNCT
aiua-10337	107	36	42	42	NUM
aiua-10337	107	37	)	)	PUNCT
aiua-10337	107	38	.	.	PUNCT
aiua-10337	108	1	on	on	ADP
aiua-10337	108	2	the	the	DET
aiua-10337	108	3	other	other	ADJ
aiua-10337	108	4	hand	hand	NOUN
aiua-10337	108	5	,	,	PUNCT
aiua-10337	108	6	some	some	DET
aiua-10337	108	7	case	case	NOUN
aiua-10337	108	8	reports	report	NOUN
aiua-10337	108	9	have	have	AUX
aiua-10337	108	10	suggested	suggest	VERB
aiua-10337	108	11	that	that	SCONJ
aiua-10337	108	12	pravastatin	pravastatin	NOUN
aiua-10337	108	13	,	,	PUNCT
aiua-10337	108	14	atorvastatin	atorvastatin	PROPN
aiua-10337	108	15	,	,	PUNCT
aiua-10337	108	16	and	and	CCONJ
aiua-10337	108	17	rosuvastatin	rosuvastatin	NOUN
aiua-10337	108	18	may	may	AUX
aiua-10337	108	19	cause	cause	VERB
aiua-10337	108	20	gynecomastia	gynecomastia	NOUN
aiua-10337	108	21	that	that	PRON
aiua-10337	108	22	can	can	AUX
aiua-10337	108	23	be	be	AUX
aiua-10337	108	24	reverted	revert	VERB
aiua-10337	108	25	by	by	ADP
aiua-10337	108	26	withdrawal	withdrawal	NOUN
aiua-10337	108	27	or	or	CCONJ
aiua-10337	108	28	substitution	substitution	NOUN
aiua-10337	108	29	with	with	ADP
aiua-10337	108	30	a	a	DET
aiua-10337	108	31	less	less	ADV
aiua-10337	108	32	potent	potent	ADJ
aiua-10337	108	33	statin	statin	NOUN
aiua-10337	108	34	.	.	PUNCT
aiua-10337	109	1	in	in	ADP
aiua-10337	109	2	addition	addition	NOUN
aiua-10337	109	3	,	,	PUNCT
aiua-10337	109	4	pharmacovigilance	pharmacovigilance	NOUN
aiua-10337	109	5	studies	study	NOUN
aiua-10337	109	6	include	include	VERB
aiua-10337	109	7	hmg	hmg	NOUN
aiua-10337	109	8	-	-	PUNCT
aiua-10337	109	9	coa	coa	NOUN
aiua-10337	109	10	reductase	reductase	NOUN
aiua-10337	109	11	inhibitors	inhibitor	NOUN
aiua-10337	109	12	among	among	ADP
aiua-10337	109	13	the	the	DET
aiua-10337	109	14	most	most	ADV
aiua-10337	109	15	frequent	frequent	ADJ
aiua-10337	109	16	causes	cause	NOUN
aiua-10337	109	17	of	of	ADP
aiua-10337	109	18	drug	drug	NOUN
aiua-10337	109	19	-	-	PUNCT
aiua-10337	109	20	induced	induce	VERB
aiua-10337	109	21	gynecomastia	gynecomastia	NOUN
aiua-10337	109	22	(	(	PUNCT
aiua-10337	109	23	43	43	NUM
aiua-10337	109	24	,	,	PUNCT
aiua-10337	109	25	44	44	NUM
aiua-10337	109	26	)	)	PUNCT
aiua-10337	109	27	.	.	PUNCT
aiua-10337	110	1	some	some	DET
aiua-10337	110	2	antipsychotics	antipsychotic	NOUN
aiua-10337	110	3	are	be	AUX
aiua-10337	110	4	correlated	correlate	VERB
aiua-10337	110	5	with	with	ADP
aiua-10337	110	6	the	the	DET
aiua-10337	110	7	risk	risk	NOUN
aiua-10337	110	8	of	of	ADP
aiua-10337	110	9	gynecomastia	gynecomastia	NOUN
aiua-10337	110	10	because	because	SCONJ
aiua-10337	110	11	of	of	ADP
aiua-10337	110	12	their	their	PRON
aiua-10337	110	13	effect	effect	NOUN
aiua-10337	110	14	on	on	ADP
aiua-10337	110	15	prolactin	prolactin	ADJ
aiua-10337	110	16	secretion	secretion	NOUN
aiua-10337	110	17	.	.	PUNCT
aiua-10337	111	1	antipsychotics	antipsychotic	NOUN
aiua-10337	111	2	block	block	VERB
aiua-10337	111	3	pituitary	pituitary	ADJ
aiua-10337	111	4	dopamine	dopamine	NOUN
aiua-10337	111	5	d2	d2	NOUN
aiua-10337	111	6	receptors	receptor	NOUN
aiua-10337	111	7	and	and	CCONJ
aiua-10337	111	8	prevent	prevent	VERB
aiua-10337	111	9	their	their	PRON
aiua-10337	111	10	inhibitory	inhibitory	ADJ
aiua-10337	111	11	effect	effect	NOUN
aiua-10337	111	12	on	on	ADP
aiua-10337	111	13	prolactin	prolactin	ADJ
aiua-10337	111	14	secretion	secretion	NOUN
aiua-10337	111	15	.	.	PUNCT
aiua-10337	112	1	hyperprolactinemia	hyperprolactinemia	PROPN
aiua-10337	112	2	may	may	AUX
aiua-10337	112	3	in	in	ADP
aiua-10337	112	4	turn	turn	NOUN
aiua-10337	112	5	decrease	decrease	VERB
aiua-10337	112	6	the	the	DET
aiua-10337	112	7	secretion	secretion	NOUN
aiua-10337	112	8	of	of	ADP
aiua-10337	112	9	gnrh	gnrh	NOUN
aiua-10337	112	10	by	by	ADP
aiua-10337	112	11	hypothalamus	hypothalamus	NOUN
aiua-10337	112	12	feedback	feedback	NOUN
aiua-10337	112	13	causing	cause	VERB
aiua-10337	112	14	hypogonadism	hypogonadism	NOUN
aiua-10337	112	15	.	.	PUNCT
aiua-10337	113	1	nonetheless	nonetheless	ADV
aiua-10337	113	2	,	,	PUNCT
aiua-10337	113	3	prolactin	prolactin	NOUN
aiua-10337	113	4	receptors	receptor	NOUN
aiua-10337	113	5	have	have	AUX
aiua-10337	113	6	also	also	ADV
aiua-10337	113	7	been	be	AUX
aiua-10337	113	8	found	find	VERB
aiua-10337	113	9	in	in	ADP
aiua-10337	113	10	male	male	ADJ
aiua-10337	113	11	breast	breast	NOUN
aiua-10337	113	12	tissue	tissue	NOUN
aiua-10337	113	13	,	,	PUNCT
aiua-10337	113	14	and	and	CCONJ
aiua-10337	113	15	this	this	PRON
aiua-10337	113	16	may	may	AUX
aiua-10337	113	17	also	also	ADV
aiua-10337	113	18	contribute	contribute	VERB
aiua-10337	113	19	to	to	ADP
aiua-10337	113	20	the	the	DET
aiua-10337	113	21	development	development	NOUN
aiua-10337	113	22	of	of	ADP
aiua-10337	113	23	gynecomastia	gynecomastia	NOUN
aiua-10337	113	24	(	(	PUNCT
aiua-10337	113	25	45	45	NUM
aiua-10337	113	26	,	,	PUNCT
aiua-10337	113	27	46	46	NUM
aiua-10337	113	28	)	)	PUNCT
aiua-10337	113	29	.	.	PUNCT
aiua-10337	114	1	most	most	ADJ
aiua-10337	114	2	first	first	ADJ
aiua-10337	114	3	-	-	PUNCT
aiua-10337	114	4	generation	generation	NOUN
aiua-10337	114	5	antipsychotics	antipsychotic	NOUN
aiua-10337	114	6	and	and	CCONJ
aiua-10337	114	7	some	some	DET
aiua-10337	114	8	secondgeneration	secondgeneration	NOUN
aiua-10337	114	9	antipsychotics	antipsychotic	NOUN
aiua-10337	114	10	,	,	PUNCT
aiua-10337	114	11	particularly	particularly	ADV
aiua-10337	114	12	risperidone	risperidone	NOUN
aiua-10337	114	13	and	and	CCONJ
aiua-10337	114	14	paliperidone	paliperidone	NOUN
aiua-10337	114	15	,	,	PUNCT
aiua-10337	114	16	have	have	AUX
aiua-10337	114	17	been	be	AUX
aiua-10337	114	18	found	find	VERB
aiua-10337	114	19	to	to	PART
aiua-10337	114	20	increase	increase	VERB
aiua-10337	114	21	prolactin	prolactin	ADJ
aiua-10337	114	22	levels	level	NOUN
aiua-10337	114	23	,	,	PUNCT
aiua-10337	114	24	with	with	ADP
aiua-10337	114	25	accompanying	accompany	VERB
aiua-10337	114	26	gynecomastia	gynecomastia	NOUN
aiua-10337	114	27	.	.	PUNCT
aiua-10337	115	1	the	the	DET
aiua-10337	115	2	onset	onset	NOUN
aiua-10337	115	3	of	of	ADP
aiua-10337	115	4	gynecomastia	gynecomastia	NOUN
aiua-10337	115	5	after	after	ADP
aiua-10337	115	6	administration	administration	NOUN
aiua-10337	115	7	of	of	ADP
aiua-10337	115	8	risperidone	risperidone	NOUN
aiua-10337	115	9	is	be	AUX
aiua-10337	115	10	more	more	ADV
aiua-10337	115	11	frequently	frequently	ADV
aiua-10337	115	12	associated	associate	VERB
aiua-10337	115	13	with	with	ADP
aiua-10337	115	14	the	the	DET
aiua-10337	115	15	use	use	NOUN
aiua-10337	115	16	of	of	ADP
aiua-10337	115	17	high	high	ADJ
aiua-10337	115	18	doses	dose	NOUN
aiua-10337	115	19	of	of	ADP
aiua-10337	115	20	the	the	DET
aiua-10337	115	21	drug	drug	NOUN
aiua-10337	115	22	and	and	CCONJ
aiua-10337	115	23	can	can	AUX
aiua-10337	115	24	be	be	AUX
aiua-10337	115	25	triggered	trigger	VERB
aiua-10337	115	26	by	by	ADP
aiua-10337	115	27	the	the	DET
aiua-10337	115	28	simultaneous	simultaneous	ADJ
aiua-10337	115	29	administration	administration	NOUN
aiua-10337	115	30	of	of	ADP
aiua-10337	115	31	fluoxetine	fluoxetine	NOUN
aiua-10337	115	32	which	which	PRON
aiua-10337	115	33	can	can	AUX
aiua-10337	115	34	interfere	interfere	VERB
aiua-10337	115	35	in	in	ADP
aiua-10337	115	36	the	the	DET
aiua-10337	115	37	metabolism	metabolism	NOUN
aiua-10337	115	38	of	of	ADP
aiua-10337	115	39	risperidone	risperidone	NOUN
aiua-10337	115	40	by	by	ADP
aiua-10337	115	41	inhibition	inhibition	NOUN
aiua-10337	115	42	of	of	ADP
aiua-10337	115	43	cytochrome	cytochrome	ADJ
aiua-10337	115	44	p450.our	p450.our	NOUN
aiua-10337	115	45	meta	meta	ADJ
aiua-10337	115	46	-	-	PUNCT
aiua-10337	115	47	analysis	analysis	NOUN
aiua-10337	115	48	confirmed	confirm	VERB
aiua-10337	115	49	a	a	DET
aiua-10337	115	50	greater	great	ADJ
aiua-10337	115	51	risk	risk	NOUN
aiua-10337	115	52	of	of	ADP
aiua-10337	115	53	gynecomastia	gynecomastia	NOUN
aiua-10337	115	54	associated	associate	VERB
aiua-10337	115	55	with	with	ADP
aiua-10337	115	56	the	the	DET
aiua-10337	115	57	use	use	NOUN
aiua-10337	115	58	of	of	ADP
aiua-10337	115	59	risperidone	risperidone	NOUN
aiua-10337	115	60	compared	compare	VERB
aiua-10337	115	61	to	to	ADP
aiua-10337	115	62	another	another	DET
aiua-10337	115	63	atypical	atypical	ADJ
aiua-10337	115	64	antipsychotics	antipsychotic	NOUN
aiua-10337	115	65	.	.	PUNCT
aiua-10337	116	1	a	a	DET
aiua-10337	116	2	limitation	limitation	NOUN
aiua-10337	116	3	of	of	ADP
aiua-10337	116	4	the	the	DET
aiua-10337	116	5	meta	meta	ADJ
aiua-10337	116	6	-	-	PUNCT
aiua-10337	116	7	analysis	analysis	NOUN
aiua-10337	116	8	evidence	evidence	NOUN
aiua-10337	116	9	presented	present	VERB
aiua-10337	116	10	in	in	ADP
aiua-10337	116	11	this	this	DET
aiua-10337	116	12	review	review	NOUN
aiua-10337	116	13	is	be	AUX
aiua-10337	116	14	the	the	DET
aiua-10337	116	15	possible	possible	ADJ
aiua-10337	116	16	under	under	NOUN
aiua-10337	116	17	-	-	PUNCT
aiua-10337	116	18	reporting	reporting	NOUN
aiua-10337	116	19	of	of	ADP
aiua-10337	116	20	breast	breast	NOUN
aiua-10337	116	21	enlargement	enlargement	NOUN
aiua-10337	116	22	or	or	CCONJ
aiua-10337	116	23	gynecomastia	gynecomastia	NOUN
aiua-10337	116	24	in	in	ADP
aiua-10337	116	25	the	the	DET
aiua-10337	116	26	female	female	ADJ
aiua-10337	116	27	population	population	NOUN
aiua-10337	116	28	taking	take	VERB
aiua-10337	116	29	spironolactone	spironolactone	NOUN
aiua-10337	116	30	or	or	CCONJ
aiua-10337	116	31	antipsychotics	antipsychotic	NOUN
aiua-10337	116	32	because	because	SCONJ
aiua-10337	116	33	this	this	DET
aiua-10337	116	34	effect	effect	NOUN
aiua-10337	116	35	may	may	AUX
aiua-10337	116	36	be	be	AUX
aiua-10337	116	37	unnoticed	unnoticed	ADJ
aiua-10337	116	38	or	or	CCONJ
aiua-10337	116	39	even	even	ADV
aiua-10337	116	40	considered	consider	VERB
aiua-10337	116	41	a	a	DET
aiua-10337	116	42	beneficial	beneficial	ADJ
aiua-10337	116	43	effect	effect	NOUN
aiua-10337	116	44	by	by	ADP
aiua-10337	116	45	female	female	ADJ
aiua-10337	116	46	patients	patient	NOUN
aiua-10337	116	47	,	,	PUNCT
aiua-10337	116	48	while	while	SCONJ
aiua-10337	116	49	in	in	ADP
aiua-10337	116	50	the	the	DET
aiua-10337	116	51	male	male	ADJ
aiua-10337	116	52	population	population	NOUN
aiua-10337	116	53	it	it	PRON
aiua-10337	116	54	may	may	AUX
aiua-10337	116	55	have	have	AUX
aiua-10337	116	56	been	be	AUX
aiua-10337	116	57	reported	report	VERB
aiua-10337	116	58	with	with	ADP
aiua-10337	116	59	more	more	ADJ
aiua-10337	116	60	attention	attention	NOUN
aiua-10337	116	61	,	,	PUNCT
aiua-10337	116	62	as	as	SCONJ
aiua-10337	116	63	it	it	PRON
aiua-10337	116	64	modifies	modify	VERB
aiua-10337	116	65	the	the	DET
aiua-10337	116	66	body	body	NOUN
aiua-10337	116	67	image	image	NOUN
aiua-10337	116	68	more	more	ADV
aiua-10337	116	69	heavily	heavily	ADV
aiua-10337	116	70	.	.	PUNCT
aiua-10337	117	1	unfortunately	unfortunately	ADV
aiua-10337	117	2	,	,	PUNCT
aiua-10337	117	3	no	no	DET
aiua-10337	117	4	study	study	NOUN
aiua-10337	117	5	has	have	AUX
aiua-10337	117	6	provided	provide	VERB
aiua-10337	117	7	a	a	DET
aiua-10337	117	8	separate	separate	ADJ
aiua-10337	117	9	assessment	assessment	NOUN
aiua-10337	117	10	of	of	ADP
aiua-10337	117	11	the	the	DET
aiua-10337	117	12	appearance	appearance	NOUN
aiua-10337	117	13	of	of	ADP
aiua-10337	117	14	this	this	DET
aiua-10337	117	15	side	side	ADJ
aiua-10337	117	16	effect	effect	NOUN
aiua-10337	117	17	in	in	ADP
aiua-10337	117	18	relation	relation	NOUN
aiua-10337	117	19	to	to	ADP
aiua-10337	117	20	gender	gender	NOUN
aiua-10337	117	21	.	.	PUNCT
aiua-10337	118	1	in	in	ADP
aiua-10337	118	2	populations	population	NOUN
aiua-10337	118	3	of	of	ADP
aiua-10337	118	4	adult	adult	NOUN
aiua-10337	118	5	women	woman	NOUN
aiua-10337	118	6	who	who	PRON
aiua-10337	118	7	took	take	VERB
aiua-10337	118	8	spironolactone	spironolactone	NOUN
aiua-10337	118	9	for	for	ADP
aiua-10337	118	10	the	the	DET
aiua-10337	118	11	treatment	treatment	NOUN
aiua-10337	118	12	of	of	ADP
aiua-10337	118	13	acne	acne	NOUN
aiua-10337	118	14	,	,	PUNCT
aiua-10337	118	15	the	the	DET
aiua-10337	118	16	appearance	appearance	NOUN
aiua-10337	118	17	of	of	ADP
aiua-10337	118	18	breast	breast	NOUN
aiua-10337	118	19	tenderness	tenderness	NOUN
aiua-10337	118	20	and	and	CCONJ
aiua-10337	118	21	breast	breast	NOUN
aiua-10337	118	22	enlargement	enlargement	NOUN
aiua-10337	118	23	was	be	AUX
aiua-10337	118	24	estimated	estimate	VERB
aiua-10337	118	25	at	at	ADP
aiua-10337	118	26	2.5	2.5	NUM
aiua-10337	118	27	%	%	NOUN
aiua-10337	118	28	and	and	CCONJ
aiua-10337	118	29	2.1	2.1	NUM
aiua-10337	118	30	%	%	NOUN
aiua-10337	118	31	respectively	respectively	ADV
aiua-10337	118	32	(	(	PUNCT
aiua-10337	118	33	47	47	NUM
aiua-10337	118	34	,	,	PUNCT
aiua-10337	118	35	48	48	NUM
aiua-10337	118	36	)	)	PUNCT
aiua-10337	118	37	.	.	PUNCT
aiua-10337	119	1	the	the	DET
aiua-10337	119	2	prevalence	prevalence	NOUN
aiua-10337	119	3	of	of	ADP
aiua-10337	119	4	gynecomastia	gynecomastia	NOUN
aiua-10337	119	5	could	could	AUX
aiua-10337	119	6	therefore	therefore	ADV
aiua-10337	119	7	be	be	AUX
aiua-10337	119	8	underestimated	underestimate	VERB
aiua-10337	119	9	in	in	ADP
aiua-10337	119	10	mixed	mixed	ADJ
aiua-10337	119	11	gender	gender	NOUN
aiua-10337	119	12	populations	population	NOUN
aiua-10337	119	13	taking	take	VERB
aiua-10337	119	14	spironolactone	spironolactone	NOUN
aiua-10337	119	15	or	or	CCONJ
aiua-10337	119	16	antipsychotics	antipsychotic	NOUN
aiua-10337	119	17	compared	compare	VERB
aiua-10337	119	18	to	to	ADP
aiua-10337	119	19	male	male	ADJ
aiua-10337	119	20	populations	population	NOUN
aiua-10337	119	21	receiving	receive	VERB
aiua-10337	119	22	antiandrogens	antiandrogen	NOUN
aiua-10337	119	23	or	or	CCONJ
aiua-10337	119	24	alpha	alpha	NOUN
aiua-10337	119	25	-	-	PUNCT
aiua-10337	119	26	reductase	reductase	NOUN
aiua-10337	119	27	inhibitors	inhibitor	NOUN
aiua-10337	119	28	.	.	PUNCT
aiua-10337	120	1	in	in	ADP
aiua-10337	120	2	conclusion	conclusion	NOUN
aiua-10337	120	3	,	,	PUNCT
aiua-10337	120	4	our	our	PRON
aiua-10337	120	5	study	study	NOUN
aiua-10337	120	6	confirmed	confirm	VERB
aiua-10337	120	7	the	the	DET
aiua-10337	120	8	high	high	ADJ
aiua-10337	120	9	risk	risk	NOUN
aiua-10337	120	10	of	of	ADP
aiua-10337	120	11	gynecomastia	gynecomastia	NOUN
aiua-10337	120	12	in	in	ADP
aiua-10337	120	13	patients	patient	NOUN
aiua-10337	120	14	taking	take	VERB
aiua-10337	120	15	antiandrogens	antiandrogen	NOUN
aiua-10337	120	16	for	for	ADP
aiua-10337	120	17	the	the	DET
aiua-10337	120	18	treatment	treatment	NOUN
aiua-10337	120	19	of	of	ADP
aiua-10337	120	20	prostate	prostate	NOUN
aiua-10337	120	21	cancer	cancer	NOUN
aiua-10337	120	22	.	.	PUNCT
aiua-10337	121	1	the	the	DET
aiua-10337	121	2	frequent	frequent	ADJ
aiua-10337	121	3	occurrence	occurrence	NOUN
aiua-10337	121	4	of	of	ADP
aiua-10337	121	5	gynecomastia	gynecomastia	NOUN
aiua-10337	121	6	is	be	AUX
aiua-10337	121	7	a	a	DET
aiua-10337	121	8	limiting	limit	VERB
aiua-10337	121	9	factor	factor	NOUN
aiua-10337	121	10	of	of	ADP
aiua-10337	121	11	this	this	DET
aiua-10337	121	12	treatment	treatment	NOUN
aiua-10337	121	13	and	and	CCONJ
aiua-10337	121	14	ablation	ablation	NOUN
aiua-10337	121	15	of	of	ADP
aiua-10337	121	16	the	the	DET
aiua-10337	121	17	breast	breast	NOUN
aiua-10337	121	18	tissue	tissue	NOUN
aiua-10337	121	19	by	by	ADP
aiua-10337	121	20	ionizing	ionize	VERB
aiua-10337	121	21	radiation	radiation	NOUN
aiua-10337	121	22	is	be	AUX
aiua-10337	121	23	sometimes	sometimes	ADV
aiua-10337	121	24	used	use	VERB
aiua-10337	121	25	to	to	PART
aiua-10337	121	26	prevent	prevent	VERB
aiua-10337	121	27	this	this	DET
aiua-10337	121	28	effect	effect	NOUN
aiua-10337	121	29	.	.	PUNCT
aiua-10337	122	1	the	the	DET
aiua-10337	122	2	risk	risk	NOUN
aiua-10337	122	3	of	of	ADP
aiua-10337	122	4	gynecomastia	gynecomastia	NOUN
aiua-10337	122	5	is	be	AUX
aiua-10337	122	6	lower	low	ADJ
aiua-10337	122	7	but	but	CCONJ
aiua-10337	122	8	significantly	significantly	ADV
aiua-10337	122	9	higher	high	ADJ
aiua-10337	122	10	than	than	ADP
aiua-10337	122	11	placebo	placebo	NOUN
aiua-10337	122	12	in	in	ADP
aiua-10337	122	13	patients	patient	NOUN
aiua-10337	122	14	receiving	receive	VERB
aiua-10337	122	15	spironolactone	spironolactone	NOUN
aiua-10337	122	16	,	,	PUNCT
aiua-10337	122	17	5	5	NUM
aiua-10337	122	18	-	-	PUNCT
aiua-10337	122	19	alpha	alpha	NOUN
aiua-10337	122	20	-	-	PUNCT
aiua-10337	122	21	reductase	reductase	NOUN
aiua-10337	122	22	inhibitors	inhibitor	NOUN
aiua-10337	122	23	,	,	PUNCT
aiua-10337	122	24	and	and	CCONJ
aiua-10337	122	25	atypical	atypical	ADJ
aiua-10337	122	26	antipsychotics	antipsychotic	NOUN
aiua-10337	122	27	(	(	PUNCT
aiua-10337	122	28	risperidone	risperidone	NOUN
aiua-10337	122	29	vs.	vs.	X
aiua-10337	122	30	quetiapine	quetiapine	NOUN
aiua-10337	122	31	)	)	PUNCT
aiua-10337	122	32	.	.	PUNCT
aiua-10337	123	1	the	the	DET
aiua-10337	123	2	potential	potential	ADJ
aiua-10337	123	3	risk	risk	NOUN
aiua-10337	123	4	of	of	ADP
aiua-10337	123	5	gynecomastia	gynecomastia	NOUN
aiua-10337	123	6	associated	associate	VERB
aiua-10337	123	7	with	with	ADP
aiua-10337	123	8	the	the	DET
aiua-10337	123	9	use	use	NOUN
aiua-10337	123	10	of	of	ADP
aiua-10337	123	11	statins	statin	NOUN
aiua-10337	123	12	should	should	AUX
aiua-10337	123	13	be	be	AUX
aiua-10337	123	14	better	well	ADV
aiua-10337	123	15	assessed	assess	VERB
aiua-10337	123	16	with	with	ADP
aiua-10337	123	17	studies	study	NOUN
aiua-10337	123	18	evaluating	evaluate	VERB
aiua-10337	123	19	the	the	DET
aiua-10337	123	20	long	long	ADJ
aiua-10337	123	21	-	-	PUNCT
aiua-10337	123	22	term	term	NOUN
aiua-10337	123	23	side	side	NOUN
aiua-10337	123	24	effects	effect	NOUN
aiua-10337	123	25	of	of	ADP
aiua-10337	123	26	these	these	DET
aiua-10337	123	27	drugs	drug	NOUN
aiua-10337	123	28	.	.	PUNCT
aiua-10337	124	1	in	in	ADP
aiua-10337	124	2	the	the	DET
aiua-10337	124	3	clinical	clinical	ADJ
aiua-10337	124	4	practice	practice	NOUN
aiua-10337	124	5	,	,	PUNCT
aiua-10337	124	6	the	the	DET
aiua-10337	124	7	possible	possible	ADJ
aiua-10337	124	8	additive	additive	ADJ
aiua-10337	124	9	or	or	CCONJ
aiua-10337	124	10	synergic	synergic	ADJ
aiua-10337	124	11	interaction	interaction	NOUN
aiua-10337	124	12	of	of	ADP
aiua-10337	124	13	several	several	ADJ
aiua-10337	124	14	drugs	drug	NOUN
aiua-10337	124	15	predisposing	predispose	VERB
aiua-10337	124	16	to	to	ADP
aiua-10337	124	17	the	the	DET
aiua-10337	124	18	onset	onset	NOUN
aiua-10337	124	19	of	of	ADP
aiua-10337	124	20	gynecomastia	gynecomastia	NOUN
aiua-10337	124	21	must	must	AUX
aiua-10337	124	22	be	be	AUX
aiua-10337	124	23	cautiously	cautiously	ADV
aiua-10337	124	24	considered	consider	VERB
aiua-10337	124	25	.	.	PUNCT
aiua-10337	125	1	references	reference	NOUN
aiua-10337	125	2	1	1	NUM
aiua-10337	125	3	.	.	PUNCT
aiua-10337	125	4	bowman	bowman	PROPN
aiua-10337	125	5	jd	jd	PROPN
aiua-10337	125	6	,	,	PUNCT
aiua-10337	125	7	hyunah	hyunah	PROPN
aiua-10337	125	8	kim	kim	PROPN
aiua-10337	125	9	h	h	PROPN
aiua-10337	125	10	,	,	PUNCT
aiua-10337	125	11	bustamante	bustamante	PROPN
aiua-10337	125	12	jj	jj	PROPN
aiua-10337	125	13	.	.	PROPN
aiua-10337	125	14	drug	drug	NOUN
aiua-10337	125	15	-	-	PUNCT
aiua-10337	125	16	induced	induce	VERB
aiua-10337	125	17	gynecomastia	gynecomastia	NOUN
aiua-10337	125	18	.	.	PUNCT
aiua-10337	126	1	pharmacotherapy	pharmacotherapy	NOUN
aiua-10337	126	2	.	.	PUNCT
aiua-10337	127	1	2012	2012	NUM
aiua-10337	127	2	;	;	PUNCT
aiua-10337	127	3	32:1123	32:1123	NUM
aiua-10337	127	4	-	-	SYM
aiua-10337	127	5	1140	1140	NUM
aiua-10337	127	6	2	2	NUM
aiua-10337	127	7	.	.	PUNCT
aiua-10337	128	1	higgins	higgins	PROPN
aiua-10337	128	2	jp	jp	PROPN
aiua-10337	128	3	,	,	PUNCT
aiua-10337	128	4	altman	altman	PROPN
aiua-10337	128	5	dg	dg	PROPN
aiua-10337	128	6	,	,	PUNCT
aiua-10337	128	7	gøtzsche	gøtzsche	PROPN
aiua-10337	128	8	p	p	PROPN
aiua-10337	128	9	,	,	PUNCT
aiua-10337	128	10	cet	cet	PROPN
aiua-10337	128	11	al.cochrane	al.cochrane	PROPN
aiua-10337	128	12	bias	bias	NOUN
aiua-10337	128	13	methods	method	NOUN
aiua-10337	128	14	group	group	NOUN
aiua-10337	128	15	;	;	PUNCT
aiua-10337	128	16	cochrane	cochrane	PROPN
aiua-10337	128	17	statistical	statistical	ADJ
aiua-10337	128	18	methods	method	NOUN
aiua-10337	128	19	group	group	NOUN
aiua-10337	128	20	.	.	PUNCT
aiua-10337	129	1	the	the	DET
aiua-10337	129	2	cochrane	cochrane	PROPN
aiua-10337	129	3	collaboration	collaboration	NOUN
aiua-10337	129	4	's	's	PART
aiua-10337	129	5	tool	tool	NOUN
aiua-10337	129	6	for	for	ADP
aiua-10337	129	7	assessing	assess	VERB
aiua-10337	129	8	risk	risk	NOUN
aiua-10337	129	9	of	of	ADP
aiua-10337	129	10	bias	bias	NOUN
aiua-10337	129	11	in	in	ADP
aiua-10337	129	12	randomised	randomised	ADJ
aiua-10337	129	13	trials	trial	NOUN
aiua-10337	129	14	.	.	PUNCT
aiua-10337	130	1	bmj	bmj	PROPN
aiua-10337	130	2	.	.	PUNCT
aiua-10337	131	1	2011	2011	NUM
aiua-10337	131	2	;	;	PUNCT
aiua-10337	131	3	343	343	NUM
aiua-10337	131	4	:	:	PUNCT
aiua-10337	131	5	d5928	d5928	ADJ
aiua-10337	131	6	.	.	PUNCT
aiua-10337	132	1	3	3	X
aiua-10337	132	2	.	.	X
aiua-10337	133	1	moher	moher	PROPN
aiua-10337	133	2	d	d	PROPN
aiua-10337	133	3	,	,	PUNCT
aiua-10337	133	4	liberati	liberati	PROPN
aiua-10337	133	5	a	a	PRON
aiua-10337	133	6	,	,	PUNCT
aiua-10337	133	7	tetzlaff	tetzlaff	PROPN
aiua-10337	133	8	j	j	PROPN
aiua-10337	133	9	,	,	PUNCT
aiua-10337	133	10	altman	altman	PROPN
aiua-10337	133	11	dg	dg	PROPN
aiua-10337	133	12	.	.	PUNCT
aiua-10337	134	1	the	the	DET
aiua-10337	134	2	prisma	prisma	PROPN
aiua-10337	134	3	group	group	NOUN
aiua-10337	134	4	(	(	PUNCT
aiua-10337	134	5	2009	2009	NUM
aiua-10337	134	6	)	)	PUNCT
aiua-10337	134	7	preferred	preferred	ADJ
aiua-10337	134	8	reporting	reporting	NOUN
aiua-10337	134	9	items	item	NOUN
aiua-10337	134	10	for	for	ADP
aiua-10337	134	11	systematic	systematic	ADJ
aiua-10337	134	12	reviews	review	NOUN
aiua-10337	134	13	and	and	CCONJ
aiua-10337	134	14	metaanalyses	metaanalyse	NOUN
aiua-10337	134	15	:	:	PUNCT
aiua-10337	134	16	the	the	DET
aiua-10337	134	17	prisma	prisma	PROPN
aiua-10337	134	18	statement	statement	NOUN
aiua-10337	134	19	.	.	PUNCT
aiua-10337	135	1	plos	plos	PROPN
aiua-10337	135	2	med	me	VERB
aiua-10337	135	3	6	6	NUM
aiua-10337	135	4	:	:	PUNCT
aiua-10337	135	5	e1000097	e1000097	PROPN
aiua-10337	135	6	.	.	PROPN
aiua-10337	136	1	4	4	NUM
aiua-10337	136	2	.	.	X
aiua-10337	136	3	iversen	iversen	PROPN
aiua-10337	136	4	p	p	PROPN
aiua-10337	136	5	,	,	PUNCT
aiua-10337	136	6	mcleod	mcleod	PROPN
aiua-10337	136	7	dg	dg	PROPN
aiua-10337	136	8	,	,	PUNCT
aiua-10337	136	9	see	see	VERB
aiua-10337	136	10	wa	wa	PROPN
aiua-10337	136	11	,	,	PUNCT
aiua-10337	136	12	et	et	PROPN
aiua-10337	136	13	al	al	PROPN
aiua-10337	136	14	.	.	PROPN
aiua-10337	136	15	casodex	casodex	PROPN
aiua-10337	136	16	early	early	ADJ
aiua-10337	136	17	prostate	prostate	NOUN
aiua-10337	136	18	cancer	cancer	NOUN
aiua-10337	136	19	trialists	trialist	NOUN
aiua-10337	136	20	'	'	PART
aiua-10337	136	21	group	group	NOUN
aiua-10337	136	22	.	.	PUNCT
aiua-10337	137	1	antiandrogen	antiandrogen	PROPN
aiua-10337	137	2	monotherapy	monotherapy	NOUN
aiua-10337	137	3	in	in	ADP
aiua-10337	137	4	patients	patient	NOUN
aiua-10337	137	5	with	with	ADP
aiua-10337	137	6	localized	localized	ADJ
aiua-10337	137	7	or	or	CCONJ
aiua-10337	137	8	locally	locally	ADV
aiua-10337	137	9	advanced	advanced	ADJ
aiua-10337	137	10	prostate	prostate	NOUN
aiua-10337	137	11	cancer	cancer	NOUN
aiua-10337	137	12	:	:	PUNCT
aiua-10337	137	13	final	final	ADJ
aiua-10337	137	14	results	result	NOUN
aiua-10337	137	15	from	from	ADP
aiua-10337	137	16	the	the	DET
aiua-10337	137	17	bicalutamide	bicalutamide	NOUN
aiua-10337	137	18	early	early	ADJ
aiua-10337	137	19	prostate	prostate	NOUN
aiua-10337	137	20	cancer	cancer	NOUN
aiua-10337	137	21	programme	programme	NOUN
aiua-10337	137	22	at	at	ADP
aiua-10337	137	23	a	a	DET
aiua-10337	137	24	median	median	ADJ
aiua-10337	137	25	followup	followup	NOUN
aiua-10337	137	26	of	of	ADP
aiua-10337	137	27	9.7	9.7	NUM
aiua-10337	137	28	years	year	NOUN
aiua-10337	137	29	.	.	PUNCT
aiua-10337	138	1	bju	bju	NOUN
aiua-10337	138	2	int	int	PROPN
aiua-10337	138	3	.	.	PUNCT
aiua-10337	139	1	2010	2010	NUM
aiua-10337	139	2	;	;	PUNCT
aiua-10337	139	3	105:1074	105:1074	NUM
aiua-10337	139	4	-	-	SYM
aiua-10337	139	5	81	81	NUM
aiua-10337	139	6	.	.	PUNCT
aiua-10337	140	1	5	5	NUM
aiua-10337	140	2	.	.	X
aiua-10337	140	3	shipley	shipley	PROPN
aiua-10337	140	4	wu	wu	PROPN
aiua-10337	140	5	,	,	PUNCT
aiua-10337	140	6	seiferheld	seiferheld	PROPN
aiua-10337	140	7	w	w	PROPN
aiua-10337	140	8	,	,	PUNCT
aiua-10337	140	9	lukka	lukka	PROPN
aiua-10337	140	10	hr	hr	PROPN
aiua-10337	140	11	,	,	PUNCT
aiua-10337	140	12	et	et	PROPN
aiua-10337	140	13	al	al	PROPN
aiua-10337	140	14	.	.	PUNCT
aiua-10337	141	1	nrg	nrg	PROPN
aiua-10337	141	2	oncology	oncology	PROPN
aiua-10337	141	3	rtog	rtog	PROPN
aiua-10337	141	4	.	.	PUNCT
aiua-10337	142	1	radiation	radiation	NOUN
aiua-10337	142	2	with	with	ADP
aiua-10337	142	3	or	or	CCONJ
aiua-10337	142	4	without	without	ADP
aiua-10337	142	5	antiandrogen	antiandrogen	NOUN
aiua-10337	142	6	therapy	therapy	NOUN
aiua-10337	142	7	in	in	ADP
aiua-10337	142	8	recurrent	recurrent	ADJ
aiua-10337	142	9	prostate	prostate	NOUN
aiua-10337	142	10	cancer	cancer	NOUN
aiua-10337	142	11	.	.	PUNCT
aiua-10337	143	1	n	n	PROPN
aiua-10337	143	2	engl	engl	PROPN
aiua-10337	143	3	j	j	PROPN
aiua-10337	143	4	med	med	PROPN
aiua-10337	143	5	.	.	PROPN
aiua-10337	143	6	2017	2017	NUM
aiua-10337	143	7	;	;	PUNCT
aiua-10337	143	8	376:417	376:417	NUM
aiua-10337	143	9	-	-	PUNCT
aiua-10337	143	10	428	428	NUM
aiua-10337	143	11	.	.	NOUN
aiua-10337	144	1	6	6	NUM
aiua-10337	144	2	.	.	X
aiua-10337	144	3	zanardi	zanardi	PROPN
aiua-10337	144	4	s	s	PROPN
aiua-10337	144	5	,	,	PUNCT
aiua-10337	144	6	puntoni	puntoni	PROPN
aiua-10337	144	7	m	m	PROPN
aiua-10337	144	8	,	,	PUNCT
aiua-10337	144	9	maffezzini	maffezzini	PROPN
aiua-10337	144	10	m	m	PROPN
aiua-10337	144	11	,	,	PUNCT
aiua-10337	145	1	et	et	PROPN
aiua-10337	145	2	al	al	PROPN
aiua-10337	145	3	.	.	PROPN
aiua-10337	145	4	phase	phase	PROPN
aiua-10337	145	5	i	i	PROPN
aiua-10337	145	6	-	-	PUNCT
aiua-10337	145	7	ii	ii	PROPN
aiua-10337	145	8	trial	trial	NOUN
aiua-10337	145	9	of	of	ADP
aiua-10337	145	10	weekly	weekly	ADJ
aiua-10337	145	11	bicalutamide	bicalutamide	NOUN
aiua-10337	145	12	in	in	ADP
aiua-10337	145	13	men	man	NOUN
aiua-10337	145	14	with	with	ADP
aiua-10337	145	15	elevated	elevated	ADJ
aiua-10337	145	16	prostate	prostate	NOUN
aiua-10337	145	17	-	-	PUNCT
aiua-10337	145	18	specific	specific	ADJ
aiua-10337	145	19	antigen	antigen	NOUN
aiua-10337	145	20	and	and	CCONJ
aiua-10337	145	21	negative	negative	ADJ
aiua-10337	145	22	prostate	prostate	NOUN
aiua-10337	145	23	biopsies	biopsy	NOUN
aiua-10337	145	24	.	.	PUNCT
aiua-10337	146	1	cancer	cancer	NOUN
aiua-10337	146	2	prev	prev	PROPN
aiua-10337	146	3	res	res	PROPN
aiua-10337	146	4	(	(	PUNCT
aiua-10337	146	5	phila	phila	PROPN
aiua-10337	146	6	)	)	PUNCT
aiua-10337	146	7	.	.	PUNCT
aiua-10337	147	1	2009	2009	NUM
aiua-10337	147	2	;	;	PUNCT
aiua-10337	147	3	2:377	2:377	NUM
aiua-10337	147	4	-	-	SYM
aiua-10337	147	5	84	84	NUM
aiua-10337	147	6	.	.	PUNCT
aiua-10337	148	1	7	7	X
aiua-10337	148	2	.	.	PUNCT
aiua-10337	148	3	alberts	alberts	PROPN
aiua-10337	148	4	sr	sr	PROPN
aiua-10337	148	5	,	,	PUNCT
aiua-10337	148	6	novotny	novotny	PROPN
aiua-10337	148	7	pj	pj	PROPN
aiua-10337	148	8	,	,	PUNCT
aiua-10337	148	9	sloan	sloan	PROPN
aiua-10337	148	10	ja	ja	PROPN
aiua-10337	148	11	,	,	PUNCT
aiua-10337	148	12	et	et	PROPN
aiua-10337	148	13	al	al	PROPN
aiua-10337	148	14	.	.	PROPN
aiua-10337	148	15	flutamide	flutamide	PROPN
aiua-10337	148	16	in	in	ADP
aiua-10337	148	17	men	man	NOUN
aiua-10337	148	18	with	with	ADP
aiua-10337	148	19	prostatic	prostatic	ADJ
aiua-10337	148	20	intraepithelial	intraepithelial	ADJ
aiua-10337	148	21	neoplasia	neoplasia	NOUN
aiua-10337	148	22	:	:	PUNCT
aiua-10337	148	23	a	a	DET
aiua-10337	148	24	randomized	randomized	ADJ
aiua-10337	148	25	,	,	PUNCT
aiua-10337	148	26	placebo	placebo	NOUN
aiua-10337	148	27	-	-	PUNCT
aiua-10337	148	28	controlled	control	VERB
aiua-10337	148	29	chemoprevention	chemoprevention	NOUN
aiua-10337	148	30	trial	trial	NOUN
aiua-10337	148	31	american	american	PROPN
aiua-10337	148	32	journal	journal	PROPN
aiua-10337	148	33	of	of	ADP
aiua-10337	148	34	therapeutics	therapeutic	NOUN
aiua-10337	148	35	.	.	PUNCT
aiua-10337	149	1	2006	2006	NUM
aiua-10337	149	2	;	;	PUNCT
aiua-10337	149	3	13:4(291	13:4(291	NUM
aiua-10337	149	4	-	-	SYM
aiua-10337	149	5	297	297	NUM
aiua-10337	149	6	)	)	PUNCT
aiua-10337	149	7	.	.	PUNCT
aiua-10337	150	1	8	8	X
aiua-10337	150	2	.	.	PUNCT
aiua-10337	150	3	narayan	narayan	PROPN
aiua-10337	151	1	p	p	X
aiua-10337	151	2	,	,	PUNCT
aiua-10337	151	3	trachtenberg	trachtenberg	PROPN
aiua-10337	151	4	j	j	PROPN
aiua-10337	151	5	,	,	PUNCT
aiua-10337	151	6	lepor	lepor	ADJ
aiua-10337	151	7	h	h	NOUN
aiua-10337	151	8	,	,	PUNCT
aiua-10337	151	9	et	et	PROPN
aiua-10337	151	10	al	al	PROPN
aiua-10337	151	11	.	.	PUNCT
aiua-10337	152	1	a	a	DET
aiua-10337	152	2	dose	dose	NOUN
aiua-10337	152	3	-	-	PUNCT
aiua-10337	152	4	response	response	NOUN
aiua-10337	152	5	study	study	NOUN
aiua-10337	152	6	of	of	ADP
aiua-10337	152	7	the	the	DET
aiua-10337	152	8	effect	effect	NOUN
aiua-10337	152	9	of	of	ADP
aiua-10337	152	10	flutamide	flutamide	NOUN
aiua-10337	152	11	on	on	ADP
aiua-10337	152	12	benign	benign	ADJ
aiua-10337	152	13	prostatic	prostatic	ADJ
aiua-10337	152	14	hyperplasia	hyperplasia	NOUN
aiua-10337	152	15	:	:	PUNCT
aiua-10337	152	16	results	result	NOUN
aiua-10337	152	17	of	of	ADP
aiua-10337	152	18	a	a	DET
aiua-10337	152	19	multicenter	multicenter	ADJ
aiua-10337	152	20	study	study	NOUN
aiua-10337	152	21	.	.	PUNCT
aiua-10337	153	1	urology	urology	NOUN
aiua-10337	153	2	.	.	PUNCT
aiua-10337	154	1	1996	1996	NUM
aiua-10337	154	2	;	;	PUNCT
aiua-10337	155	1	47:497	47:497	NUM
aiua-10337	155	2	-	-	SYM
aiua-10337	155	3	504	504	NUM
aiua-10337	155	4	.	.	PUNCT
aiua-10337	156	1	9	9	NUM
aiua-10337	156	2	.	.	PUNCT
aiua-10337	156	3	berger	berger	PROPN
aiua-10337	156	4	bm	bm	PROPN
aiua-10337	156	5	,	,	PUNCT
aiua-10337	156	6	naadimuthu	naadimuthu	ADV
aiua-10337	156	7	a	a	PROPN
aiua-10337	156	8	,	,	PUNCT
aiua-10337	156	9	boddy	boddy	PROPN
aiua-10337	156	10	a	a	PROPN
aiua-10337	156	11	,	,	PUNCT
aiua-10337	156	12	et	et	PROPN
aiua-10337	156	13	al	al	PROPN
aiua-10337	156	14	.	.	PUNCT
aiua-10337	157	1	the	the	DET
aiua-10337	157	2	effect	effect	NOUN
aiua-10337	157	3	of	of	ADP
aiua-10337	157	4	zanoterone	zanoterone	NOUN
aiua-10337	157	5	,	,	PUNCT
aiua-10337	157	6	a	a	DET
aiua-10337	157	7	steroidal	steroidal	NOUN
aiua-10337	157	8	androgen	androgen	NOUN
aiua-10337	157	9	receptor	receptor	NOUN
aiua-10337	157	10	antagonist	antagonist	NOUN
aiua-10337	157	11	,	,	PUNCT
aiua-10337	157	12	in	in	ADP
aiua-10337	157	13	men	man	NOUN
aiua-10337	157	14	with	with	ADP
aiua-10337	157	15	benign	benign	ADJ
aiua-10337	157	16	prostatic	prostatic	ADJ
aiua-10337	157	17	hyperplasia	hyperplasia	NOUN
aiua-10337	157	18	.	.	PUNCT
aiua-10337	158	1	the	the	DET
aiua-10337	158	2	zanoterone	zanoterone	NOUN
aiua-10337	158	3	study	study	NOUN
aiua-10337	158	4	group	group	NOUN
aiua-10337	158	5	.	.	PUNCT
aiua-10337	159	1	j	j	PROPN
aiua-10337	159	2	urol	urol	PROPN
aiua-10337	159	3	.	.	PUNCT
aiua-10337	159	4	1995	1995	NUM
aiua-10337	159	5	;	;	PUNCT
aiua-10337	159	6	154:1060	154:1060	NUM
aiua-10337	159	7	-	-	SYM
aiua-10337	159	8	4	4	NUM
aiua-10337	159	9	.	.	PUNCT
aiua-10337	160	1	495archivio	495archivio	NOUN
aiua-10337	160	2	italiano	italiano	NOUN
aiua-10337	160	3	di	di	PROPN
aiua-10337	160	4	urologia	urologia	PROPN
aiua-10337	160	5	e	e	PROPN
aiua-10337	160	6	andrologia	andrologia	NOUN
aiua-10337	160	7	2021	2021	NUM
aiua-10337	160	8	;	;	PUNCT
aiua-10337	160	9	93	93	NUM
aiua-10337	160	10	,	,	PUNCT
aiua-10337	160	11	4	4	NUM
aiua-10337	160	12	drug	drug	NOUN
aiua-10337	160	13	-	-	PUNCT
aiua-10337	160	14	induced	induce	VERB
aiua-10337	160	15	gynecomastia	gynecomastia	NOUN
aiua-10337	160	16	10	10	NUM
aiua-10337	160	17	.	.	PUNCT
aiua-10337	160	18	andriole	andriole	PROPN
aiua-10337	160	19	gl	gl	PROPN
aiua-10337	160	20	,	,	PUNCT
aiua-10337	160	21	bostwick	bostwick	PROPN
aiua-10337	160	22	dg	dg	PROPN
aiua-10337	160	23	,	,	PUNCT
aiua-10337	160	24	brawley	brawley	PROPN
aiua-10337	160	25	ow	ow	PROPN
aiua-10337	160	26	,	,	PUNCT
aiua-10337	160	27	et	et	PROPN
aiua-10337	160	28	al	al	PROPN
aiua-10337	160	29	.	.	PROPN
aiua-10337	160	30	reduce	reduce	VERB
aiua-10337	160	31	study	study	NOUN
aiua-10337	160	32	group	group	NOUN
aiua-10337	160	33	effect	effect	NOUN
aiua-10337	160	34	of	of	ADP
aiua-10337	160	35	dutasteride	dutasteride	NOUN
aiua-10337	160	36	on	on	ADP
aiua-10337	160	37	the	the	DET
aiua-10337	160	38	risk	risk	NOUN
aiua-10337	160	39	of	of	ADP
aiua-10337	160	40	prostate	prostate	NOUN
aiua-10337	160	41	cancer	cancer	NOUN
aiua-10337	160	42	.	.	PUNCT
aiua-10337	161	1	n	n	PROPN
aiua-10337	161	2	engl	engl	PROPN
aiua-10337	161	3	j	j	PROPN
aiua-10337	161	4	med	med	PROPN
aiua-10337	161	5	.	.	PUNCT
aiua-10337	161	6	2010	2010	NUM
aiua-10337	161	7	;	;	PUNCT
aiua-10337	161	8	362:1192	362:1192	NUM
aiua-10337	161	9	-	-	SYM
aiua-10337	161	10	202	202	NUM
aiua-10337	161	11	11	11	NUM
aiua-10337	161	12	.	.	PUNCT
aiua-10337	162	1	na	na	PUNCT
aiua-10337	162	2	y	y	PROPN
aiua-10337	162	3	,	,	PUNCT
aiua-10337	162	4	ye	ye	PROPN
aiua-10337	162	5	z	z	PROPN
aiua-10337	162	6	,	,	PUNCT
aiua-10337	162	7	zhang	zhang	PROPN
aiua-10337	162	8	s.	s.	PROPN
aiua-10337	162	9	efficacy	efficacy	PROPN
aiua-10337	162	10	and	and	CCONJ
aiua-10337	162	11	safety	safety	NOUN
aiua-10337	162	12	of	of	ADP
aiua-10337	162	13	dutasteride	dutasteride	NOUN
aiua-10337	162	14	in	in	ADP
aiua-10337	162	15	chinese	chinese	ADJ
aiua-10337	162	16	adults	adult	NOUN
aiua-10337	162	17	with	with	ADP
aiua-10337	162	18	symptomatic	symptomatic	ADJ
aiua-10337	162	19	benign	benign	ADJ
aiua-10337	162	20	prostatic	prostatic	ADJ
aiua-10337	162	21	hyperplasia	hyperplasia	NOUN
aiua-10337	162	22	:	:	PUNCT
aiua-10337	162	23	a	a	DET
aiua-10337	162	24	randomized	randomized	ADJ
aiua-10337	162	25	,	,	PUNCT
aiua-10337	162	26	double	double	ADJ
aiua-10337	162	27	-	-	PUNCT
aiua-10337	162	28	blind	blind	ADJ
aiua-10337	162	29	,	,	PUNCT
aiua-10337	162	30	parallel	parallel	NOUN
aiua-10337	162	31	-	-	PUNCT
aiua-10337	162	32	group	group	NOUN
aiua-10337	162	33	,	,	PUNCT
aiua-10337	162	34	placebo	placebo	NOUN
aiua-10337	162	35	-	-	PUNCT
aiua-10337	162	36	controlled	control	VERB
aiua-10337	162	37	study	study	NOUN
aiua-10337	162	38	with	with	ADP
aiua-10337	162	39	an	an	DET
aiua-10337	162	40	open	open	ADJ
aiua-10337	162	41	-	-	PUNCT
aiua-10337	162	42	label	label	NOUN
aiua-10337	162	43	extension	extension	NOUN
aiua-10337	162	44	.	.	PUNCT
aiua-10337	163	1	clin	clin	PROPN
aiua-10337	163	2	drug	drug	PROPN
aiua-10337	163	3	investig	investig	PROPN
aiua-10337	163	4	.	.	PROPN
aiua-10337	163	5	2012	2012	NUM
aiua-10337	163	6	;	;	PUNCT
aiua-10337	163	7	32:29	32:29	NUM
aiua-10337	163	8	-	-	SYM
aiua-10337	163	9	39	39	NUM
aiua-10337	163	10	.	.	PUNCT
aiua-10337	164	1	12	12	NUM
aiua-10337	164	2	.	.	PUNCT
aiua-10337	165	1	roehrborn	roehrborn	ADJ
aiua-10337	165	2	cg	cg	PROPN
aiua-10337	165	3	,	,	PUNCT
aiua-10337	165	4	boyle	boyle	PROPN
aiua-10337	165	5	p	p	PROPN
aiua-10337	165	6	,	,	PUNCT
aiua-10337	165	7	nickel	nickel	NOUN
aiua-10337	165	8	j	j	PROPN
aiua-10337	165	9	,	,	PUNCT
aiua-10337	165	10	et	et	PROPN
aiua-10337	165	11	al	al	PROPN
aiua-10337	165	12	.	.	PROPN
aiua-10337	165	13	efficacy	efficacy	NOUN
aiua-10337	165	14	and	and	CCONJ
aiua-10337	165	15	safety	safety	NOUN
aiua-10337	165	16	of	of	ADP
aiua-10337	165	17	a	a	DET
aiua-10337	165	18	dual	dual	ADJ
aiua-10337	165	19	inhibitor	inhibitor	NOUN
aiua-10337	165	20	of	of	ADP
aiua-10337	165	21	5	5	NUM
aiua-10337	165	22	-	-	PUNCT
aiua-10337	165	23	alpha	alpha	NOUN
aiua-10337	165	24	-	-	PUNCT
aiua-10337	165	25	reductase	reductase	NOUN
aiua-10337	165	26	types	type	NOUN
aiua-10337	165	27	1	1	NUM
aiua-10337	165	28	and	and	CCONJ
aiua-10337	165	29	2	2	NUM
aiua-10337	165	30	(	(	PUNCT
aiua-10337	165	31	dutasteride	dutasteride	NOUN
aiua-10337	165	32	)	)	PUNCT
aiua-10337	165	33	in	in	ADP
aiua-10337	165	34	men	man	NOUN
aiua-10337	165	35	with	with	ADP
aiua-10337	165	36	benign	benign	ADJ
aiua-10337	165	37	prostatic	prostatic	ADJ
aiua-10337	165	38	hyperplasia	hyperplasia	NOUN
aiua-10337	165	39	urology	urology	NOUN
aiua-10337	165	40	.	.	PUNCT
aiua-10337	166	1	2002	2002	NUM
aiua-10337	166	2	;	;	PUNCT
aiua-10337	166	3	60:3(434	60:3(434	NUM
aiua-10337	166	4	-	-	SYM
aiua-10337	166	5	441	441	NUM
aiua-10337	166	6	)	)	PUNCT
aiua-10337	166	7	.	.	PUNCT
aiua-10337	167	1	13	13	NUM
aiua-10337	167	2	.	.	PUNCT
aiua-10337	167	3	mcconnell	mcconnell	PROPN
aiua-10337	167	4	jd	jd	PROPN
aiua-10337	167	5	,	,	PUNCT
aiua-10337	167	6	bruskewitz	bruskewitz	PROPN
aiua-10337	167	7	r	r	PROPN
aiua-10337	167	8	,	,	PUNCT
aiua-10337	167	9	walsh	walsh	NOUN
aiua-10337	167	10	p	p	PROPN
aiua-10337	167	11	,	,	PUNCT
aiua-10337	167	12	et	et	PROPN
aiua-10337	167	13	al	al	PROPN
aiua-10337	167	14	.	.	PUNCT
aiua-10337	168	1	the	the	DET
aiua-10337	168	2	effect	effect	NOUN
aiua-10337	168	3	of	of	ADP
aiua-10337	168	4	finasteride	finasteride	NOUN
aiua-10337	168	5	on	on	ADP
aiua-10337	168	6	the	the	DET
aiua-10337	168	7	risk	risk	NOUN
aiua-10337	168	8	of	of	ADP
aiua-10337	168	9	acute	acute	ADJ
aiua-10337	168	10	urinary	urinary	ADJ
aiua-10337	168	11	retention	retention	NOUN
aiua-10337	168	12	and	and	CCONJ
aiua-10337	168	13	the	the	DET
aiua-10337	168	14	need	need	NOUN
aiua-10337	168	15	for	for	ADP
aiua-10337	168	16	surgical	surgical	ADJ
aiua-10337	168	17	treatment	treatment	NOUN
aiua-10337	168	18	among	among	ADP
aiua-10337	168	19	men	man	NOUN
aiua-10337	168	20	with	with	ADP
aiua-10337	168	21	benign	benign	ADJ
aiua-10337	168	22	prostatic	prostatic	ADJ
aiua-10337	168	23	hyperplasia	hyperplasia	NOUN
aiua-10337	168	24	.	.	PUNCT
aiua-10337	169	1	finasteride	finasteride	ADJ
aiua-10337	169	2	long	long	ADJ
aiua-10337	169	3	-	-	PUNCT
aiua-10337	169	4	term	term	NOUN
aiua-10337	169	5	efficacy	efficacy	NOUN
aiua-10337	169	6	and	and	CCONJ
aiua-10337	169	7	safety	safety	NOUN
aiua-10337	169	8	study	study	NOUN
aiua-10337	169	9	group	group	NOUN
aiua-10337	169	10	.	.	PUNCT
aiua-10337	170	1	n	n	PROPN
aiua-10337	170	2	engl	engl	PROPN
aiua-10337	170	3	j	j	PROPN
aiua-10337	170	4	med	med	PROPN
aiua-10337	170	5	.	.	PUNCT
aiua-10337	171	1	1998	1998	NUM
aiua-10337	171	2	;	;	PUNCT
aiua-10337	172	1	338:557	338:557	PROPN
aiua-10337	172	2	-	-	SYM
aiua-10337	172	3	63	63	NUM
aiua-10337	172	4	.	.	PUNCT
aiua-10337	172	5	14	14	NUM
aiua-10337	172	6	.	.	PUNCT
aiua-10337	173	1	thompson	thompson	PROPN
aiua-10337	173	2	i	i	PRON
aiua-10337	173	3	m	m	PROPN
aiua-10337	173	4	,	,	PUNCT
aiua-10337	173	5	goodman	goodman	PROPN
aiua-10337	173	6	pj	pj	PROPN
aiua-10337	173	7	,	,	PUNCT
aiua-10337	173	8	tangen	tangen	PROPN
aiua-10337	173	9	cm	cm	PROPN
aiua-10337	173	10	,	,	PUNCT
aiua-10337	173	11	et	et	PROPN
aiua-10337	173	12	al	al	PROPN
aiua-10337	173	13	.	.	PUNCT
aiua-10337	174	1	the	the	DET
aiua-10337	174	2	influence	influence	NOUN
aiua-10337	174	3	of	of	ADP
aiua-10337	174	4	finasteride	finasteride	NOUN
aiua-10337	174	5	on	on	ADP
aiua-10337	174	6	the	the	DET
aiua-10337	174	7	development	development	NOUN
aiua-10337	174	8	of	of	ADP
aiua-10337	174	9	prostate	prostate	NOUN
aiua-10337	174	10	cancer.n	cancer.n	ADP
aiua-10337	174	11	engl	engl	PROPN
aiua-10337	174	12	j	j	PROPN
aiua-10337	174	13	med	med	PROPN
aiua-10337	174	14	.	.	PUNCT
aiua-10337	174	15	2003	2003	NUM
aiua-10337	174	16	;	;	PUNCT
aiua-10337	175	1	349:215	349:215	NUM
aiua-10337	175	2	-	-	SYM
aiua-10337	175	3	24	24	NUM
aiua-10337	175	4	.	.	PUNCT
aiua-10337	176	1	15	15	NUM
aiua-10337	176	2	.	.	PUNCT
aiua-10337	177	1	amory	amory	PROPN
aiua-10337	177	2	jk	jk	PROPN
aiua-10337	177	3	,	,	PUNCT
aiua-10337	177	4	wang	wang	PROPN
aiua-10337	177	5	c	c	PROPN
aiua-10337	177	6	,	,	PUNCT
aiua-10337	177	7	swerdloff	swerdloff	ADJ
aiua-10337	177	8	rs	rs	NOUN
aiua-10337	177	9	,	,	PUNCT
aiua-10337	177	10	et	et	PROPN
aiua-10337	177	11	al	al	PROPN
aiua-10337	177	12	.	.	PUNCT
aiua-10337	178	1	the	the	DET
aiua-10337	178	2	effect	effect	NOUN
aiua-10337	178	3	of	of	ADP
aiua-10337	178	4	5a	5a	NUM
aiua-10337	178	5	-	-	PUNCT
aiua-10337	178	6	reductase	reductase	NOUN
aiua-10337	178	7	inhibition	inhibition	NOUN
aiua-10337	178	8	with	with	ADP
aiua-10337	178	9	dutasteride	dutasteride	NOUN
aiua-10337	178	10	and	and	CCONJ
aiua-10337	178	11	finasteride	finasteride	ADV
aiua-10337	178	12	on	on	ADP
aiua-10337	178	13	semen	semen	NOUN
aiua-10337	178	14	parameters	parameter	NOUN
aiua-10337	178	15	and	and	CCONJ
aiua-10337	178	16	serum	serum	NOUN
aiua-10337	178	17	hormones	hormone	NOUN
aiua-10337	178	18	in	in	ADP
aiua-10337	178	19	healthy	healthy	ADJ
aiua-10337	178	20	men	man	NOUN
aiua-10337	178	21	journal	journal	NOUN
aiua-10337	178	22	of	of	ADP
aiua-10337	178	23	clinical	clinical	ADJ
aiua-10337	178	24	endocrinology	endocrinology	NOUN
aiua-10337	178	25	and	and	CCONJ
aiua-10337	178	26	metabolism	metabolism	NOUN
aiua-10337	178	27	.	.	PUNCT
aiua-10337	179	1	2007	2007	NUM
aiua-10337	179	2	;	;	PUNCT
aiua-10337	179	3	92:5(1659	92:5(1659	NUM
aiua-10337	179	4	-	-	SYM
aiua-10337	179	5	1665	1665	NUM
aiua-10337	179	6	)	)	PUNCT
aiua-10337	179	7	.	.	PUNCT
aiua-10337	180	1	16	16	NUM
aiua-10337	180	2	.	.	PUNCT
aiua-10337	181	1	nickel	nickel	PROPN
aiua-10337	181	2	jc	jc	PROPN
aiua-10337	181	3	,	,	PUNCT
aiua-10337	181	4	gilling	gille	VERB
aiua-10337	181	5	p	p	NOUN
aiua-10337	181	6	,	,	PUNCT
aiua-10337	181	7	tammela	tammela	PROPN
aiua-10337	181	8	tl	tl	PROPN
aiua-10337	181	9	,	,	PUNCT
aiua-10337	181	10	et	et	PROPN
aiua-10337	181	11	al	al	PROPN
aiua-10337	181	12	.	.	PROPN
aiua-10337	181	13	comparison	comparison	NOUN
aiua-10337	181	14	of	of	ADP
aiua-10337	181	15	dutasteride	dutasteride	NOUN
aiua-10337	181	16	and	and	CCONJ
aiua-10337	181	17	finasteride	finasteride	ADV
aiua-10337	181	18	for	for	ADP
aiua-10337	181	19	treating	treat	VERB
aiua-10337	181	20	benign	benign	ADJ
aiua-10337	181	21	prostatic	prostatic	ADJ
aiua-10337	181	22	hyperplasia	hyperplasia	NOUN
aiua-10337	181	23	:	:	PUNCT
aiua-10337	181	24	the	the	DET
aiua-10337	181	25	enlarged	enlarged	ADJ
aiua-10337	181	26	prostate	prostate	NOUN
aiua-10337	181	27	international	international	ADJ
aiua-10337	181	28	comparator	comparator	NOUN
aiua-10337	181	29	study	study	NOUN
aiua-10337	181	30	(	(	PUNCT
aiua-10337	181	31	epics	epic	NOUN
aiua-10337	181	32	)	)	PUNCT
aiua-10337	181	33	.	.	PUNCT
aiua-10337	182	1	bju	bju	NOUN
aiua-10337	182	2	int	int	PROPN
aiua-10337	182	3	.	.	PUNCT
aiua-10337	183	1	2011	2011	NUM
aiua-10337	183	2	;	;	PUNCT
aiua-10337	183	3	108:388	108:388	NUM
aiua-10337	183	4	-	-	SYM
aiua-10337	183	5	94	94	NUM
aiua-10337	183	6	.	.	PUNCT
aiua-10337	184	1	17	17	NUM
aiua-10337	184	2	.	.	PUNCT
aiua-10337	185	1	bianchi	bianchi	PROPN
aiua-10337	185	2	s	s	PROPN
aiua-10337	185	3	,	,	PUNCT
aiua-10337	185	4	bigazzi	bigazzi	ADJ
aiua-10337	185	5	r	r	NOUN
aiua-10337	185	6	,	,	PUNCT
aiua-10337	185	7	campese	campese	PROPN
aiua-10337	185	8	vm	vm	PROPN
aiua-10337	185	9	.	.	PROPN
aiua-10337	185	10	long	long	ADJ
aiua-10337	185	11	-	-	PUNCT
aiua-10337	185	12	term	term	NOUN
aiua-10337	185	13	effects	effect	NOUN
aiua-10337	185	14	of	of	ADP
aiua-10337	185	15	spironolactone	spironolactone	NOUN
aiua-10337	185	16	on	on	ADP
aiua-10337	185	17	proteinuria	proteinuria	NOUN
aiua-10337	185	18	and	and	CCONJ
aiua-10337	185	19	kidney	kidney	NOUN
aiua-10337	185	20	function	function	NOUN
aiua-10337	185	21	in	in	ADP
aiua-10337	185	22	patients	patient	NOUN
aiua-10337	185	23	with	with	ADP
aiua-10337	185	24	chronic	chronic	ADJ
aiua-10337	185	25	kidney	kidney	NOUN
aiua-10337	185	26	disease	disease	NOUN
aiua-10337	185	27	kidney	kidney	NOUN
aiua-10337	185	28	international	international	ADJ
aiua-10337	185	29	2006	2006	NUM
aiua-10337	185	30	;	;	PUNCT
aiua-10337	185	31	70:2116	70:2116	NOUN
aiua-10337	185	32	-	-	PUNCT
aiua-10337	185	33	2123	2123	NUM
aiua-10337	185	34	.	.	PUNCT
aiua-10337	186	1	18	18	NUM
aiua-10337	186	2	.	.	X
aiua-10337	186	3	charytan	charytan	PROPN
aiua-10337	186	4	dm	dm	PROPN
aiua-10337	186	5	,	,	PUNCT
aiua-10337	186	6	himmelfarb	himmelfarb	PROPN
aiua-10337	186	7	j	j	PROPN
aiua-10337	186	8	,	,	PUNCT
aiua-10337	186	9	ikizler	ikizler	NOUN
aiua-10337	186	10	ta	ta	PROPN
aiua-10337	186	11	,	,	PUNCT
aiua-10337	186	12	et	et	PROPN
aiua-10337	186	13	al	al	PROPN
aiua-10337	186	14	.	.	PUNCT
aiua-10337	187	1	hemodialysis	hemodialysis	NOUN
aiua-10337	187	2	novel	novel	NOUN
aiua-10337	187	3	therapies	therapie	VERB
aiua-10337	187	4	consortium	consortium	NOUN
aiua-10337	187	5	.	.	PUNCT
aiua-10337	188	1	safety	safety	NOUN
aiua-10337	188	2	and	and	CCONJ
aiua-10337	188	3	cardiovascular	cardiovascular	ADJ
aiua-10337	188	4	efficacy	efficacy	NOUN
aiua-10337	188	5	of	of	ADP
aiua-10337	188	6	spironolactone	spironolactone	NOUN
aiua-10337	188	7	in	in	ADP
aiua-10337	188	8	dialysis	dialysis	NOUN
aiua-10337	188	9	-	-	PUNCT
aiua-10337	188	10	dependent	dependent	ADJ
aiua-10337	188	11	esrd	esrd	PROPN
aiua-10337	188	12	(	(	PUNCT
aiua-10337	188	13	spin	spin	NOUN
aiua-10337	188	14	-	-	PUNCT
aiua-10337	188	15	d	d	NOUN
aiua-10337	188	16	):	):	PUNCT
aiua-10337	188	17	a	a	DET
aiua-10337	188	18	randomized	randomized	ADJ
aiua-10337	188	19	,	,	PUNCT
aiua-10337	188	20	placebocontrolled	placebocontrolle	VERB
aiua-10337	188	21	,	,	PUNCT
aiua-10337	188	22	multiple	multiple	ADJ
aiua-10337	188	23	dosage	dosage	NOUN
aiua-10337	188	24	trial	trial	NOUN
aiua-10337	188	25	.	.	PUNCT
aiua-10337	189	1	kidney	kidney	NOUN
aiua-10337	189	2	int	int	NOUN
aiua-10337	189	3	.	.	PUNCT
aiua-10337	190	1	2019	2019	NUM
aiua-10337	190	2	;	;	PUNCT
aiua-10337	190	3	95:973	95:973	NUM
aiua-10337	190	4	-	-	SYM
aiua-10337	190	5	982	982	NUM
aiua-10337	190	6	.	.	NOUN
aiua-10337	191	1	19	19	NUM
aiua-10337	191	2	.	.	PUNCT
aiua-10337	192	1	edelmann	edelmann	PROPN
aiua-10337	192	2	f	f	NOUN
aiua-10337	192	3	,	,	PUNCT
aiua-10337	192	4	wachter	wachter	NOUN
aiua-10337	192	5	r	r	NOUN
aiua-10337	192	6	,	,	PUNCT
aiua-10337	192	7	schmidt	schmidt	PROPN
aiua-10337	192	8	ag	ag	PROPN
aiua-10337	192	9	,	,	PUNCT
aiua-10337	192	10	et	et	PROPN
aiua-10337	192	11	al	al	PROPN
aiua-10337	192	12	.	.	PROPN
aiua-10337	192	13	effect	effect	NOUN
aiua-10337	192	14	of	of	ADP
aiua-10337	192	15	spironolactone	spironolactone	NOUN
aiua-10337	192	16	on	on	ADP
aiua-10337	192	17	diastolic	diastolic	ADJ
aiua-10337	192	18	function	function	NOUN
aiua-10337	192	19	and	and	CCONJ
aiua-10337	192	20	exercise	exercise	NOUN
aiua-10337	192	21	capacity	capacity	NOUN
aiua-10337	192	22	in	in	ADP
aiua-10337	192	23	patients	patient	NOUN
aiua-10337	192	24	with	with	ADP
aiua-10337	192	25	heart	heart	NOUN
aiua-10337	192	26	failure	failure	NOUN
aiua-10337	192	27	with	with	ADP
aiua-10337	192	28	preserved	preserve	VERB
aiua-10337	192	29	ejection	ejection	NOUN
aiua-10337	192	30	fraction	fraction	NOUN
aiua-10337	192	31	:	:	PUNCT
aiua-10337	192	32	the	the	DET
aiua-10337	192	33	aldo	aldo	PROPN
aiua-10337	192	34	-	-	PUNCT
aiua-10337	192	35	dhf	dhf	NOUN
aiua-10337	192	36	randomized	randomize	VERB
aiua-10337	192	37	controlled	control	VERB
aiua-10337	192	38	trial	trial	NOUN
aiua-10337	192	39	jama	jama	PROPN
aiua-10337	192	40	journal	journal	NOUN
aiua-10337	192	41	of	of	ADP
aiua-10337	192	42	the	the	DET
aiua-10337	192	43	american	american	PROPN
aiua-10337	192	44	medical	medical	PROPN
aiua-10337	192	45	association	association	PROPN
aiua-10337	192	46	2013	2013	NUM
aiua-10337	192	47	;	;	PUNCT
aiua-10337	192	48	309:781	309:781	NUM
aiua-10337	192	49	-	-	SYM
aiua-10337	192	50	791	791	NUM
aiua-10337	192	51	.	.	PUNCT
aiua-10337	193	1	20	20	NUM
aiua-10337	193	2	.	.	PUNCT
aiua-10337	194	1	gao	gao	PROPN
aiua-10337	194	2	x	x	PROPN
aiua-10337	194	3	,	,	PUNCT
aiua-10337	194	4	peng	peng	PROPN
aiua-10337	194	5	l	l	PROPN
aiua-10337	194	6	,	,	PUNCT
aiua-10337	194	7	adhikari	adhikari	PROPN
aiua-10337	194	8	cm	cm	PROPN
aiua-10337	194	9	,	,	PUNCT
aiua-10337	194	10	et	et	PROPN
aiua-10337	194	11	al	al	PROPN
aiua-10337	194	12	.	.	PUNCT
aiua-10337	195	1	spironolactone	spironolactone	PROPN
aiua-10337	195	2	reduced	reduce	VERB
aiua-10337	195	3	arrhythmia	arrhythmia	NOUN
aiua-10337	195	4	and	and	CCONJ
aiua-10337	195	5	maintained	maintain	VERB
aiua-10337	195	6	magnesium	magnesium	NOUN
aiua-10337	195	7	homeostasis	homeostasis	NOUN
aiua-10337	195	8	in	in	ADP
aiua-10337	195	9	patients	patient	NOUN
aiua-10337	195	10	with	with	ADP
aiua-10337	195	11	congestive	congestive	ADJ
aiua-10337	195	12	heart	heart	NOUN
aiua-10337	195	13	failure	failure	NOUN
aiua-10337	195	14	journal	journal	NOUN
aiua-10337	195	15	of	of	ADP
aiua-10337	195	16	cardiac	cardiac	ADJ
aiua-10337	195	17	failure	failure	NOUN
aiua-10337	195	18	2007	2007	NUM
aiua-10337	195	19	;	;	PUNCT
aiua-10337	195	20	13:170	13:170	NUM
aiua-10337	195	21	-	-	SYM
aiua-10337	195	22	177	177	NUM
aiua-10337	195	23	.	.	PUNCT
aiua-10337	196	1	21	21	NUM
aiua-10337	196	2	.	.	PUNCT
aiua-10337	197	1	ito	ito	PROPN
aiua-10337	197	2	y	y	PROPN
aiua-10337	197	3	,	,	PUNCT
aiua-10337	197	4	mizuno	mizuno	PROPN
aiua-10337	197	5	m	m	PROPN
aiua-10337	197	6	,	,	PUNCT
aiua-10337	197	7	suzuki	suzuki	PROPN
aiua-10337	197	8	y	y	PROPN
aiua-10337	197	9	,	,	PUNCT
aiua-10337	197	10	et	et	PROPN
aiua-10337	197	11	al	al	PROPN
aiua-10337	197	12	.	.	PUNCT
aiua-10337	198	1	long	long	ADJ
aiua-10337	198	2	-	-	PUNCT
aiua-10337	198	3	term	term	NOUN
aiua-10337	198	4	effects	effect	NOUN
aiua-10337	198	5	of	of	ADP
aiua-10337	198	6	spironolactone	spironolactone	NOUN
aiua-10337	198	7	in	in	ADP
aiua-10337	198	8	peritoneal	peritoneal	ADJ
aiua-10337	198	9	dialysis	dialysis	NOUN
aiua-10337	198	10	patients	patient	NOUN
aiua-10337	198	11	journal	journal	NOUN
aiua-10337	198	12	of	of	ADP
aiua-10337	198	13	the	the	DET
aiua-10337	198	14	american	american	ADJ
aiua-10337	198	15	society	society	NOUN
aiua-10337	198	16	of	of	ADP
aiua-10337	198	17	nephrology	nephrology	NOUN
aiua-10337	198	18	.	.	PUNCT
aiua-10337	199	1	2014	2014	NUM
aiua-10337	199	2	;	;	PUNCT
aiua-10337	199	3	25:1094	25:1094	NUM
aiua-10337	199	4	-	-	SYM
aiua-10337	199	5	1102	1102	NUM
aiua-10337	199	6	.	.	PUNCT
aiua-10337	200	1	22	22	NUM
aiua-10337	200	2	.	.	PUNCT
aiua-10337	201	1	kayrak	kayrak	PROPN
aiua-10337	201	2	m	m	PROPN
aiua-10337	201	3	,	,	PUNCT
aiua-10337	201	4	bacaksiz	bacaksiz	ADV
aiua-10337	201	5	a	a	PRON
aiua-10337	201	6	,	,	PUNCT
aiua-10337	201	7	vatankulu	vatankulu	ADJ
aiua-10337	201	8	ma	ma	PROPN
aiua-10337	201	9	,	,	PUNCT
aiua-10337	201	10	et	et	PROPN
aiua-10337	201	11	al	al	PROPN
aiua-10337	201	12	.	.	PUNCT
aiua-10337	202	1	the	the	DET
aiua-10337	202	2	effects	effect	NOUN
aiua-10337	202	3	of	of	ADP
aiua-10337	202	4	spironolactone	spironolactone	NOUN
aiua-10337	202	5	on	on	ADP
aiua-10337	202	6	atrial	atrial	ADJ
aiua-10337	202	7	remodeling	remodeling	NOUN
aiua-10337	202	8	in	in	ADP
aiua-10337	202	9	patients	patient	NOUN
aiua-10337	202	10	with	with	ADP
aiua-10337	202	11	preserved	preserve	VERB
aiua-10337	202	12	left	left	ADJ
aiua-10337	202	13	ventricular	ventricular	ADJ
aiua-10337	202	14	function	function	NOUN
aiua-10337	202	15	after	after	ADP
aiua-10337	202	16	an	an	DET
aiua-10337	202	17	acute	acute	ADJ
aiua-10337	202	18	myocardial	myocardial	ADJ
aiua-10337	202	19	infarction	infarction	NOUN
aiua-10337	202	20	:	:	PUNCT
aiua-10337	202	21	a	a	DET
aiua-10337	202	22	randomized	randomized	ADJ
aiua-10337	202	23	follow	follow	NOUN
aiua-10337	202	24	-	-	PUNCT
aiua-10337	202	25	up	up	ADP
aiua-10337	202	26	study	study	NOUN
aiua-10337	202	27	coronary	coronary	ADJ
aiua-10337	202	28	artery	artery	NOUN
aiua-10337	202	29	disease	disease	NOUN
aiua-10337	202	30	.	.	PUNCT
aiua-10337	203	1	2010	2010	NUM
aiua-10337	203	2	;	;	PUNCT
aiua-10337	203	3	21:477	21:477	NUM
aiua-10337	203	4	-	-	SYM
aiua-10337	203	5	485	485	NUM
aiua-10337	203	6	.	.	PUNCT
aiua-10337	204	1	23	23	NUM
aiua-10337	204	2	.	.	PUNCT
aiua-10337	205	1	matsumoto	matsumoto	PROPN
aiua-10337	205	2	y	y	PROPN
aiua-10337	205	3	,	,	PUNCT
aiua-10337	205	4	mori	mori	PROPN
aiua-10337	205	5	y	y	PROPN
aiua-10337	205	6	,	,	PUNCT
aiua-10337	205	7	kageyama	kageyama	PROPN
aiua-10337	205	8	s	s	PART
aiua-10337	205	9	,	,	PUNCT
aiua-10337	205	10	et	et	PROPN
aiua-10337	205	11	al	al	PROPN
aiua-10337	205	12	.	.	PUNCT
aiua-10337	206	1	spironolactone	spironolactone	NOUN
aiua-10337	206	2	reduces	reduce	VERB
aiua-10337	206	3	cardiovascular	cardiovascular	ADJ
aiua-10337	206	4	and	and	CCONJ
aiua-10337	206	5	cerebrovascular	cerebrovascular	ADJ
aiua-10337	206	6	morbidity	morbidity	NOUN
aiua-10337	206	7	and	and	CCONJ
aiua-10337	206	8	mortality	mortality	NOUN
aiua-10337	206	9	in	in	ADP
aiua-10337	206	10	hemodialysis	hemodialysis	NOUN
aiua-10337	206	11	patients	patient	NOUN
aiua-10337	206	12	.	.	PUNCT
aiua-10337	207	1	j	j	PROPN
aiua-10337	207	2	am	be	AUX
aiua-10337	207	3	coll	coll	PROPN
aiua-10337	207	4	cardiol	cardiol	NOUN
aiua-10337	207	5	.	.	PUNCT
aiua-10337	208	1	2014	2014	NUM
aiua-10337	208	2	;	;	PUNCT
aiua-10337	208	3	63:528	63:528	NUM
aiua-10337	208	4	-	-	SYM
aiua-10337	208	5	36	36	NUM
aiua-10337	208	6	.	.	PUNCT
aiua-10337	209	1	24	24	NUM
aiua-10337	209	2	.	.	PUNCT
aiua-10337	210	1	ni	ni	PROPN
aiua-10337	210	2	x	x	PROPN
aiua-10337	210	3	,	,	PUNCT
aiua-10337	210	4	zhang	zhang	PROPN
aiua-10337	210	5	j	j	PROPN
aiua-10337	210	6	,	,	PUNCT
aiua-10337	210	7	zhang	zhang	PROPN
aiua-10337	210	8	p	p	PROPN
aiua-10337	210	9	,	,	PUNCT
aiua-10337	210	10	et	et	PROPN
aiua-10337	210	11	al	al	PROPN
aiua-10337	210	12	.	.	PUNCT
aiua-10337	210	13	effects	effect	NOUN
aiua-10337	210	14	of	of	ADP
aiua-10337	210	15	spironolactone	spironolactone	NOUN
aiua-10337	210	16	on	on	ADP
aiua-10337	210	17	dialysis	dialysis	NOUN
aiua-10337	210	18	patients	patient	NOUN
aiua-10337	210	19	with	with	ADP
aiua-10337	210	20	refractory	refractory	NOUN
aiua-10337	210	21	hypertension	hypertension	NOUN
aiua-10337	210	22	:	:	PUNCT
aiua-10337	210	23	a	a	DET
aiua-10337	210	24	randomized	randomized	ADJ
aiua-10337	210	25	controlled	control	VERB
aiua-10337	210	26	study	study	NOUN
aiua-10337	210	27	journal	journal	NOUN
aiua-10337	210	28	of	of	ADP
aiua-10337	210	29	clinical	clinical	ADJ
aiua-10337	210	30	hypertension	hypertension	NOUN
aiua-10337	210	31	.	.	PUNCT
aiua-10337	211	1	2014	2014	NUM
aiua-10337	211	2	;	;	PUNCT
aiua-10337	211	3	16:658	16:658	NUM
aiua-10337	211	4	-	-	SYM
aiua-10337	211	5	663	663	NUM
aiua-10337	211	6	.	.	PUNCT
aiua-10337	212	1	25	25	NUM
aiua-10337	212	2	.	.	PUNCT
aiua-10337	213	1	pitt	pitt	PROPN
aiua-10337	213	2	b	b	PROPN
aiua-10337	213	3	,	,	PUNCT
aiua-10337	213	4	zannad	zannad	PROPN
aiua-10337	213	5	f	f	NOUN
aiua-10337	213	6	,	,	PUNCT
aiua-10337	213	7	remme	remme	VERB
aiua-10337	213	8	wj	wj	PROPN
aiua-10337	213	9	,	,	PUNCT
aiua-10337	213	10	et	et	PROPN
aiua-10337	213	11	al	al	PROPN
aiua-10337	213	12	.	.	PUNCT
aiua-10337	214	1	the	the	DET
aiua-10337	214	2	effect	effect	NOUN
aiua-10337	214	3	of	of	ADP
aiua-10337	214	4	spironolactone	spironolactone	NOUN
aiua-10337	214	5	on	on	ADP
aiua-10337	214	6	morbidity	morbidity	NOUN
aiua-10337	214	7	and	and	CCONJ
aiua-10337	214	8	mortality	mortality	NOUN
aiua-10337	214	9	in	in	ADP
aiua-10337	214	10	patients	patient	NOUN
aiua-10337	214	11	with	with	ADP
aiua-10337	214	12	severe	severe	ADJ
aiua-10337	214	13	heart	heart	NOUN
aiua-10337	214	14	failure	failure	NOUN
aiua-10337	214	15	.	.	PUNCT
aiua-10337	215	1	randomized	randomize	VERB
aiua-10337	215	2	aldactone	aldactone	PROPN
aiua-10337	215	3	evaluation	evaluation	NOUN
aiua-10337	215	4	study	study	NOUN
aiua-10337	215	5	investigators	investigator	NOUN
aiua-10337	215	6	.	.	PUNCT
aiua-10337	216	1	n	n	PROPN
aiua-10337	216	2	engl	engl	PROPN
aiua-10337	216	3	j	j	PROPN
aiua-10337	216	4	med	med	PROPN
aiua-10337	216	5	.	.	PUNCT
aiua-10337	216	6	1999	1999	NUM
aiua-10337	216	7	;	;	PUNCT
aiua-10337	217	1	341:709	341:709	NUM
aiua-10337	217	2	-	-	SYM
aiua-10337	217	3	17	17	NUM
aiua-10337	217	4	.	.	PUNCT
aiua-10337	217	5	26	26	NUM
aiua-10337	217	6	.	.	PUNCT
aiua-10337	218	1	skvortsov	skvortsov	PROPN
aiua-10337	218	2	aa	aa	PROPN
aiua-10337	218	3	,	,	PUNCT
aiua-10337	218	4	mareev	mareev	PROPN
aiua-10337	218	5	vy	vy	PROPN
aiua-10337	218	6	,	,	PUNCT
aiua-10337	218	7	chelmakina	chelmakina	PROPN
aiua-10337	218	8	sm	sm	PROPN
aiua-10337	218	9	,	,	PUNCT
aiua-10337	218	10	et	et	PROPN
aiua-10337	218	11	al	al	PROPN
aiua-10337	218	12	.	.	PROPN
aiua-10337	218	13	efficacy	efficacy	NOUN
aiua-10337	218	14	and	and	CCONJ
aiua-10337	218	15	safety	safety	NOUN
aiua-10337	218	16	of	of	ADP
aiua-10337	218	17	long	long	ADJ
aiua-10337	218	18	-	-	PUNCT
aiua-10337	218	19	term	term	NOUN
aiua-10337	218	20	application	application	NOUN
aiua-10337	218	21	of	of	ADP
aiua-10337	218	22	spironolactone	spironolactone	NOUN
aiua-10337	218	23	in	in	ADP
aiua-10337	218	24	patients	patient	NOUN
aiua-10337	218	25	with	with	ADP
aiua-10337	218	26	moderate	moderate	ADJ
aiua-10337	218	27	and	and	CCONJ
aiua-10337	218	28	severe	severe	ADJ
aiua-10337	218	29	chronic	chronic	ADJ
aiua-10337	218	30	heart	heart	NOUN
aiua-10337	218	31	failure	failure	NOUN
aiua-10337	218	32	receiving	receive	VERB
aiua-10337	218	33	optimal	optimal	ADJ
aiua-10337	218	34	therapy	therapy	NOUN
aiua-10337	218	35	.	.	PUNCT
aiua-10337	219	1	kardiologiia	kardiologiia	PROPN
aiua-10337	219	2	.	.	PUNCT
aiua-10337	220	1	2007	2007	NUM
aiua-10337	220	2	;	;	PUNCT
aiua-10337	220	3	47:12	47:12	NUM
aiua-10337	220	4	-	-	SYM
aiua-10337	220	5	23	23	NUM
aiua-10337	220	6	.	.	PUNCT
aiua-10337	221	1	27	27	NUM
aiua-10337	221	2	.	.	PUNCT
aiua-10337	222	1	tofte	tofte	PROPN
aiua-10337	222	2	n	n	CCONJ
aiua-10337	222	3	,	,	PUNCT
aiua-10337	222	4	lindhardt	lindhardt	PROPN
aiua-10337	222	5	m	m	PROPN
aiua-10337	222	6	,	,	PUNCT
aiua-10337	222	7	adamova	adamova	PROPN
aiua-10337	222	8	k	k	PROPN
aiua-10337	222	9	,	,	PUNCT
aiua-10337	222	10	et	et	PROPN
aiua-10337	222	11	al	al	PROPN
aiua-10337	222	12	.	.	PROPN
aiua-10337	222	13	priority	priority	NOUN
aiua-10337	222	14	investigators	investigator	NOUN
aiua-10337	222	15	.	.	PUNCT
aiua-10337	223	1	early	early	ADJ
aiua-10337	223	2	detection	detection	NOUN
aiua-10337	223	3	of	of	ADP
aiua-10337	223	4	diabetic	diabetic	ADJ
aiua-10337	223	5	kidney	kidney	NOUN
aiua-10337	223	6	disease	disease	NOUN
aiua-10337	223	7	by	by	ADP
aiua-10337	223	8	urinary	urinary	ADJ
aiua-10337	223	9	proteomics	proteomic	NOUN
aiua-10337	223	10	and	and	CCONJ
aiua-10337	223	11	subsequent	subsequent	ADJ
aiua-10337	223	12	intervention	intervention	NOUN
aiua-10337	223	13	with	with	ADP
aiua-10337	223	14	spironolactone	spironolactone	PROPN
aiua-10337	223	15	to	to	PART
aiua-10337	223	16	delay	delay	VERB
aiua-10337	223	17	progression	progression	NOUN
aiua-10337	223	18	(	(	PUNCT
aiua-10337	223	19	priority	priority	NOUN
aiua-10337	223	20	):	):	PUNCT
aiua-10337	223	21	a	a	DET
aiua-10337	223	22	prospective	prospective	ADJ
aiua-10337	223	23	observational	observational	ADJ
aiua-10337	223	24	study	study	NOUN
aiua-10337	223	25	and	and	CCONJ
aiua-10337	223	26	embedded	embed	VERB
aiua-10337	223	27	randomised	randomised	ADJ
aiua-10337	223	28	placebo	placebo	NOUN
aiua-10337	223	29	-	-	PUNCT
aiua-10337	223	30	controlled	control	VERB
aiua-10337	223	31	trial	trial	NOUN
aiua-10337	223	32	.	.	PUNCT
aiua-10337	224	1	lancet	lancet	NOUN
aiua-10337	224	2	diabetes	diabetes	NOUN
aiua-10337	224	3	endocrinol	endocrinol	NOUN
aiua-10337	224	4	.	.	PUNCT
aiua-10337	225	1	2020	2020	NUM
aiua-10337	225	2	;	;	PUNCT
aiua-10337	225	3	8:301	8:301	NUM
aiua-10337	225	4	-	-	PUNCT
aiua-10337	225	5	312	312	NUM
aiua-10337	225	6	.	.	PUNCT
aiua-10337	225	7	28	28	NUM
aiua-10337	225	8	.	.	PUNCT
aiua-10337	226	1	vatankulu	vatankulu	PROPN
aiua-10337	226	2	ma	ma	PROPN
aiua-10337	226	3	,	,	PUNCT
aiua-10337	226	4	bacaksiz	bacaksiz	PROPN
aiua-10337	226	5	a	a	PRON
aiua-10337	226	6	,	,	PUNCT
aiua-10337	226	7	sonmez	sonmez	NOUN
aiua-10337	226	8	o	o	NOUN
aiua-10337	226	9	,	,	PUNCT
aiua-10337	226	10	et	et	PROPN
aiua-10337	226	11	al	al	PROPN
aiua-10337	226	12	.	.	PROPN
aiua-10337	226	13	does	do	AUX
aiua-10337	226	14	spironolactone	spironolactone	PROPN
aiua-10337	226	15	have	have	VERB
aiua-10337	226	16	a	a	DET
aiua-10337	226	17	dose	dose	NOUN
aiua-10337	226	18	-	-	PUNCT
aiua-10337	226	19	dependent	dependent	ADJ
aiua-10337	226	20	effect	effect	NOUN
aiua-10337	226	21	on	on	ADP
aiua-10337	226	22	left	left	ADJ
aiua-10337	226	23	ventricular	ventricular	ADJ
aiua-10337	226	24	remodeling	remodeling	NOUN
aiua-10337	226	25	in	in	ADP
aiua-10337	226	26	patients	patient	NOUN
aiua-10337	226	27	with	with	ADP
aiua-10337	226	28	preserved	preserve	VERB
aiua-10337	226	29	left	left	ADJ
aiua-10337	226	30	ventricular	ventricular	ADJ
aiua-10337	226	31	function	function	NOUN
aiua-10337	226	32	after	after	ADP
aiua-10337	226	33	an	an	DET
aiua-10337	226	34	acute	acute	ADJ
aiua-10337	226	35	myocardial	myocardial	ADJ
aiua-10337	226	36	infarction	infarction	NOUN
aiua-10337	226	37	?	?	PUNCT
aiua-10337	227	1	cardiovascular	cardiovascular	ADJ
aiua-10337	227	2	therapeutics	therapeutic	NOUN
aiua-10337	227	3	.	.	PUNCT
aiua-10337	228	1	2013	2013	NUM
aiua-10337	228	2	;	;	PUNCT
aiua-10337	228	3	31:224	31:224	NUM
aiua-10337	228	4	-	-	SYM
aiua-10337	228	5	229	229	NUM
aiua-10337	228	6	.	.	PUNCT
aiua-10337	229	1	29	29	NUM
aiua-10337	229	2	.	.	PUNCT
aiua-10337	230	1	vizzardi	vizzardi	PROPN
aiua-10337	230	2	e	e	PROPN
aiua-10337	230	3	,	,	PUNCT
aiua-10337	230	4	pina	pina	NOUN
aiua-10337	230	5	pd	pd	PROPN
aiua-10337	230	6	,	,	PUNCT
aiua-10337	230	7	caretta	caretta	NOUN
aiua-10337	230	8	g	g	NOUN
aiua-10337	230	9	,	,	PUNCT
aiua-10337	230	10	et	et	PROPN
aiua-10337	230	11	al	al	PROPN
aiua-10337	230	12	.	.	PUNCT
aiua-10337	231	1	the	the	DET
aiua-10337	231	2	effect	effect	NOUN
aiua-10337	231	3	of	of	ADP
aiua-10337	231	4	aldosteroneantagonist	aldosteroneantagonist	NOUN
aiua-10337	231	5	therapy	therapy	NOUN
aiua-10337	231	6	on	on	ADP
aiua-10337	231	7	aortic	aortic	ADJ
aiua-10337	231	8	elastic	elastic	ADJ
aiua-10337	231	9	properties	property	NOUN
aiua-10337	231	10	in	in	ADP
aiua-10337	231	11	patients	patient	NOUN
aiua-10337	231	12	with	with	ADP
aiua-10337	231	13	nonischemic	nonischemic	ADJ
aiua-10337	231	14	dilated	dilated	ADJ
aiua-10337	231	15	cardiomyopathy	cardiomyopathy	ADJ
aiua-10337	231	16	journal	journal	NOUN
aiua-10337	231	17	of	of	ADP
aiua-10337	231	18	cardiovascular	cardiovascular	ADJ
aiua-10337	231	19	medicine	medicine	NOUN
aiua-10337	231	20	.	.	PUNCT
aiua-10337	232	1	2015	2015	NUM
aiua-10337	232	2	;	;	PUNCT
aiua-10337	232	3	16:597	16:597	NUM
aiua-10337	232	4	-	-	SYM
aiua-10337	232	5	602	602	NUM
aiua-10337	232	6	.	.	PUNCT
aiua-10337	233	1	30	30	NUM
aiua-10337	233	2	.	.	PUNCT
aiua-10337	234	1	zarraga	zarraga	PROPN
aiua-10337	234	2	ige	ige	PROPN
aiua-10337	234	3	,	,	PUNCT
aiua-10337	234	4	dougherty	dougherty	PROPN
aiua-10337	234	5	cm	cm	PROPN
aiua-10337	234	6	,	,	PUNCT
aiua-10337	234	7	macmurdy	macmurdy	ADJ
aiua-10337	234	8	ks	ks	NOUN
aiua-10337	234	9	,	,	PUNCT
aiua-10337	234	10	raitt	raitt	PROPN
aiua-10337	234	11	mh	mh	PROPN
aiua-10337	234	12	.	.	PUNCT
aiua-10337	234	13	tachyarrhythmias	tachyarrhythmias	PROPN
aiua-10337	234	14	the	the	DET
aiua-10337	234	15	effect	effect	NOUN
aiua-10337	234	16	of	of	ADP
aiua-10337	234	17	spironolactone	spironolactone	NOUN
aiua-10337	234	18	on	on	ADP
aiua-10337	234	19	ventricular	ventricular	ADJ
aiua-10337	234	20	tachyarrhythmias	tachyarrhythmia	NOUN
aiua-10337	234	21	in	in	ADP
aiua-10337	234	22	patients	patient	NOUN
aiua-10337	234	23	with	with	ADP
aiua-10337	234	24	implantable	implantable	ADJ
aiua-10337	234	25	cardioverter	cardioverter	NOUN
aiua-10337	234	26	-	-	PUNCT
aiua-10337	234	27	defibrillators	defibrillator	NOUN
aiua-10337	234	28	circulation	circulation	NOUN
aiua-10337	234	29	:	:	PUNCT
aiua-10337	234	30	arrhythmia	arrhythmia	NOUN
aiua-10337	234	31	and	and	CCONJ
aiua-10337	234	32	electrophysiology	electrophysiology	NOUN
aiua-10337	234	33	.	.	PUNCT
aiua-10337	235	1	2012	2012	NUM
aiua-10337	235	2	;	;	PUNCT
aiua-10337	235	3	5:739	5:739	NUM
aiua-10337	235	4	-	-	SYM
aiua-10337	235	5	747	747	NUM
aiua-10337	235	6	.	.	PUNCT
aiua-10337	236	1	31	31	NUM
aiua-10337	236	2	.	.	PUNCT
aiua-10337	237	1	kelly	kelly	PROPN
aiua-10337	237	2	dl	dl	PROPN
aiua-10337	237	3	.	.	PROPN
aiua-10337	237	4	,	,	PUNCT
aiua-10337	237	5	conley	conley	PROPN
aiua-10337	237	6	rr	rr	PROPN
aiua-10337	237	7	.	.	PUNCT
aiua-10337	238	1	a	a	DET
aiua-10337	238	2	randomized	randomized	ADJ
aiua-10337	238	3	double	double	ADJ
aiua-10337	238	4	-	-	PUNCT
aiua-10337	238	5	blind	blind	ADJ
aiua-10337	238	6	12	12	NUM
aiua-10337	238	7	-	-	PUNCT
aiua-10337	238	8	week	week	NOUN
aiua-10337	238	9	study	study	NOUN
aiua-10337	238	10	of	of	ADP
aiua-10337	238	11	quetiapine	quetiapine	NOUN
aiua-10337	238	12	,	,	PUNCT
aiua-10337	238	13	risperidone	risperidone	NOUN
aiua-10337	238	14	or	or	CCONJ
aiua-10337	238	15	fluphenazine	fluphenazine	NOUN
aiua-10337	238	16	on	on	ADP
aiua-10337	238	17	sexual	sexual	ADJ
aiua-10337	238	18	functioning	functioning	NOUN
aiua-10337	238	19	in	in	ADP
aiua-10337	238	20	people	people	NOUN
aiua-10337	238	21	with	with	ADP
aiua-10337	238	22	schizophrenia	schizophrenia	NOUN
aiua-10337	238	23	psychoneuroendocrinology	psychoneuroendocrinology	NOUN
aiua-10337	238	24	.	.	PUNCT
aiua-10337	239	1	2006	2006	NUM
aiua-10337	239	2	;	;	PUNCT
aiua-10337	239	3	31:340346	31:340346	NUM
aiua-10337	239	4	.	.	X
aiua-10337	240	1	32	32	NUM
aiua-10337	240	2	.	.	PUNCT
aiua-10337	241	1	mcevoy	mcevoy	PROPN
aiua-10337	241	2	jp	jp	PROPN
aiua-10337	241	3	,	,	PUNCT
aiua-10337	241	4	lieberman	lieberman	PROPN
aiua-10337	241	5	ja	ja	PROPN
aiua-10337	241	6	,	,	PUNCT
aiua-10337	241	7	stroup	stroup	PROPN
aiua-10337	241	8	ts	ts	PROPN
aiua-10337	241	9	,	,	PUNCT
aiua-10337	241	10	et	et	PROPN
aiua-10337	241	11	al	al	PROPN
aiua-10337	241	12	.	.	PUNCT
aiua-10337	242	1	catie	catie	PROPN
aiua-10337	242	2	investigators	investigator	NOUN
aiua-10337	242	3	.	.	PUNCT
aiua-10337	243	1	effectiveness	effectiveness	NOUN
aiua-10337	243	2	of	of	ADP
aiua-10337	243	3	clozapine	clozapine	NOUN
aiua-10337	243	4	versus	versus	ADP
aiua-10337	243	5	olanzapine	olanzapine	NOUN
aiua-10337	243	6	,	,	PUNCT
aiua-10337	243	7	quetiapine	quetiapine	NOUN
aiua-10337	243	8	,	,	PUNCT
aiua-10337	243	9	and	and	CCONJ
aiua-10337	243	10	risperidone	risperidone	NOUN
aiua-10337	243	11	in	in	ADP
aiua-10337	243	12	patients	patient	NOUN
aiua-10337	243	13	with	with	ADP
aiua-10337	243	14	chronic	chronic	ADJ
aiua-10337	243	15	schizophrenia	schizophrenia	NOUN
aiua-10337	243	16	who	who	PRON
aiua-10337	243	17	did	do	AUX
aiua-10337	243	18	not	not	PART
aiua-10337	243	19	respond	respond	VERB
aiua-10337	243	20	to	to	ADP
aiua-10337	243	21	prior	prior	ADJ
aiua-10337	243	22	atypical	atypical	ADJ
aiua-10337	243	23	antipsychotic	antipsychotic	ADJ
aiua-10337	243	24	treatment	treatment	NOUN
aiua-10337	243	25	.	.	PUNCT
aiua-10337	244	1	am	be	AUX
aiua-10337	244	2	j	j	PROPN
aiua-10337	244	3	psychiatry	psychiatry	NOUN
aiua-10337	244	4	.	.	PUNCT
aiua-10337	245	1	2006	2006	NUM
aiua-10337	245	2	;	;	PUNCT
aiua-10337	245	3	163:600	163:600	NOUN
aiua-10337	245	4	-	-	SYM
aiua-10337	245	5	10	10	NUM
aiua-10337	245	6	.	.	PUNCT
aiua-10337	246	1	33	33	NUM
aiua-10337	246	2	.	.	PUNCT
aiua-10337	247	1	mcevoy	mcevoy	PROPN
aiua-10337	247	2	jp	jp	PROPN
aiua-10337	247	3	,	,	PUNCT
aiua-10337	247	4	lieberman	lieberman	PROPN
aiua-10337	247	5	ja	ja	PROPN
aiua-10337	247	6	,	,	PUNCT
aiua-10337	247	7	perkins	perkins	PROPN
aiua-10337	247	8	do	do	VERB
aiua-10337	247	9	,	,	PUNCT
aiua-10337	247	10	et	et	PROPN
aiua-10337	247	11	al	al	PROPN
aiua-10337	247	12	.	.	PROPN
aiua-10337	247	13	efficacy	efficacy	NOUN
aiua-10337	247	14	and	and	CCONJ
aiua-10337	247	15	tolerability	tolerability	NOUN
aiua-10337	247	16	of	of	ADP
aiua-10337	247	17	olanzapine	olanzapine	NOUN
aiua-10337	247	18	,	,	PUNCT
aiua-10337	247	19	quetiapine	quetiapine	NOUN
aiua-10337	247	20	,	,	PUNCT
aiua-10337	247	21	and	and	CCONJ
aiua-10337	247	22	risperidone	risperidone	NOUN
aiua-10337	247	23	in	in	ADP
aiua-10337	247	24	the	the	DET
aiua-10337	247	25	treatment	treatment	NOUN
aiua-10337	247	26	of	of	ADP
aiua-10337	247	27	early	early	ADJ
aiua-10337	247	28	psychosis	psychosis	NOUN
aiua-10337	247	29	:	:	PUNCT
aiua-10337	247	30	a	a	DET
aiua-10337	247	31	randomized	randomized	ADJ
aiua-10337	247	32	,	,	PUNCT
aiua-10337	247	33	double	double	ADJ
aiua-10337	247	34	-	-	PUNCT
aiua-10337	247	35	blind	blind	ADJ
aiua-10337	247	36	52	52	NUM
aiua-10337	247	37	-	-	PUNCT
aiua-10337	247	38	week	week	NOUN
aiua-10337	247	39	comparison	comparison	NOUN
aiua-10337	247	40	american	american	PROPN
aiua-10337	247	41	journal	journal	PROPN
aiua-10337	247	42	of	of	ADP
aiua-10337	247	43	psychiatry	psychiatry	NOUN
aiua-10337	247	44	.	.	PUNCT
aiua-10337	248	1	2007	2007	NUM
aiua-10337	248	2	;	;	PUNCT
aiua-10337	248	3	164:1050	164:1050	NUM
aiua-10337	248	4	-	-	SYM
aiua-10337	248	5	1060	1060	NUM
aiua-10337	248	6	.	.	PUNCT
aiua-10337	249	1	34	34	NUM
aiua-10337	249	2	.	.	PUNCT
aiua-10337	250	1	mcevoy	mcevoy	PROPN
aiua-10337	250	2	jp	jp	PROPN
aiua-10337	250	3	,	,	PUNCT
aiua-10337	250	4	byerly	byerly	ADV
aiua-10337	250	5	m	m	PROPN
aiua-10337	250	6	,	,	PUNCT
aiua-10337	250	7	hamer	hamer	PROPN
aiua-10337	250	8	rm	rm	PROPN
aiua-10337	250	9	,	,	PUNCT
aiua-10337	250	10	et	et	PROPN
aiua-10337	250	11	al	al	PROPN
aiua-10337	250	12	.	.	PROPN
aiua-10337	250	13	effectiveness	effectiveness	NOUN
aiua-10337	250	14	of	of	ADP
aiua-10337	250	15	paliperidone	paliperidone	NOUN
aiua-10337	250	16	palmitate	palmitate	NOUN
aiua-10337	250	17	vs	vs	ADP
aiua-10337	250	18	haloperidol	haloperidol	NOUN
aiua-10337	250	19	decanoate	decanoate	NOUN
aiua-10337	250	20	for	for	ADP
aiua-10337	250	21	maintenance	maintenance	NOUN
aiua-10337	250	22	treatment	treatment	NOUN
aiua-10337	250	23	of	of	ADP
aiua-10337	250	24	schizophrenia	schizophrenia	NOUN
aiua-10337	250	25	:	:	PUNCT
aiua-10337	250	26	a	a	DET
aiua-10337	250	27	randomized	randomized	ADJ
aiua-10337	250	28	clinical	clinical	ADJ
aiua-10337	250	29	trial	trial	NOUN
aiua-10337	250	30	.	.	PUNCT
aiua-10337	251	1	jama	jama	PROPN
aiua-10337	251	2	.	.	PUNCT
aiua-10337	252	1	2014	2014	NUM
aiua-10337	252	2	;	;	PUNCT
aiua-10337	252	3	311:1978	311:1978	PROPN
aiua-10337	252	4	-	-	SYM
aiua-10337	252	5	87	87	NUM
aiua-10337	252	6	.	.	PUNCT
aiua-10337	253	1	35	35	NUM
aiua-10337	253	2	.	.	PUNCT
aiua-10337	253	3	schröder	schröder	PROPN
aiua-10337	253	4	fh	fh	PROPN
aiua-10337	253	5	,	,	PUNCT
aiua-10337	253	6	whelan	whelan	PROPN
aiua-10337	253	7	p	p	PROPN
aiua-10337	253	8	,	,	PUNCT
aiua-10337	253	9	de	de	PROPN
aiua-10337	253	10	reijke	reijke	PROPN
aiua-10337	253	11	tm	tm	PROPN
aiua-10337	253	12	,	,	PUNCT
aiua-10337	253	13	et	et	PROPN
aiua-10337	253	14	al	al	PROPN
aiua-10337	253	15	.	.	PUNCT
aiua-10337	253	16	members	member	NOUN
aiua-10337	253	17	of	of	ADP
aiua-10337	253	18	the	the	DET
aiua-10337	253	19	eortc	eortc	ADJ
aiua-10337	253	20	genito	genito	ADJ
aiua-10337	253	21	-	-	PUNCT
aiua-10337	253	22	urinary	urinary	ADJ
aiua-10337	253	23	group	group	NOUN
aiua-10337	253	24	.	.	PUNCT
aiua-10337	254	1	metastatic	metastatic	ADJ
aiua-10337	254	2	prostate	prostate	NOUN
aiua-10337	254	3	cancer	cancer	NOUN
aiua-10337	254	4	treated	treat	VERB
aiua-10337	254	5	by	by	ADP
aiua-10337	254	6	flutamide	flutamide	NOUN
aiua-10337	254	7	versus	versus	ADP
aiua-10337	254	8	cyproterone	cyproterone	NOUN
aiua-10337	254	9	acetate	acetate	NOUN
aiua-10337	254	10	.	.	PUNCT
aiua-10337	255	1	final	final	ADJ
aiua-10337	255	2	analysis	analysis	NOUN
aiua-10337	255	3	of	of	ADP
aiua-10337	255	4	the	the	DET
aiua-10337	255	5	"	"	PUNCT
aiua-10337	255	6	european	european	ADJ
aiua-10337	255	7	organization	organization	NOUN
aiua-10337	255	8	for	for	ADP
aiua-10337	255	9	research	research	NOUN
aiua-10337	255	10	and	and	CCONJ
aiua-10337	255	11	treatment	treatment	NOUN
aiua-10337	255	12	of	of	ADP
aiua-10337	255	13	cancer	cancer	NOUN
aiua-10337	255	14	"	"	PUNCT
aiua-10337	255	15	(	(	PUNCT
aiua-10337	255	16	eortc	eortc	NOUN
aiua-10337	255	17	)	)	PUNCT
aiua-10337	255	18	protocol	protocol	NOUN
aiua-10337	255	19	30892	30892	NUM
aiua-10337	255	20	.	.	PUNCT
aiua-10337	256	1	eur	eur	PROPN
aiua-10337	256	2	urol	urol	PROPN
aiua-10337	256	3	.	.	PUNCT
aiua-10337	257	1	2004	2004	NUM
aiua-10337	257	2	;	;	PUNCT
aiua-10337	257	3	45:457	45:457	NUM
aiua-10337	257	4	-	-	SYM
aiua-10337	257	5	64	64	NUM
aiua-10337	257	6	.	.	PUNCT
aiua-10337	258	1	36	36	NUM
aiua-10337	258	2	.	.	X
aiua-10337	259	1	narula	narula	PROPN
aiua-10337	259	2	hs	hs	PROPN
aiua-10337	259	3	,	,	PUNCT
aiua-10337	259	4	carlson	carlson	PROPN
aiua-10337	259	5	he	he	PRON
aiua-10337	259	6	.	.	PUNCT
aiua-10337	260	1	gynaecomastia	gynaecomastia	NOUN
aiua-10337	260	2	-	-	PUNCT
aiua-10337	260	3	pathophysiology	pathophysiology	NOUN
aiua-10337	260	4	,	,	PUNCT
aiua-10337	260	5	diagnosis	diagnosis	NOUN
aiua-10337	260	6	and	and	CCONJ
aiua-10337	260	7	treatment	treatment	NOUN
aiua-10337	260	8	.	.	PUNCT
aiua-10337	261	1	nat	nat	PROPN
aiua-10337	261	2	rev	rev	PROPN
aiua-10337	261	3	endocrinol	endocrinol	NOUN
aiua-10337	261	4	.	.	PUNCT
aiua-10337	261	5	2014	2014	NUM
aiua-10337	261	6	;	;	PUNCT
aiua-10337	261	7	10:684	10:684	NUM
aiua-10337	261	8	-	-	SYM
aiua-10337	261	9	698	698	NUM
aiua-10337	261	10	.	.	PUNCT
aiua-10337	262	1	37	37	NUM
aiua-10337	262	2	.	.	PUNCT
aiua-10337	263	1	kanakis	kanakis	PROPN
aiua-10337	263	2	ga	ga	PROPN
aiua-10337	263	3	,	,	PUNCT
aiua-10337	263	4	nordkap	nordkap	PROPN
aiua-10337	263	5	l	l	PROPN
aiua-10337	263	6	,	,	PUNCT
aiua-10337	263	7	bang	bang	PROPN
aiua-10337	263	8	ak	ak	PROPN
aiua-10337	263	9	,	,	PUNCT
aiua-10337	263	10	et	et	PROPN
aiua-10337	263	11	al	al	PROPN
aiua-10337	263	12	.	.	PUNCT
aiua-10337	264	1	eaa	eaa	PROPN
aiua-10337	264	2	clinical	clinical	ADJ
aiua-10337	264	3	practice	practice	NOUN
aiua-10337	264	4	guidelines	guideline	NOUN
aiua-10337	264	5	-	-	PUNCT
aiua-10337	264	6	gynecomastia	gynecomastia	NOUN
aiua-10337	264	7	evaluation	evaluation	NOUN
aiua-10337	264	8	and	and	CCONJ
aiua-10337	264	9	management	management	NOUN
aiua-10337	264	10	.	.	PUNCT
aiua-10337	265	1	andrology	andrology	PROPN
aiua-10337	265	2	.	.	PUNCT
aiua-10337	266	1	2019	2019	NUM
aiua-10337	266	2	;	;	PUNCT
aiua-10337	266	3	7:778	7:778	NUM
aiua-10337	266	4	-	-	SYM
aiua-10337	266	5	793	793	NUM
aiua-10337	266	6	.	.	NOUN
aiua-10337	266	7	38	38	NUM
aiua-10337	266	8	.	.	PUNCT
aiua-10337	267	1	wirth	wirth	PROPN
aiua-10337	267	2	m	m	PROPN
aiua-10337	267	3	,	,	PUNCT
aiua-10337	267	4	tyrrell	tyrrell	PROPN
aiua-10337	267	5	c	c	PROPN
aiua-10337	267	6	,	,	PUNCT
aiua-10337	267	7	wallace	wallace	PROPN
aiua-10337	267	8	m	m	PROPN
aiua-10337	267	9	,	,	PUNCT
aiua-10337	268	1	et	et	PROPN
aiua-10337	268	2	al	al	PROPN
aiua-10337	268	3	.	.	PROPN
aiua-10337	268	4	bicalutamide	bicalutamide	PROPN
aiua-10337	268	5	(	(	PUNCT
aiua-10337	268	6	casodex	casodex	NOUN
aiua-10337	268	7	)	)	PUNCT
aiua-10337	268	8	150	150	NUM
aiua-10337	268	9	mg	mg	NOUN
aiua-10337	268	10	as	as	ADP
aiua-10337	268	11	immediate	immediate	ADJ
aiua-10337	268	12	therapy	therapy	NOUN
aiua-10337	268	13	in	in	ADP
aiua-10337	268	14	patients	patient	NOUN
aiua-10337	268	15	with	with	ADP
aiua-10337	268	16	localized	localized	ADJ
aiua-10337	268	17	or	or	CCONJ
aiua-10337	268	18	locally	locally	ADV
aiua-10337	268	19	advanced	advanced	ADJ
aiua-10337	268	20	prostate	prostate	NOUN
aiua-10337	268	21	cancer	cancer	NOUN
aiua-10337	268	22	significantly	significantly	ADV
aiua-10337	268	23	reduces	reduce	VERB
aiua-10337	268	24	the	the	DET
aiua-10337	268	25	risk	risk	NOUN
aiua-10337	268	26	of	of	ADP
aiua-10337	268	27	disease	disease	NOUN
aiua-10337	268	28	progression	progression	NOUN
aiua-10337	268	29	urology	urology	NOUN
aiua-10337	268	30	.	.	PUNCT
aiua-10337	269	1	2001	2001	NUM
aiua-10337	269	2	;	;	PUNCT
aiua-10337	269	3	58:146	58:146	NUM
aiua-10337	269	4	-	-	SYM
aiua-10337	269	5	150	150	NUM
aiua-10337	269	6	.	.	NOUN
aiua-10337	270	1	39	39	NUM
aiua-10337	270	2	.	.	PUNCT
aiua-10337	271	1	wirth	wirth	PROPN
aiua-10337	271	2	m	m	PROPN
aiua-10337	271	3	,	,	PUNCT
aiua-10337	271	4	tyrrell	tyrrell	PROPN
aiua-10337	271	5	c	c	NOUN
aiua-10337	271	6	,	,	PUNCT
aiua-10337	271	7	delaere	delaere	ADV
aiua-10337	271	8	k	k	NOUN
aiua-10337	271	9	,	,	PUNCT
aiua-10337	272	1	et	et	PROPN
aiua-10337	272	2	al	al	PROPN
aiua-10337	272	3	.	.	PROPN
aiua-10337	272	4	bicalutamide	bicalutamide	PROPN
aiua-10337	272	5	(	(	PUNCT
aiua-10337	272	6	'	'	PUNCT
aiua-10337	272	7	casodex	casodex	NOUN
aiua-10337	272	8	'	'	PUNCT
aiua-10337	272	9	)	)	PUNCT
aiua-10337	272	10	150	150	NUM
aiua-10337	272	11	mg	mg	NOUN
aiua-10337	272	12	in	in	ADP
aiua-10337	272	13	addition	addition	NOUN
aiua-10337	272	14	to	to	ADP
aiua-10337	272	15	standard	standard	ADJ
aiua-10337	272	16	care	care	NOUN
aiua-10337	272	17	in	in	ADP
aiua-10337	272	18	patients	patient	NOUN
aiua-10337	272	19	with	with	ADP
aiua-10337	272	20	nonmetastatic	nonmetastatic	ADJ
aiua-10337	272	21	prostate	prostate	NOUN
aiua-10337	272	22	cancer	cancer	NOUN
aiua-10337	272	23	:	:	PUNCT
aiua-10337	272	24	updated	update	VERB
aiua-10337	272	25	results	result	NOUN
aiua-10337	272	26	from	from	ADP
aiua-10337	272	27	a	a	DET
aiua-10337	272	28	randomised	randomised	ADJ
aiua-10337	272	29	double	double	ADJ
aiua-10337	272	30	-	-	PUNCT
aiua-10337	272	31	blind	blind	ADJ
aiua-10337	272	32	phase	phase	NOUN
aiua-10337	272	33	iii	iii	NUM
aiua-10337	272	34	study	study	NOUN
aiua-10337	272	35	(	(	PUNCT
aiua-10337	272	36	median	median	ADJ
aiua-10337	272	37	follow	follow	NOUN
aiua-10337	272	38	-	-	PUNCT
aiua-10337	272	39	up	up	NOUN
aiua-10337	272	40	5.1y	5.1y	NUM
aiua-10337	272	41	)	)	PUNCT
aiua-10337	272	42	in	in	ADP
aiua-10337	272	43	the	the	DET
aiua-10337	272	44	early	early	ADJ
aiua-10337	272	45	prostate	prostate	NOUN
aiua-10337	272	46	cancer	cancer	NOUN
aiua-10337	272	47	programme	programme	NOUN
aiua-10337	272	48	prostate	prostate	NOUN
aiua-10337	272	49	cancer	cancer	NOUN
aiua-10337	272	50	and	and	CCONJ
aiua-10337	272	51	prostatic	prostatic	ADJ
aiua-10337	272	52	diseases	disease	NOUN
aiua-10337	272	53	2005	2005	NUM
aiua-10337	272	54	;	;	PUNCT
aiua-10337	272	55	8:194200	8:194200	NUM
aiua-10337	272	56	.	.	X
aiua-10337	273	1	40	40	NUM
aiua-10337	273	2	.	.	PUNCT
aiua-10337	274	1	iversen	iversen	PROPN
aiua-10337	274	2	p	p	PROPN
aiua-10337	274	3	,	,	PUNCT
aiua-10337	274	4	mcleod	mcleod	PROPN
aiua-10337	274	5	dg	dg	PROPN
aiua-10337	274	6	,	,	PUNCT
aiua-10337	274	7	see	see	VERB
aiua-10337	274	8	wa	wa	PROPN
aiua-10337	274	9	,	,	PUNCT
aiua-10337	274	10	et	et	PROPN
aiua-10337	274	11	al	al	PROPN
aiua-10337	274	12	.	.	PROPN
aiua-10337	274	13	casodex	casodex	PROPN
aiua-10337	274	14	early	early	ADJ
aiua-10337	274	15	prostate	prostate	NOUN
aiua-10337	274	16	archivio	archivio	NOUN
aiua-10337	274	17	italiano	italiano	NOUN
aiua-10337	274	18	di	di	X
aiua-10337	274	19	urologia	urologia	PROPN
aiua-10337	274	20	e	e	PROPN
aiua-10337	274	21	andrologia	andrologia	NOUN
aiua-10337	274	22	2021	2021	NUM
aiua-10337	274	23	;	;	PUNCT
aiua-10337	274	24	93	93	NUM
aiua-10337	274	25	,	,	PUNCT
aiua-10337	274	26	4	4	NUM
aiua-10337	274	27	a.	a.	NOUN
aiua-10337	274	28	trinchieri	trinchieri	PROPN
aiua-10337	274	29	,	,	PUNCT
aiua-10337	274	30	g.	g.	PROPN
aiua-10337	274	31	perletti	perletti	PROPN
aiua-10337	274	32	,	,	PUNCT
aiua-10337	274	33	v.	v.	ADP
aiua-10337	274	34	magri	magri	NOUN
aiua-10337	274	35	,	,	PUNCT
aiua-10337	274	36	k.	k.	PROPN
aiua-10337	274	37	stamatiou	stamatiou	PROPN
aiua-10337	274	38	,	,	PUNCT
aiua-10337	274	39	m.	m.	NOUN
aiua-10337	274	40	trinchieri	trinchieri	PROPN
aiua-10337	274	41	,	,	PUNCT
aiua-10337	274	42	e.	e.	PROPN
aiua-10337	274	43	montanari	montanari	PROPN
aiua-10337	274	44	496	496	NUM
aiua-10337	274	45	cancer	cancer	NOUN
aiua-10337	274	46	trialists	trialist	NOUN
aiua-10337	274	47	'	'	PART
aiua-10337	274	48	group	group	NOUN
aiua-10337	274	49	.	.	PUNCT
aiua-10337	275	1	antiandrogen	antiandrogen	PROPN
aiua-10337	275	2	monotherapy	monotherapy	NOUN
aiua-10337	275	3	in	in	ADP
aiua-10337	275	4	patients	patient	NOUN
aiua-10337	275	5	with	with	ADP
aiua-10337	275	6	localized	localized	ADJ
aiua-10337	275	7	or	or	CCONJ
aiua-10337	275	8	locally	locally	ADV
aiua-10337	275	9	advanced	advanced	ADJ
aiua-10337	275	10	prostate	prostate	NOUN
aiua-10337	275	11	cancer	cancer	NOUN
aiua-10337	275	12	:	:	PUNCT
aiua-10337	275	13	final	final	ADJ
aiua-10337	275	14	results	result	NOUN
aiua-10337	275	15	from	from	ADP
aiua-10337	275	16	the	the	DET
aiua-10337	275	17	bicalutamide	bicalutamide	NOUN
aiua-10337	275	18	early	early	ADJ
aiua-10337	275	19	prostate	prostate	NOUN
aiua-10337	275	20	cancer	cancer	NOUN
aiua-10337	275	21	programme	programme	NOUN
aiua-10337	275	22	at	at	ADP
aiua-10337	275	23	a	a	DET
aiua-10337	275	24	median	median	ADJ
aiua-10337	275	25	followup	followup	NOUN
aiua-10337	275	26	of	of	ADP
aiua-10337	275	27	9.7	9.7	NUM
aiua-10337	275	28	years.bju	years.bju	NOUN
aiua-10337	275	29	int	int	NOUN
aiua-10337	275	30	.	.	PUNCT
aiua-10337	276	1	2010	2010	NUM
aiua-10337	276	2	;	;	PUNCT
aiua-10337	276	3	105:1074	105:1074	NUM
aiua-10337	276	4	-	-	SYM
aiua-10337	276	5	81	81	NUM
aiua-10337	276	6	.	.	PUNCT
aiua-10337	277	1	41	41	NUM
aiua-10337	277	2	.	.	PUNCT
aiua-10337	278	1	skeldon	skeldon	PROPN
aiua-10337	278	2	sc	sc	PROPN
aiua-10337	278	3	,	,	PUNCT
aiua-10337	278	4	carleton	carleton	PROPN
aiua-10337	278	5	b	b	PROPN
aiua-10337	278	6	,	,	PUNCT
aiua-10337	278	7	brophy	brophy	PROPN
aiua-10337	278	8	jm	jm	PROPN
aiua-10337	278	9	,	,	PUNCT
aiua-10337	278	10	et	et	PROPN
aiua-10337	278	11	al	al	PROPN
aiua-10337	278	12	.	.	PROPN
aiua-10337	279	1	statin	statin	PROPN
aiua-10337	279	2	medications	medication	NOUN
aiua-10337	279	3	and	and	CCONJ
aiua-10337	279	4	the	the	DET
aiua-10337	279	5	risk	risk	NOUN
aiua-10337	279	6	of	of	ADP
aiua-10337	279	7	gynecomastia	gynecomastia	PROPN
aiua-10337	279	8	.	.	PUNCT
aiua-10337	280	1	clin	clin	PROPN
aiua-10337	280	2	endocrinol	endocrinol	NOUN
aiua-10337	280	3	(	(	PUNCT
aiua-10337	280	4	oxf	oxf	PROPN
aiua-10337	280	5	)	)	PUNCT
aiua-10337	280	6	.	.	PUNCT
aiua-10337	280	7	2018	2018	NUM
aiua-10337	280	8	;	;	PUNCT
aiua-10337	280	9	89:470	89:470	NUM
aiua-10337	280	10	-	-	SYM
aiua-10337	280	11	473	473	NUM
aiua-10337	280	12	.	.	PUNCT
aiua-10337	280	13	42	42	NUM
aiua-10337	280	14	.	.	PUNCT
aiua-10337	281	1	schooling	school	VERB
aiua-10337	281	2	cm	cm	NUM
aiua-10337	281	3	,	,	PUNCT
aiua-10337	281	4	au	au	PROPN
aiua-10337	281	5	yeung	yeung	PROPN
aiua-10337	281	6	sl	sl	PROPN
aiua-10337	281	7	,	,	PUNCT
aiua-10337	281	8	freeman	freeman	PROPN
aiua-10337	281	9	g	g	PROPN
aiua-10337	281	10	,	,	PUNCT
aiua-10337	281	11	cowling	cowl	VERB
aiua-10337	281	12	bj	bj	NOUN
aiua-10337	281	13	.	.	PUNCT
aiua-10337	282	1	the	the	DET
aiua-10337	282	2	effect	effect	NOUN
aiua-10337	282	3	of	of	ADP
aiua-10337	282	4	statins	statin	NOUN
aiua-10337	282	5	on	on	ADP
aiua-10337	282	6	testosterone	testosterone	NOUN
aiua-10337	282	7	in	in	ADP
aiua-10337	282	8	men	man	NOUN
aiua-10337	282	9	and	and	CCONJ
aiua-10337	282	10	women	woman	NOUN
aiua-10337	282	11	,	,	PUNCT
aiua-10337	282	12	a	a	DET
aiua-10337	282	13	systematic	systematic	ADJ
aiua-10337	282	14	review	review	NOUN
aiua-10337	282	15	and	and	CCONJ
aiua-10337	282	16	meta	meta	NOUN
aiua-10337	282	17	-	-	PUNCT
aiua-10337	282	18	analysis	analysis	NOUN
aiua-10337	282	19	of	of	ADP
aiua-10337	282	20	randomized	randomized	ADJ
aiua-10337	282	21	controlled	control	VERB
aiua-10337	282	22	trials	trial	NOUN
aiua-10337	282	23	.	.	PUNCT
aiua-10337	283	1	bmc	bmc	PROPN
aiua-10337	283	2	med	med	PROPN
aiua-10337	283	3	.	.	PUNCT
aiua-10337	283	4	2013	2013	NUM
aiua-10337	283	5	;	;	PUNCT
aiua-10337	283	6	11:57	11:57	NUM
aiua-10337	283	7	.	.	PUNCT
aiua-10337	284	1	43	43	NUM
aiua-10337	284	2	.	.	PUNCT
aiua-10337	285	1	roberto	roberto	PROPN
aiua-10337	285	2	g	g	PROPN
aiua-10337	285	3	,	,	PUNCT
aiua-10337	285	4	biagi	biagi	PROPN
aiua-10337	285	5	c	c	PROPN
aiua-10337	285	6	,	,	PUNCT
aiua-10337	285	7	montanaro	montanaro	NOUN
aiua-10337	285	8	n	n	CCONJ
aiua-10337	285	9	,	,	PUNCT
aiua-10337	285	10	et	et	PROPN
aiua-10337	285	11	al	al	PROPN
aiua-10337	285	12	.	.	PUNCT
aiua-10337	285	13	statin	statin	PROPN
aiua-10337	285	14	-	-	PUNCT
aiua-10337	285	15	associated	associate	VERB
aiua-10337	285	16	gynecomastia	gynecomastia	NOUN
aiua-10337	285	17	:	:	PUNCT
aiua-10337	285	18	evidence	evidence	NOUN
aiua-10337	285	19	coming	come	VERB
aiua-10337	285	20	from	from	ADP
aiua-10337	285	21	the	the	DET
aiua-10337	285	22	italian	italian	ADJ
aiua-10337	285	23	spontaneous	spontaneous	ADJ
aiua-10337	285	24	adr	adr	PROPN
aiua-10337	285	25	reporting	report	VERB
aiua-10337	285	26	database	database	NOUN
aiua-10337	285	27	and	and	CCONJ
aiua-10337	285	28	literature	literature	NOUN
aiua-10337	285	29	.	.	PUNCT
aiua-10337	286	1	eur	eur	PROPN
aiua-10337	286	2	j	j	PROPN
aiua-10337	286	3	clin	clin	PROPN
aiua-10337	286	4	pharmacol	pharmacol	PROPN
aiua-10337	286	5	.	.	PROPN
aiua-10337	286	6	2012	2012	NUM
aiua-10337	286	7	;	;	PUNCT
aiua-10337	286	8	68:1007	68:1007	X
aiua-10337	286	9	-	-	SYM
aiua-10337	286	10	11	11	NUM
aiua-10337	286	11	.	.	PUNCT
aiua-10337	287	1	44	44	NUM
aiua-10337	287	2	.	.	PUNCT
aiua-10337	288	1	batteux	batteux	PROPN
aiua-10337	288	2	b	b	PROPN
aiua-10337	288	3	,	,	PUNCT
aiua-10337	288	4	llopis	llopis	ADJ
aiua-10337	288	5	b	b	PROPN
aiua-10337	288	6	,	,	PUNCT
aiua-10337	288	7	muller	muller	NOUN
aiua-10337	288	8	c	c	PROPN
aiua-10337	288	9	,	,	PUNCT
aiua-10337	288	10	et	et	PROPN
aiua-10337	288	11	al	al	PROPN
aiua-10337	288	12	.	.	PROPN
aiua-10337	289	1	french	french	ADJ
aiua-10337	289	2	national	national	ADJ
aiua-10337	289	3	network	network	NOUN
aiua-10337	289	4	of	of	ADP
aiua-10337	289	5	pharmacovigilance	pharmacovigilance	NOUN
aiua-10337	289	6	centres	centre	NOUN
aiua-10337	289	7	.	.	PUNCT
aiua-10337	290	1	the	the	DET
aiua-10337	290	2	drugs	drug	NOUN
aiua-10337	290	3	that	that	PRON
aiua-10337	290	4	mostly	mostly	ADV
aiua-10337	290	5	frequently	frequently	ADV
aiua-10337	290	6	induce	induce	VERB
aiua-10337	290	7	gynecomastia	gynecomastia	NOUN
aiua-10337	290	8	:	:	PUNCT
aiua-10337	290	9	a	a	DET
aiua-10337	290	10	national	national	ADJ
aiua-10337	290	11	case	case	NOUN
aiua-10337	290	12	noncase	noncase	NOUN
aiua-10337	290	13	study	study	NOUN
aiua-10337	290	14	.	.	PUNCT
aiua-10337	291	1	therapie	therapie	PROPN
aiua-10337	291	2	.	.	PUNCT
aiua-10337	292	1	2020	2020	NUM
aiua-10337	292	2	;	;	PUNCT
aiua-10337	292	3	75:225	75:225	NUM
aiua-10337	292	4	-	-	SYM
aiua-10337	292	5	238	238	NUM
aiua-10337	292	6	.	.	PUNCT
aiua-10337	292	7	45	45	NUM
aiua-10337	292	8	.	.	PUNCT
aiua-10337	293	1	grigg	grigg	PROPN
aiua-10337	293	2	j	j	PROPN
aiua-10337	293	3	,	,	PUNCT
aiua-10337	293	4	worsley	worsley	PROPN
aiua-10337	293	5	r	r	NOUN
aiua-10337	293	6	,	,	PUNCT
aiua-10337	293	7	thew	thew	NOUN
aiua-10337	293	8	c	c	NOUN
aiua-10337	293	9	,	,	PUNCT
aiua-10337	293	10	et	et	PROPN
aiua-10337	293	11	al	al	PROPN
aiua-10337	293	12	.	.	PUNCT
aiua-10337	293	13	antipsychotic	antipsychotic	PROPN
aiua-10337	293	14	-	-	PUNCT
aiua-10337	293	15	induced	induce	VERB
aiua-10337	293	16	hyperprolactinemia	hyperprolactinemia	NOUN
aiua-10337	293	17	:	:	PUNCT
aiua-10337	293	18	synthesis	synthesis	NOUN
aiua-10337	293	19	of	of	ADP
aiua-10337	293	20	world	world	NOUN
aiua-10337	293	21	-	-	PUNCT
aiua-10337	293	22	wide	wide	ADJ
aiua-10337	293	23	guidelines	guideline	NOUN
aiua-10337	293	24	and	and	CCONJ
aiua-10337	293	25	integrated	integrated	ADJ
aiua-10337	293	26	recommendations	recommendation	NOUN
aiua-10337	293	27	for	for	ADP
aiua-10337	293	28	assessment	assessment	NOUN
aiua-10337	293	29	,	,	PUNCT
aiua-10337	293	30	management	management	NOUN
aiua-10337	293	31	and	and	CCONJ
aiua-10337	293	32	future	future	ADJ
aiua-10337	293	33	research	research	NOUN
aiua-10337	293	34	.	.	PUNCT
aiua-10337	294	1	psychopharmacology	psychopharmacology	NOUN
aiua-10337	294	2	.	.	PUNCT
aiua-10337	295	1	2017	2017	NUM
aiua-10337	295	2	;	;	PUNCT
aiua-10337	295	3	234:3279	234:3279	NUM
aiua-10337	295	4	-	-	SYM
aiua-10337	295	5	3297	3297	NUM
aiua-10337	295	6	.	.	PUNCT
aiua-10337	296	1	46	46	NUM
aiua-10337	296	2	.	.	PUNCT
aiua-10337	297	1	ferreira	ferreira	PROPN
aiua-10337	297	2	m	m	PROPN
aiua-10337	297	3	,	,	PUNCT
aiua-10337	297	4	mesquita	mesquita	PROPN
aiua-10337	297	5	m	m	PROPN
aiua-10337	297	6	,	,	PUNCT
aiua-10337	297	7	quaresma	quaresma	PROPN
aiua-10337	297	8	m	m	PROPN
aiua-10337	297	9	&	&	CCONJ
aiua-10337	297	10	andré	andré	PROPN
aiua-10337	297	11	s.	s.	PROPN
aiua-10337	297	12	prolactin	prolactin	PROPN
aiua-10337	297	13	receptor	receptor	NOUN
aiua-10337	297	14	expression	expression	NOUN
aiua-10337	297	15	in	in	ADP
aiua-10337	297	16	gynaecomastia	gynaecomastia	NOUN
aiua-10337	297	17	and	and	CCONJ
aiua-10337	297	18	male	male	ADJ
aiua-10337	297	19	breast	breast	NOUN
aiua-10337	297	20	carcinoma	carcinoma	NOUN
aiua-10337	297	21	.	.	PUNCT
aiua-10337	298	1	histopathology	histopathology	NOUN
aiua-10337	298	2	.	.	PUNCT
aiua-10337	299	1	2008	2008	NUM
aiua-10337	299	2	;	;	PUNCT
aiua-10337	299	3	53:56	53:56	NUM
aiua-10337	299	4	-	-	SYM
aiua-10337	299	5	61	61	NUM
aiua-10337	299	6	.	.	PUNCT
aiua-10337	300	1	47	47	NUM
aiua-10337	300	2	.	.	PUNCT
aiua-10337	301	1	layton	layton	PROPN
aiua-10337	301	2	am	am	PROPN
aiua-10337	301	3	,	,	PUNCT
aiua-10337	301	4	eady	eady	ADJ
aiua-10337	301	5	ea	ea	PROPN
aiua-10337	301	6	,	,	PUNCT
aiua-10337	301	7	whitehouse	whitehouse	NOUN
aiua-10337	301	8	h	h	NOUN
aiua-10337	301	9	,	,	PUNCT
aiua-10337	301	10	et	et	PROPN
aiua-10337	301	11	al	al	PROPN
aiua-10337	301	12	.	.	PROPN
aiua-10337	302	1	oral	oral	ADJ
aiua-10337	302	2	spironolactone	spironolactone	NOUN
aiua-10337	302	3	for	for	ADP
aiua-10337	302	4	acne	acne	NOUN
aiua-10337	302	5	vulgaris	vulgaris	NOUN
aiua-10337	302	6	in	in	ADP
aiua-10337	302	7	adult	adult	NOUN
aiua-10337	302	8	females	female	NOUN
aiua-10337	302	9	:	:	PUNCT
aiua-10337	302	10	a	a	DET
aiua-10337	302	11	hybrid	hybrid	ADJ
aiua-10337	302	12	systematic	systematic	ADJ
aiua-10337	302	13	review	review	NOUN
aiua-10337	302	14	.	.	PUNCT
aiua-10337	303	1	am	be	AUX
aiua-10337	303	2	j	j	PROPN
aiua-10337	303	3	clin	clin	PROPN
aiua-10337	303	4	dermatol	dermatol	NOUN
aiua-10337	303	5	.	.	PUNCT
aiua-10337	304	1	2017	2017	NUM
aiua-10337	304	2	;	;	PUNCT
aiua-10337	304	3	18:169	18:169	NUM
aiua-10337	304	4	-	-	SYM
aiua-10337	304	5	191	191	NUM
aiua-10337	304	6	.	.	PUNCT
aiua-10337	305	1	48	48	NUM
aiua-10337	305	2	.	.	PUNCT
aiua-10337	306	1	muhlemann	muhlemann	PROPN
aiua-10337	306	2	mf	mf	PROPN
aiua-10337	306	3	,	,	PUNCT
aiua-10337	306	4	carter	carter	PROPN
aiua-10337	306	5	gd	gd	PROPN
aiua-10337	306	6	,	,	PUNCT
aiua-10337	306	7	cream	cream	NOUN
aiua-10337	306	8	jj	jj	PROPN
aiua-10337	306	9	,	,	PUNCT
aiua-10337	306	10	wise	wise	ADJ
aiua-10337	306	11	p.	p.	PROPN
aiua-10337	306	12	oral	oral	ADJ
aiua-10337	307	1	spironolactone	spironolactone	NOUN
aiua-10337	307	2	:	:	PUNCT
aiua-10337	307	3	an	an	DET
aiua-10337	307	4	effective	effective	ADJ
aiua-10337	307	5	treatment	treatment	NOUN
aiua-10337	307	6	for	for	ADP
aiua-10337	307	7	acne	acne	NOUN
aiua-10337	307	8	vulgaris	vulgaris	NOUN
aiua-10337	307	9	in	in	ADP
aiua-10337	307	10	women	woman	NOUN
aiua-10337	307	11	.	.	PUNCT
aiua-10337	308	1	br	br	PROPN
aiua-10337	308	2	j	j	PROPN
aiua-10337	308	3	dermatol	dermatol	NOUN
aiua-10337	308	4	.	.	PUNCT
aiua-10337	309	1	1986	1986	NUM
aiua-10337	309	2	;	;	PUNCT
aiua-10337	310	1	115:227	115:227	NOUN
aiua-10337	310	2	-	-	SYM
aiua-10337	310	3	32	32	NUM
aiua-10337	310	4	.	.	PUNCT
aiua-10337	311	1	correspondence	correspondence	NOUN
aiua-10337	311	2	alberto	alberto	PROPN
aiua-10337	311	3	trinchieri	trinchieri	PROPN
aiua-10337	311	4	,	,	PUNCT
aiua-10337	311	5	md	md	PROPN
aiua-10337	311	6	(	(	PUNCT
aiua-10337	311	7	corresponding	correspond	VERB
aiua-10337	311	8	author	author	NOUN
aiua-10337	311	9	)	)	PUNCT
aiua-10337	311	10	alberto.trinchieri@gmail.com	alberto.trinchieri@gmail.com	X
aiua-10337	311	11	school	school	NOUN
aiua-10337	311	12	of	of	ADP
aiua-10337	311	13	urology	urology	NOUN
aiua-10337	311	14	,	,	PUNCT
aiua-10337	311	15	university	university	PROPN
aiua-10337	311	16	of	of	ADP
aiua-10337	311	17	milan	milan	PROPN
aiua-10337	311	18	via	via	ADP
aiua-10337	311	19	commenda	commenda	PROPN
aiua-10337	311	20	15	15	NUM
aiua-10337	311	21	,	,	PUNCT
aiua-10337	311	22	20100	20100	NUM
aiua-10337	311	23	milano	milano	PROPN
aiua-10337	311	24	(	(	PUNCT
aiua-10337	311	25	italy	italy	PROPN
aiua-10337	311	26	)	)	PUNCT
aiua-10337	311	27	gianpaolo	gianpaolo	PROPN
aiua-10337	311	28	perletti	perletti	PROPN
aiua-10337	311	29	,	,	PUNCT
aiua-10337	311	30	phd	phd	PROPN
aiua-10337	311	31	gianpaolo.perletti@uninsubria.it	gianpaolo.perletti@uninsubria.it	PROPN
aiua-10337	311	32	department	department	PROPN
aiua-10337	311	33	of	of	ADP
aiua-10337	311	34	biotechnology	biotechnology	NOUN
aiua-10337	311	35	and	and	CCONJ
aiua-10337	311	36	life	life	NOUN
aiua-10337	311	37	sciences	science	NOUN
aiua-10337	311	38	,	,	PUNCT
aiua-10337	311	39	section	section	NOUN
aiua-10337	311	40	of	of	ADP
aiua-10337	311	41	medical	medical	ADJ
aiua-10337	311	42	and	and	CCONJ
aiua-10337	311	43	surgical	surgical	ADJ
aiua-10337	311	44	sciences	science	NOUN
aiua-10337	311	45	,	,	PUNCT
aiua-10337	311	46	university	university	NOUN
aiua-10337	311	47	of	of	ADP
aiua-10337	311	48	insubria	insubria	PROPN
aiua-10337	311	49	,	,	PUNCT
aiua-10337	311	50	varese	varese	PROPN
aiua-10337	311	51	(	(	PUNCT
aiua-10337	311	52	italy	italy	PROPN
aiua-10337	311	53	)	)	PUNCT
aiua-10337	311	54	vittorio	vittorio	PROPN
aiua-10337	311	55	magri	magri	PROPN
aiua-10337	311	56	,	,	PUNCT
aiua-10337	311	57	md	md	PROPN
aiua-10337	311	58	vittorio.magri@yahoo.it	vittorio.magri@yahoo.it	PUNCT
aiua-10337	311	59	urology	urology	NOUN
aiua-10337	311	60	secondary	secondary	ADJ
aiua-10337	311	61	care	care	NOUN
aiua-10337	311	62	clinic	clinic	NOUN
aiua-10337	311	63	,	,	PUNCT
aiua-10337	311	64	asst	asst	NOUN
aiua-10337	311	65	-	-	PUNCT
aiua-10337	311	66	nord	nord	PROPN
aiua-10337	311	67	,	,	PUNCT
aiua-10337	311	68	milan	milan	PROPN
aiua-10337	311	69	(	(	PUNCT
aiua-10337	311	70	italy	italy	PROPN
aiua-10337	311	71	)	)	PUNCT
aiua-10337	311	72	konstantinos	konstantinos	PROPN
aiua-10337	311	73	stamatiou	stamatiou	PROPN
aiua-10337	311	74	,	,	PUNCT
aiua-10337	311	75	md	md	PROPN
aiua-10337	311	76	stamatiouk@gmail.com	stamatiouk@gmail.com	PROPN
aiua-10337	311	77	department	department	PROPN
aiua-10337	311	78	of	of	ADP
aiua-10337	311	79	urology	urology	NOUN
aiua-10337	311	80	,	,	PUNCT
aiua-10337	311	81	tzaneio	tzaneio	ADJ
aiua-10337	311	82	hospital	hospital	PROPN
aiua-10337	311	83	,	,	PUNCT
aiua-10337	311	84	pireus	pireus	PROPN
aiua-10337	311	85	(	(	PUNCT
aiua-10337	311	86	greece	greece	PROPN
aiua-10337	311	87	)	)	PUNCT
aiua-10337	311	88	margherita	margherita	PROPN
aiua-10337	311	89	trinchieri	trinchieri	PROPN
aiua-10337	311	90	,	,	PUNCT
aiua-10337	311	91	md	md	PROPN
aiua-10337	311	92	margherita.trinchieri11@gmail.com	margherita.trinchieri11@gmail.com	PROPN
aiua-10337	311	93	department	department	PROPN
aiua-10337	311	94	of	of	ADP
aiua-10337	311	95	neuroscience	neuroscience	NOUN
aiua-10337	311	96	,	,	PUNCT
aiua-10337	311	97	psychiatric	psychiatric	ADJ
aiua-10337	311	98	unit	unit	NOUN
aiua-10337	311	99	,	,	PUNCT
aiua-10337	311	100	university	university	NOUN
aiua-10337	311	101	of	of	ADP
aiua-10337	311	102	parma	parma	PROPN
aiua-10337	311	103	,	,	PUNCT
aiua-10337	311	104	parma	parma	PROPN
aiua-10337	311	105	(	(	PUNCT
aiua-10337	311	106	italy	italy	PROPN
aiua-10337	311	107	)	)	PUNCT
aiua-10337	311	108	emanuele	emanuele	PROPN
aiua-10337	311	109	montanari	montanari	PROPN
aiua-10337	311	110	,	,	PUNCT
aiua-10337	311	111	md	md	PROPN
aiua-10337	311	112	emanuele.montanari@unimi.it	emanuele.montanari@unimi.it	PROPN
aiua-10337	311	113	department	department	PROPN
aiua-10337	311	114	of	of	ADP
aiua-10337	311	115	urology	urology	NOUN
aiua-10337	311	116	,	,	PUNCT
aiua-10337	311	117	irccs	irccs	NOUN
aiua-10337	311	118	ca	ca	NOUN
aiua-10337	311	119	’	'	PUNCT
aiua-10337	311	120	granda	granda	PROPN
aiua-10337	311	121	ospedale	ospedale	PROPN
aiua-10337	311	122	maggiore	maggiore	PROPN
aiua-10337	311	123	policlinico	policlinico	PROPN
aiua-10337	311	124	university	university	PROPN
aiua-10337	311	125	of	of	ADP
aiua-10337	311	126	milan	milan	PROPN
aiua-10337	311	127	,	,	PUNCT
aiua-10337	311	128	milan	milan	PROPN
aiua-10337	311	129	(	(	PUNCT
aiua-10337	311	130	italy	italy	PROPN
aiua-10337	311	131	)	)	PUNCT